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ABSTRACT 
The apolipoprotein genes are important protein components 
of plasma lipoprotein fractions, act as cofactors for many 
of the lipoprotein enzymes, and interact with lipoprotein 
receptors. Defects in the genes for apolipoproteins, 
lipoprotein enzymes and lipoprotein receptors are now 
recognised as the cause of a number of clinical 
lipoproteinemias, as well as being identified as 
determinants of plasma cholesterol and triglyceride 
concentrations in the general population. The genes coding 
for apolipoproteins, lipoprotein enzymes and receptors have 
also been implicated in the aetiology of cardiovascular 
disease. 
The primary metabolic alteration and underlying biochemical 
cause of non-insulin dependent diabetes mellitus remains 
undetermined. The disorder is often accompanied by general 
obesity and central adiposity, and these three states are 
associated with altered lipoprotein metabolism. The 
Micronesian population of the Republic of Nauru is affected 
by high prevalences of both non-insulin dependent diabetes 
and obesity and has formed the study population for this 
thesis. This study examines the contribution of genetic 
variability at eight lipoprotein loci to plasma cholesterol 
and triglyceride variability, central adiposity, general 
obesity, and to the occurrence of non-insulin dependent 
diabetes mellitus. 
Vl 
The frequencies of seven restriction fragment length 
polymorphisms, and of the common apolipoprotein E (APOE) 
alleles were established in the Micronesian population and 
these frequencies compared with those observed in other 
ethnic groups. MspI polymorphisms at the apolipoprotein Al 
(APOAl) and apolipoprotein A2 (APOA2) loci, TaqI 
polymorphisms at the apolipoprotein C2 (APOC2) and 
apolipoprotein D (APOD) loci, a DraI polymorphism at the 
apolipoprotein Cl (APOCl) locus and PvuII polymorphisms at 
the lipoprotein lipase (LPL) and low density lipoprotein 
receptor (LDLR) loci were all present in the population. 
Frequencies for the presence of the restriction sites 
ranged from 0.230 ± 0.035 to 0.839 ± 0.027. Micronesian APOE 
allele frequencies were APOE*2 0.048 ± 0.016, APOE*3 0.827 
± 0.029 and APOE*4 0.125 ± 0.026. 
In general, the lipoprotein allele frequencies were closer 
to those reported for Oriental populations, and most 
dissimilar to those found in Caucasoid and African 
populations. Probe/enzyme combinations generated systems 
with polymorphic information contents ranging from 0.234 to 
0.374. The restriction fragment length polymorphisms were 
"highly informative", given the restriction on information 
content due to diallelism, and the apolipoprotein E 
polymorphism was found to be "reasonably informative" 
(polymorphic information content 0.273). 
The frequencies of these eight polymorphisms were examined 
in relation to diabetes, body mass index, waist-to-hip 
Vll 
ratio, plasma triglyceride level and plasma cholesterol 
level. The nature of associations discovered between these 
lipoprotein genes and the variables listed were examined in 
both univariate and multivariate analyses. The presence of 
the APOC2 Taql 3.8kb allele was significantly associated 
with lowered plasma triglyceride levels and waist-to-hip 
ratios. The APOD Taql 2.7kb allele was significantly 
associated with non-insulin dependent diabetes mellitus and 
was more common in individuals with high cholesterol levels 
and high waist-to-hip ratios. The primary associations in 
the population are believed to be between APOC2 and plasma 
triglyceride levels, and between APOD and non-insulin 
dependent diabetes. Limited evidence was provided for an 
association between the APOE*2 allele and non-insulin 
dependent diabetes mellitus, however, there was no support 
for the often reported associations between APOE*2 and 
hypertriglyceridemia, or APOE*4 and hypercholesterolemia. 
Linkage analyses were performed between the eight 
lipoprotein loci under investigation and diabetic 
liability, hypercholesterolemia and hypertriglyceridemia. 
These analyses were performed under a range of assumptions 
C losQ... 
for mode of inheritance.J Einkage to these three disorders 
was excluded, under a model for dominant inheritance, for 
several of the loci examined. APOC2 and APOD, 
particular, were excluded from linkage with 
. 
ln 
hypertriglyceridemia, hypercholesterolemia and non-insulin 
dependent diabetes mellitus, under dominant inheritance. 
Moreover, APOC2 was excluded from linkage with 
' ' ' Vlll 
hypertriglyceridemia, and APOD from linkage with 
hypercholesterolemia, when these disorders were modelled 
under recessive inheritance. 
The lack of power of single markers to detect linkage with 
complex disorders has been discussed and it is concluded 
that the use of either highly variable polymorphisms or 
genetic maps may be required if detection of the underlying 
genetic cause, or causes, of these disorders are to be 
established. Genetic analyses of these complex disorders 
are hindered by variable age of onset and confounding 
secondary metabolic effects which make the nomination of 
individuals to affected or unaffected status difficult. 
Furthermore an improved understanding of the interactions 
between obesity and central adiposity, and of their effects 
on glucose and lipoprotein metabolism and insulin action 
will improve the likelihood of identifying the genes 
responsible for establishing a background genetic 
predisposition to diabetes, obesity and hyperlipo-
proteinemia. 
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SECTION 1 
GENERAL INTRODUCTION 
1 
1.1 INTRODUCTION 
Altered lipoprotein metabolism is strongly implicated in 
the aetiology of atherosclerosis (Goldstein and Brown, 
1983; Hegele and Breslow, 1987; Breslow, 1988). In rare 
cases, simple monogenic disorders of apolipoproteins 
(Zannis and Breslow, 1984; Galton, 1985), the low density 
lipoprotein receptor (LDLR) (Goldstein et al., 1982; 
Russell et al., 1986; Falus and Ramies, 1988) and 
lipoprotein lipase (Devlin et al., 1990; Monsalve et al., 
1990) result in hyperlipoproteinemias. More commonly, 
single genetic determinants cannot be identified for the 
lipoproteinemias. In these situations it is likely that the 
disorders are polygenic or multifactorial in origin with 
the most probable candidate genes being those associated 
with lipid transport and metabolism, that is, the 
apolipoprotein genes, the genes coding for lipoprotein 
enzymes and the lipoprotein receptor genes (Galton, 1987). 
Lipoprotein metabolism is altered in non-insulin dependent 
diabetes (NIDDM) and this alteration is accompanied by an 
increased risk for cardiac heart disease (CHO) (Brunzell et 
al., 1985; Howard, 1987; Assmann and Schulte, 1988). The 
possibility exists that the apolipoprotein and lipoprotein 
receptor and enzyme genes are also involved in the 
aetiology of NIDDM. 
1.2 MOLECULAR GENETICS OF THE LIPOPROTEIN GENES 
Lipoproteins are the maJor carriers of triglycerides, 
cholesterol, cholesteryl esters and phospholipids in human 
2 
plasma. They are synthesized mainly in the liver and 
intestine and are complex macromolecular aggregates with 
cores of non-polar lipids and coats of relatively polar 
material (Smith et al., 1978). The plasma lipoproteins vary 
greatly in size, lipid composition and peptide content. 
They have traditionally been separated by ultracentrifugal 
flotation and classified into four major density classes: 
chylomicrons, very low density lipoproteins (VLDL), low 
density lipoproteins (LDL) and high density lipoproteins 
(HDL) (Table 1.1) . 
The protein components of plasma lipoproteins are known as 
apolipoproteins, twelve of which have been identified 
(Alaupovic, 1971; Lee et al., 1983). Apolipoproteins 
participate in lipoprotein synthesis, secretion, processing 
and catabolism. In addition to being important structural 
constituents of the lipoproteins, apolipoproteins function 
in the activation and inhibition of lipoprotein lipase 
(LPL), the activation of lecithin cholesteryl acyl 
transferase (LCAT), and in the binding of LDL particles to 
the low density lipoprotein receptor (for reviews see 
Zannis and Breslow, 1984; Assmann, 1985; see also Table 
1. 2) . 
The clinical and biological importance of the 
apolipoproteins has generated much interest in their 
structure, function and evolution. Apolipoprotein structure 
and function is summarized in Table 1.2, while details of 
chromosomal location and gene organization are presented in 
Table 1.3. In the following subsections individual 
3 
apolipoproteins will be discussed separately but Tables 1. 2 
and 1.3 should be referred to for detail. 
1.2.1 Apolipoprotein Al 
Apolipoprotein Al comprises as much as 67% of the protein 
of HDL (Gal ton, 1985). APOAl promotes cholesterol efflux 
from tissues and also acts as a cofactor for lecithin 
cholesterol acyl transferase (LCAT), which is responsible 
for virtually all plasma cholesterol esterification (Soutar 
et al., 1975). APOAl is synthesized in the liver and 
intestine as a 267 amino acid residue preproapoAl (Zannis 
et al., 1983). Cotranslational and post-translational 
cleavage of an 18 residue pre-peptide and a six residue 
pro-peptide results in a 243 residue mature apoAl peptide. 
The gene for APOAl clusters with APOCJ and APOA4 on 
chromosome 11. It is approximately 2.0kb in length and 
contains three intrans (Law et al., 1984; Karathanasis, 
1985). The DNA sequence contains tandemly repeated 66bp 
regions (codons 99-230) which are thought to have arisen by 
gene duplication (Karathanasis et al., 1983a). Exon 3 of 
the gene contains a block of 33bp which is homologous to a 
similarly positioned block of APOC2 (Luo et al., 1986). 
Table 1.1 Composition and properties of the human plasma lipoproteins. Modified 
after Zannis and Breslow, 1984, Table I, and Galton, 1985, Table 6.1. 
Properties 
Density 
Electrophoretic 
mobility 
Proteins(%) 
Apolipoproteinst 
(% total protein) 
APOAl 
APOA2§ -
APOA4 
APOB 
APOCl 
APOC2 
APOC3 
APOD 
APOE 
Lipid composition 
Triglyceride 
Cholesterol 
Phospholipid 
Chylomicrons 
<0.95 
. . 
origin 
1-2 
7 
4 
maJor 
23 
15 
15 
36 
present 
. 
minor 
( % ) 
85 
6 
9 
VLDL 
0.95-1.006 
pre-beta 
6-10 
minor 
. 
minor 
trace 
37 
5-10 
5-10 
40 
minor 
13 
55 
17 
28 
LDL 
1.006-1.063 
beta 
18-22 
trace 
trace 
98 
trace 
trace 
trace 
trace 
minor 
7 
50 
43 
t major> 5%, minor< 5%. 
§ also present in lipoprotein free fraction of plasma. 
HDL 
1.063-1.21 
alpha 
45-55 
67 
20 
. 
minor 
. 
minor 
1-3 
1-3 
3-5 
1-5 
present 
5 
35 
60 
~ 
Table 1.2 Properties of the major human apolipoproteins. Modified after Zannis and Breslow, 1984, 
Table III, and Galton, 1985, Table 6.2. 
Apolipo- Molecular 
proteins weight (kD) 
APOAl 28.3 
APOA2 17.0 
APOA4 46.0 
APOB-100 549.0 
APOB-48 246.0 
APOCl 6.3 
APOC2 8.8 
APOC3 8.8 
APOD 33.0 
APOE 33.0 
Plasma 
cone. (mg /ml) 
1.00-1.20 
0.30-0.50 
0.16 
0.70-1.00 
0.04-0.06 
0.03-0.05 
0.12-0.14 
0.06-0.07 
0.03-0.05 
Isoelectric 
point 
5.85-5.40 
5.00 
5.45 
7.5 
4.9 
4.7-5.0 
5.0-5.2 
5.7-6.0 
Site of 
synthesis 
Intestine/liver 
Intestine/liver 
Intestine 
Liver 
Intestine 
Liver/intestine 
Liver/intestine 
Liver/intestine 
Widespread 
Widespread · 
Function 
Activates LCAT 
Activates LPL 
Inhibits LCAT 
Activates LCAT 
Modulates LPL 
Binds to LDLR 
Triglyceride 
transportt 
Activates LCAT 
Activates LPL 
Inhibits LCAT 
Inhibits LPL, LCAT 
and hepatic lipase 
Activates LCAT 
Binds to LDLR and 
chylomicron rem-
nant receptor 
Activates LCAT 
t APOB is also essential for the assembly and secretion of VLDL and chylomicrons. 
Ul 
Table 1.3 Molecular properties of the major apolipoproteins. Modified after Luo et al., 1986, 
Table 1. 
Length (codons) of 
coding region 
Locations of 
intrans§ 
Apolipo- Chromosomal Signal Pro- Mature Total Intron 1 Intron 2 
proteins locationt peptide segment peptide (no.bp) (no.bp) 
Al 
A2 
A4 
B-100 
B-48 
Cl 
C2 
CJ 
D 
E 
llq23-qter 
lq21-q23 
llq23-qter 
2p24-p23 
18 
18 
19q12-ql3.2 26 
19ql2-ql3.2 22 
llq23-qter 20 
3pl4.2-qter 
19ql2-ql3.2 18 
6 
5 
0 
0 
0 
0 
243 
77 
57 
79 
79 
169 
299 
267 
100 
393 
83 
101 
99 
317 
-20 
(197) 
-24 
(169-82) 
(357) 
(138) 
-13 
(2386) 
-13 
(600) 
-23 
( 7 00) 
-4 
(185) 
-1 
(293) 
(77) 
(1190) 
-4 
(167) 
-2 
( 12 5) 
-4 
(1100) 
t Frezal and Klinger, 1987. § Intron 1, upstream from AUG preceding nucleotide number cited. 
Intron 3 
(no.bp) 
+49 
(588) 
+44 
( 395) 
(none) 
(2630) 
+50 
(296) 
+40 
(1800) 
+61 
(600) 
66bp Notes 
repeats 
present homology with 
APOC2 
present 
present 
dimer in human 
plasma 
glycoprotein 
glycoprotein 
homology with 
present APOAl 
glycoprotein 
present 
glycoprotein 
homology with 
globulins 
present glycoprotein 
°' 
Intron 2, between first and second positions of codon number cited. 
Intron 3, between second and third positions of codon number cited. 
The first codon after the signal peptide cleavage site is taken as codon no. +1. 
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1.2.2 Apolipoprotein A2 
Apolipoprotein A2 is the second most abundant component of 
HDL particles (20%), can displace APOAl from HDL and has a 
role in the activation of hepatic lipase and in the 
inhibition of LCAT (Soutar et al., 1975; Jahn et al., 
1983). APOA2 is located on chromosome 1 (Knott et al., 
1984a). The protein is synthesized in the liver and to a 
lesser extent the intestine as a 100 residue preproapoA2. 
The signal peptide consists of 18 amino acids and the 
propeptide of 5 amino acids (Tsao et al., 1985). The mature 
protein is some 77 amino acids long and exists as a dimer 
in human plasma, linked by a disulphide bond at position 6 
(Brewer et al., 1972). The APOA2 gene contains three 
intrans in positions similar to those of APOAl (Breslow, 
1988). 
1.2.3 Apolipoprotein A4 
Apolipoprotein A4 is a minor component of HDL and a major 
component of chylomicrons. It is also found in the 
lipoprotein free fraction of plasma. Indirect evidence 
points to a role for APOA4 in the biogenesis and/or 
secretion of intestinal triglyceride rich lipoproteins 
(Lackner et al., 1985). 
APOA4 is located on chromosome 11 some 12 kb 3' to the 
APOAl gene. Sequencing has revealed that APOA4 contains the 
22mer periodicity already known to be present in APOAl. 
These repeats, common to a APOAl, APOA4 and APOE, give the 
proteins the potential to form amphipathic helices. It may 
be these structures in particular which are responsible for 
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the lipid binding potential of these apolipoproteins 
(Zannis and Breslow, 1984). The APOE*4 gene has three exons 
of 162, 127 and 1180 bp, but lacks an intron commonly found 
in other apolipoprotein genes in the 5' untranslated region 
(Elshourbagy et al., 1986, 1987). 
1.2.4 Apolipoprotein B 
In addition to being the principal constituent of LDL 
apolipoprotein Bis also a major component of chylomicrons 
and VLDL. Virtually all of the 18-22% protein of LDL is 
apolipoprotein B (Herbert et al., 1983). Apolipoprotein B 
is a glycoprotein with two forms, B-48 and B-100, derived 
from the intestine and liver respectively (Kane et al., 
1980). APOB-48 appears to correspond to the N-terminal 48% 
of APOB-100 (Olofsson et al., 1987). Apolipoprotein Bis 
the major protein determinant for the cellular recognition 
and catabolism of LDL by the LDL receptor. The specific 
lipid binding properties of APOB may be attributable to the 
presence of repeated amphipathic helical regions and of 
hydrophobic praline-rich domains (de Loof et al., 1987). 
Apolipoprotein Bis also essential for the assembly and 
secretion of VLDL and chylomicrons (Goldstein and Brown, 
1983) . 
The gene for APOB maps to chromosome 2 (Knott et al., 
1986), is 43kb long and contains 28 intrans (Blackhart et 
al., 1986). The protein itself is some 4563 amino acids 
long and contains a 27 amino acid signal peptide (Knott et 
al. , 19 8 6) . 
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1.2.s Apolipoprotein Cl 
Apolipoprotein Cl is a maJor constituent of VLDL, and i s 
present in all other lipoprotein classes (Herbert et al., 
1983). The APOCl protein acts as an activator for LCAT, but 
not as efficiently as apolipoprotein Al (Soutar et al., 
1975). The 249bp translated portion of APOCl is accounted 
for by a 57 amino acid mature peptide and a 26 amino acid 
prepeptide (Shulman et al., 1975). 
APOCl is located within cluster of apolipoprotein genes on 
chromosome 19 along with APOC2, APOE and APOClPl (an APOCl 
psuedogene). APOCl has been localized 4.3kb 3' to the APOE 
gene and contains three intrans (Lusis et al., 1986; Smit 
et al . , 19 8 8) . 
1.2.6 Apolipoprotein C2 
Apolipoprotein C2 is a component of VLDL and chylomicrons 
and has cofactor activity with lipoprotein lipase, the 
enzyme responsible for the hydrolysis of plasma 
triglycerides (Herbert et al., 1983). The mature peptide o f 
79 amino acids is produced after cotranslational cleavage 
of a 22 amino acid signal peptide. The genomic structure o f 
APOC2 has been determined (Wei et al., 1985) and is similar 
to that of APOAl with three intrans in similar positions. 
As already mentioned APOC2 is a member of the chromosome 19 
cluster and contains, within exon 3, a 33bp homology with 
APOAl. 
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1.2.7 Apolipoprotein C3 
Apolipoprotein CJ is a major constituent of VLDL and is 
synthesized in the liver as a glycoprotein (Herbert et al., 
1983). It has been shown to inhibit both lipoprotein and 
hepatic lipase (Quarfordt et al., 1982). Cotranslational 
cleavage of a 20 amino acid preapoCJ peptide yields a 
mature protein of 79 amino acids (Brewer et al., 1974). The 
protein is present in the plasma as three isoforms, each of 
which contains a different amount of linked carbohydrate. 
Apolipoprotein CJ is 3kb in length, and again shows three 
intrans, a feature common to a number of the 
apolipoproteins. Intron 1 (600bp) is in the untranslated 
region, intron 2 (125bp) interrupts the prepeptide, and 
intron 3 (1.8kb) interrupts the mature protein 
(Karathanasis, 1985). The gene also carries internal 
repeats with structural resemblances to APOA2 (Luo et al., 
1986). 
1.2.a Apolipoprotein D 
Apolipoprotein D, originally designated APOA3 (Kastner, 
1974), is located on chromosome 3 and produces a 
glycoprotein as a constituent of HDL (Fielding and 
Fielding, 1980; Albers et al., 1981). The 169bp mature 
protein shows no marked similarity with other 
apolipoproteins (hence the change in nomenclature) but 
rather has homology with genes of the a-globulin 
superfamily. Apolipoprotein D mRNA has been detected in 
human liver, intestine, spleen and fetal brain tissue - a 
pattern of synthesis dissimilar to most other 
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apolipoproteins, where synthesis is restricted to the liver 
and/or intestine (Drayna et al., 1986). 
The APOD gene is comprised of at least five exons, four of 
which have been sequenced. Exon 2 is 157bp long and encodes 
the 5' untranslated sequence, the signal peptide and the 
codons for the first two amino acids. Exons 3 and 4 are 122 
and 89bp long respectively. Exon 5 is 414bp 
. in length and 
encodes nearly half of the mature protein plus all of the 
3' untranslated region of the mRNA (Drayna et al., 1987a). 
Most or all of LCAT is found complexed with APOD suggesting 
that APOD is active in the efflux of cholesterol from the 
peripheral tissues and the transport of cholesteryl esters 
to the liver for catabolism. Its association with lipids 
probably has a different basis than that found in the other 
apolipoproteins (Drayna et al., 1986). 
1.2.9 Apolipoprotein E 
The major concentration of apolipoprotein Eis found in the 
liver, adrenal gland and spleen, although it is synthesized 
in all major organs. Apolipoprotein Eis a constituent of 
all lipoprotein classes and mediates lipoprotein catabolism 
extrahepatically via the LDL (or apoB/E) receptor and 
hepatically by LDLR and the chylomicron remnant receptor 
(Innerarity and Mahley, 1978). The three-dimensional 
structure of the apolipoprotein E protein has recently been 
determined and exhibits a four helix bundle, stabilized by 
a hydrophobic core, that includes leucine zipper type 
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interactions, and by numerous salt bridges (Wilson et al., 
1991). 
The gene for APOE is located within the chromosome 19 
cluster and produces a glycoprotein of 299 amino acids as a 
preapoE. PreapoE is cotranslationally cleaved of its 18 
amino acid prepeptide and secreted into the plasma as a 
sialylated apolipoprotein (Zannis et al., 1984). APOE 
consists of several isoproteins that differ in size and/or 
charge. This is the result of both genetic variation of 
APOE within the population and of post translational 
modification of APOE with carbohydrate chains containing 
sialic acid (Zannis and Breslow, 1981}. 
The gene is 3.7kb in length with three intrans. Intron 1 
(700bp) is in the 5' untranslated region, intron 2 (1.1kb) 
interrupts the prepeptide, and intron 3 (600bp) interrupts 
the mature protein (Rall et al., 1982). The pattern of 66bp 
tandem repeats is present (Das et al., 1985) and striking 
homology exists between these repeats and those of human 
APOAl and rat APOA4. The intron locations are very similar 
to those identified for APOAl, APOA2, APOCl, APOC2 and 
APOCJ and may indicate that each exon codes for a 
functionally distinct region of the protein. The similar 
splicing patterns (Fig 1.1) and homologies between many of 
the apolipoproteins have been cited as evidence in support 
of a common ancestral origin for the apolipoproteins 
(Barker and Dayhoff, 1977; Luo et al., 1986). This super 
gene family does not include the APOB or APOD genes. 
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1.2.10 Other apolipoproteins 
Apolipoprotein F has a molecular weight of 26,000 - 32,000 
and an isoelectric point of 3.75. Along with APOG (MW 
72,000), APOF is a minor component of HDL (Olofsson et al., 
1978). Apolipoprotein Hor ~2-glycoprotein (MW 43,000 -
50,000, 326 amino acids) is present in all lipoprotein 
classes (Polz and Kostner, 1979). APOH binds to 
chylomicrons and acts, with APOC2, in the activation of 
lipoprotein lipase (Nakaya et al., 1980). Three common 
alleles for APOH have been identified in both Caucasoids 
and African Americans, with a fourth allele being observed 
at polymorphic frequencies in African American populations 
only (Kamboh et al., 1988a). 
1.2.11 Low density lipoprotein receptor 
Low density lipoprotein receptors are high affinity 
receptors for LDL and as such internalize LDL by binding 
with apolipoproteins Band E (Brown and Goldstein, 1988). 
The LDLR also binds and internalizes ~-migrating VLDL and 
intermediate density lipoproteins (IDL) (Falus and Romics, 
1988). The receptor is present at some 50-100,000 copies 
per fibroblast cell, with 50-80% of the receptors being 
found clustered in coated pits on the cell surface. 
The LDLR is a glycoprotein with a molecular weight of 
160,000. It contains a signal peptide and five recognised 
domains and is coded for by a 45kb locus at 19pl3.l-pl3.J 
(Lindgren et al., 1985). The gene consists of 18 exons, the 
sequences of which bear strong correlations to the 
structural protein domains (Fig 1.2 and Sudhof et al., 
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1985). The 3' untranslated region has been shown to include 
several Alu repetitive elements (Yamamoto et al., 1984; 
Hobbs et al., 1985). As homology exists with epidermal 
growth factor (EGF), complement component (C9) and plasma 
proteases, the LDLR gene is thought to be a mosaic of 
coding sequences shared with other proteins. In all cases 
the shared sequences are encoded for by discrete exons, 
suggesting that LDLR is a member of at least two supergene 
families (Russell et al., 1986). 
1.2.12 Lipoprotein lipase 
Lipoprotein lipase is responsible for the hydrolysis of 
core triglycerides in VLDL and chylomicrons, and as such 
provides fatty acids for storage in adipose tissue, or for 
oxidation in muscle and other tissues (Garfinkel and 
Schatz, 1987). The enzyme is found on the luminal surface 
of capillary endothelial cells and plays an important role 
in the maturation of lipoproteins. As a result alterations 
in its activity have an effect on both triglyceride and 
cholesterol levels. 
The LPL gene is located at 8p22 and is a member of a gene 
family that includes hepatic lipase and pancreatic lipase 
(Wion et al., 1987). The LPL gene codes for a mature 
protein of 448 amino acids (Wion et al., 1987), and is 
approximately 30kb in length. It is comprised of ten exons, 
the first nine of which range in size from 105 to 276bp, 
with the tenth being 1948bp in length (Deeb and Peng, 1989; 
Kirchgessner et al., 1989). Exon 1 codes for the signal 
peptide, exon 2 for the protein domain that is known to 
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bind to the lipoprotein substrate, and exons 6 and 9 are 
rich in basic amimo acids and are likely to be involved in 
anchoring the enzyme to the capillary endothelium (Deeb and 
Peng, 1989). 
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Figure 1.1 Apolipoprotein mRNA structure. Solid bar= 
protein coding regions; thin lines= lengths of 5' and 3' 
untranslated regions; solid arrowheads= location of 
intrans. The beginning of all protein coding regions are 
aligned. From Breslow, 1988, Fig 6. 
APOA1 +t t 
APOA2 + t t 
APOA4 t t 
APOC1 + t t 
APOC2 +t t 
APOC3 + t t 200bp • • 
APOE +t t 
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Figure 1.2 Low density lipoprotein receptor gene 
organization and exon structural domain relationship. 
Modified after Brown and Goldstein, 1988, Fig 3. 
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1.3 DISEASE ASSOCIATIONS 
1.3.1 Classification of lipoproteinemias 
The diseases of lipid metabolism, the lipoproteinemias, 
have traditionally been separated into two major classes. 
The hypolipoproteinemias are characterized by the absence 
or lowering of a particular lipoprotein class, and the 
hyperlipoproteinemias by circulating lipoprotein 
concentrations which are higher than normal. 
The hypolipoproteinemias, or lipoprotein deficiency states, 
are of two types. The first type affects apolipoprotein B 
containing plasma lipoproteins and has been subdivided into 
abetalipoproteinemia and hypobetalipoproteinemia. 
Homozygotes for these disorders are phenotypically 
indistinguishable and present with fat malabsorption 
resulting from an absence of chylomicrons, VLDL and LDL in 
the plasma. The second type of hypolipoproteinemia is more 
often associated with premature vascular disease and 
involves the HDL particles which contain apolipoprotein A. 
This group is represented by Tangiers disease which is 
characterized by the accumulation of cholesteryl esters as 
a result of a profound HDL deficiency (Herbert et al., 
1983), and by hypoalphalipoproteinemia characterized by 
reduced biosynthesis or accelerated catabolism of HDL 
(Assmann, 1985). 
The hyperlipoproteinemias are a far more common group of 
disorders than the hypolipoproteinemias, and are 
characterized by the accumulation of lipids in the plasma 
(Gurr and James, 1980). These disorders may be monogenic or 
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polygenic in origin or may appear secondary to a systemic 
disease, a pattern of nutrition or lifestyle habit, such as 
excessive alcohol intake (Gal ton, 1985). Five major types 
of hyperlipoproteinemia are distinguished on the basis of 
the patterns of lipoprotein accumulation (Table 1.4). It 
must be stressed that each type is not a homogeneous entity 
from a clinical, genetic or pathophysiological point of 
view. 
Table 1.4 Summary and classification of the hyperlipoproteinemias. Modified after Gurr and James, 
1980, Table 6.2, Herbert et al., 1983, Table 29-5, and Galton, 1985, Table 6.3. 
Type 
I 
Ila 
IIb 
III 
Lipoprotein 
changes 
> chylomicrons 
< HDL, <LDL 
> LDL (normal) 
> LDL (normal) 
> VLDL 
> LDL 
(abnormal 
form=IDL§) 
Raised lipids 
> triglycerides 
> cholesterol 
> cholesterol 
> triglycerides 
> cholesterol 
> triglycerides 
Subtypes and/or 
primary causes 
Lipoprotein lipase 
deficiency, 
APOC2 deficiency 
Familial hyper-
cholesterolemia 
(LDLR defects) 
Familial polygenic 
hypercholesterol-
emia 
Familial combined 
hyperlipoprotein-
emia, Lipoprotein 
lipase deficiency 
defect in chylo-
micron remnant 
removal,often 
associated with 
APOE*2/APOE*2 
t Some or all features present, depending on subtype. 
§ Intermediate density lipoprotein (IDL) particle present. 
Continued overleaf. 
Clinical featurest 
of primary disease 
heptosplenomegaly, 
eruptive xanthomas, 
lipaemia retinalis, 
pancreatitis 
xanthomas, 
corneal arcus, 
premature vascular 
disease 
as for Ila 
extensive vascular 
disease 
May be secondary to: 
systemic lupus 
erythematosis, 
macroglobulinaemias 
excessive saturated 
fatty acid and 
cholesterol intake, 
hypothyroidism, 
nephrotic syndrome 
as for Ila 
diabetes, 
hypothyroidism, 
obesity 
(\.) 
0 
Table 1.4 Cont'd. Summary and classification of the hyperlipoproteinemias. Modified after Gurr and 
James, 1980, Table 6.2, Herbert et al., 1983, Table 29-5, and Galton, 1985, Table 6.3. 
Type 
IV 
V 
Lipoprotein 
changes 
> VLDL 
> chylomicrons 
> VLDL 
Raised lipids 
> triglycerides 
>triglycerides 
(higher than IV) 
Subtypes and/or 
primary causes 
Familial combined 
hyperlipopro-
teinemia, 
Familial hypertri-
glyceridemia, 
Polygenic hyper-
lipoproteinemia 
Lipoprotein lipase 
deficiency 
Familial hypertri-
glyceridemia, 
sometimes assoc-
iated with APOE*4, 
Lipoprotein lipase 
deficiency 
t Some or all features present, depending on subtype. 
§ Often with underlying lipid intolerance. 
Clinical featurest 
of primary disease 
vascular disease 
(expression greatly 
affected by envir-
onmental factors 
e.g. obesity) 
vascular disease, 
heptosplenomegaly 
xanthomas, lipaemia 
retinalis, pancrea-
titis (75% with 
impaired glucose 
tolerance) 
May be secondary to: 
diabetes§ 
exogenous oestrogen 
therapy§ 
excessive alcohol 
intake§ 
renal disease 
hypothyroidism 
as for type IV, 
secondary to many 
diseases and envir-
onmental factors 
N 
f-' 
1.3.2 Lipoprotein gene variation and associations with 
lipoproteinemias 
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No variants or associations with the lipoproteinemias are 
documented for APOA2, APOCl or APOD. A number of variants 
and associations have been found for the remaining 
apolipoproteins and for the LDLR and LPL. These will be 
discussed in the following section. 
1.3.2.1 Apolipoprotein Al 
The estimated prevalence of apolipoprotein Al mutations is 
1:1,000,000. Some variants are associated with severe 
hypolipoproteinemias, whilst others alter APOAl levels but 
do not predispose to heart disease (Assmann, 1985). Two 
variants, APOAl*Milana and APOAl*Marburg, are associated 
with decreases in HDL levels and consequent 
hypoalphalipoproteinemia, and three, APOAl*Geissen, 
APOAl*Marburg and APOAl*Munster 2a are defective in the 
activation of LCAT. The remainder of the APOAl*Munster 
variants (1, 3 and 4) lower serum levels of APOAl by 50% 
but seemingly have no other effect (Breslow, 1985). 
The recent identification of nine new variants and the 
structural analysis of the now twenty known variants has 
revealed that proline to arginine, and praline to histidine 
substitutions are over-represented, and that 
hypervariablilty of the apolipoprotein Al a-helical domain 
may result from the occurrence of CpG dinucleotides in this 
region (von Eckardstein et al., 1990). 
Tangiers disease plasma contains very low levels of 
apolipoprotein Al. However, many studies have failed to 
23 
find any APOAl structural mutation which could be 
responsible for the disease. There has, though, been one 
report of an altered apolipoprotein Al isoform being found 
in Tangiers patients (Bisgaier et al., 1987). 
Complete APOAl (or APOA1-C3) deficiency results in the 
absence of HDL, presence of multiple xanthomas and early 
onset of CHO. In a well documented case the deficiency 
. 
lS 
due to an insertion of a 6.5kb segment (which contains some 
APOC3 DNA) into the 3' end of the 3rd intron of APOAl 
(Karathanasis et al., 1983b). 
1.3.2.2 Apolipoprotein A4 
Seven protein variants, detectable by isoelectric 
focussing, have been described (Kamboh and Ferrell, 1987; 
Sepehrnia et al., 1988a). Neither heterozygosity nor 
homozygosity for minor alleles (APOA4*2 to APOA4*7) show 
association with plasma lipoprotein abnormalities or 
atherosclerosis susceptibility (Breslow, 1985). 
1.3.2.3 Apolipoprotein B 
An unknown recessive defect of APOB has been identified 
which leads to an absence of APOB from HDL and the 
occurrence of either abeta- or hypobeta-lipoproteinemia 
(Assmann, 1985). In contrast the over-production of APOB 
may be involved in familial combined hyperlipoproteinemia 
(Janus, et al., 1980). Some individuals are known to 
produce chylomicrons but have low to absent LDL-
cholesterol. These individuals have been shown to produce 
intestinal APOB-48 but not hepatic APOB-100 (Malloy, et 
al. , 19 81) . 
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A series of five allelic variants called Ag have been 
defined which are closely linked to APOB. One antigenic 
determinant Ag(x) is associated with variation in 
triglyceride and cholesterol levels, but not with an 
increase in atherosclerosis risk (Berg et al., 1986). The 
Lp(a) protein, originally thought to be an antigenic 
determinant, has now been shown to be a distinct protein 
which is bound to APOB by disulphide bonds. Increased 
levels of Lp(a) have been associated with CHO and 
cerebrovascular disease (Murai et al., 1986). 
1.3.2.4 Apolipoprotein C2 
A deficiency of APOC2 is present in a small proportion of 
individuals with type I hyperlipoproteinemia. These 
individuals may initially be diagnosed as having 
lipoprotein lipase deficiency, but it is the absence of 
APOC2, a cofactor for LPL, that is the cause of the 
disorder in these cases (Yamamura, et al., 1979). The 
molecular basis in two of the deficient APOC2 alleles has 
been determined. APOC2*Nijmegen results from a single base 
deletion of G at position 2943, causing a frame shift and 
introducing a premature termination codon (Fojo et al., 
1988a). AG to C substitution within the donor splice site 
of intron 2 has been identified in the APOC2*Hamburg allele 
(Fojo et al., 1988b). Three protein variants of unknown 
effect have also been described (Sepehrnia et al., 1988b). 
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1.3.2.5 Apolipoprotein CJ 
The three isoforms of APOCJ are the result of varying 
amounts of attached neuramic acid. APOCJ*0, APOCJ*l and 
APOC3*2 contain zero, one and two attached residues of 
neuramic acid respectively. Normal individuals have a 
preponderance of APOCJ*0. Type V hyperlipoproteinemics have 
a lowering in the proportion of APOCJ*0, whilst some cases 
of abetalipoproteinemia and one type of 
hypobetalipoproteinemia have been shown to lack the APOCJ*l 
isoprotein altogether (Herbert et al., 1983). The complete 
absence of APOCJ is found very rarely, as in the combined 
APOAl-CJ deficiency already mentioned. 
1.3.2.6 Apolipoprotein E 
Apolipoprotein E has three major alleles that contribute to 
the normal variance of plasma lipoproteins and which are 
determined by the amino acids at residues 112 and 158. The 
APOE*2 allele has a cysteine at both positions, the APOE*J 
allele has a cysteine at position 112 and an arginine at 
position 158, and APOE*4 has an arginine at both positions. 
This APOE polymorphism has a pronounced effect on LDL 
cholesterol, total plasma cholesterol, APOB and APOE 
levels. Moreover, this effect appears to be independent of 
ethnicity. Low serum cholesterol levels and LDL cholesterol 
levels are detected in APOE*2 homozygotes, and high levels 
. in APOE*4 homozygotes (Utermann, 1985). The APOE*2 allele 
is also associated with high levels of plasma triglycerides 
(Assmann et al., 1984; Sing and Davignon, 1985; Ehnholm et 
al., 1986). The APOE polymorphism accounts for 20% of the 
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variability of APOE levels, 12% of the variability of APOB 
levels and 4% of the variability of total-cholesterol 
(Boerwinkle and Utermann, 1988). 
In Type V hyperlipoproteinemia 74% of patients possess at 
least one APOE*4 allele, while in Type III 90% of sufferers 
are APOE*2/APOE*2 homozygotes (Utermann et al., 1979; 
Breslow et al., 1982a). However only 1-2% of people with 
the APOE*2/APOE*2 genotype go on to express the disease. 
Type III hyperlipoproteinemia becomes manifest only when, 
in addition to APOE*2 homozygosity, there is a further 
inborn error of lipid metabolism present or a secondary 
hypolipoproteinemia (Assmann, 1985). The APOE*2 allele is 
significantly more frequent in hypertriglyceridemia, the 
APOE*4 in hypercholesterolemia. However, both alleles are 
found more frequently in mixed hyperlipoproteinemia than in 
normal individuals, with 20% of patients having at least 
one rare allele (Utermann et al., 1984). 
1.3.2.7 Low density lipoprotein receptor 
Familial hypercholesterolemia (FH) is characterized by the 
impaired removal of LOL from blood and results from 
mutations in the low density lipoprotein receptor. 
Heterozygotes occur at a frequency of 1 in 500 in most 
populations, have LDL levels on average two times that of 
normal individuals and are likely to suffer from CHO by the 
age of fifty. Homozygotes have LOL levels up to six times 
the normal levels and develop CHO in the first or second 
decade of life (Brown and Goldstein, 1988). 
The clinical symptoms are the result of four classes of 
mutations of the receptor, each of which has a different 
phenotypic effect on the protein:-
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1) Null alleles. One third of FH homozygotes show no 
detectable LDLR protein and only minimal amounts of 
LDLR mRNA. 
2) Transport deficient alleles. The improper folding of 
the protein results in the accumulation of LDLR in 
the endoplasmic reticulum. 
3) Binding deficient alleles. LDLR reaches cell surface 
but fails to bind LDL. 
4) Internalization defective alleles. A defect in the 
cytoplasmic domain prevents targeting of the LDLR 
to coated pits on the cell surface. 
Sixteen individual mutations had been mapped or sequenced 
and assigned to the four classes by 1986 (Russell et al., 
1986). Although some populations, such as the Afrikaners in 
South Africa and the French Canadians, carry only a few 
LDLR mutations, the mutational heterogeneity at the locus 
has made it difficult to apply DNA techniques for use in 
population screening (Motulsky, 1989). This problem is 
being addressed with the application of the polymerase 
chain reaction and the examination of amplified fragment 
length polymorphisms at the locus (Savolainen et al., 
1991). 
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1.3.2.8 Lipoprotein lipase 
The genetic lesions responsible for a subset of type I 
hyperlipoproteinemia (lipoprotein lipase deficiency) have 
been determined in a number of families. These lesions 
represent a range of molecular events including gene 
duplication (Devlin et al., 1990), point substitution (Emi 
et al., 1990a, 199Gb; Hata et al., 1990a) and insertions 
(Langlois et al., 1989). 
1.3.3 Restriction fragment length polymorphism associations 
of the lipoprotein genes with hyperlipoproteinemia and 
cardiovascular disease 
From the previous section it is apparent that several of 
the hyperlipoproteinemias are associated with quantitative 
and/or qualitative alterations of the lipoprotein genes. 
The genetic mechanisms involved in many of the subtypes of 
hyperlipoproteinemia remain unclear. Associations with the 
hyperlipoproteinemias, and more generally with 
atherosclerosis, have been sought with RFLPs identified by 
the cloned lipoprotein genes. A selected review of this 
work is presented in Table 1.5. 
Most interest has focussed on the APOA1-C3-A4 cluster of 
chromosome 11. At least 11 RFLPs occur at this locus and, 
of these, six have been used in clinical studies 
(Antonarakis et al., 1986). Rees et al. (1985) claimed a 
high frequency (relative incidence=57) of the rare allele 
(S2) for the polymorphic site of SstI in the APOC3 gene in 
hypertriglyceridemics (Types IV and V) when compared with 
controls in Caucasoids from an English population. This 
association has not been found in either Type IIb (Rees et 
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al., 1983) or III (Vella et al., 1985). A large difference 
in S2 allele frequency has also been seen between survivors 
of myocardial infarct (MI) and controls (Ferns et al., 
1985). However the association appears to be population 
specific since no associations have been seen in Scottish 
(Ferns et al., 1986a; Price et al., 1986), Norwegian 
(Kessling et al., 1986), Chinese, African or Indian/Asian 
populations (Rees et al., 1985). 
Table 1.5. Associations of lipoprotein abnormalities and 
atherosclerosis with apolipoprotein gene RFLPs. From 
Breslow, 1988, Table 7. 
Apolipo-
protein 
APOAl 
APOCJ 
(APOAl) 
APOA2 
APOB 
APOC2 
APOE 
Enzyme 
XmnI 
MspI 
PstI 
EcoRI, PstI 
BamHI 
HindIII# 
SacI/SstI 
PvuII 
MspI 
XbaI 
EcoRI 
TaqI 
HpaI 
Associated phenotype 
MI resistance, CAD resistance, 
high APOAl levels, 
HLP types IIb,III, V, high TG levels 
MI, CAD resistance 
Premature CAD, MI (<60yrs), 
MI resistance (>60yrs), 
low HDL levels 
CAD, low HDL levels 
MI, CAD, HLP type V, 
low HDL levels, high TG levels 
CAD 
High APOA2 levels, high TG levels 
MI, low TG and Chol levels, 
Ag(x), Ag(c)/Ag(g) locus 
MI, Ag(t)/Ag(z) locus 
HLP type I (APOC2 deficiency) 
HLP type III 
RFLP, restriction fragment length polymorphous; HDL, high 
density lipoprotein; HLP hyperlipoproteinemia; MI, 
myocardial infarction; CAD, coronary artery disease; TG, 
triglyceride, Chol, cholesterol; Ag(c), Ag(g), Ag(t), Ag(x) 
and Ag(z) are determinants of the Ag allelic system. 
# Detects insertion/deletion. 
In an attempt to clarify the situation additional RFLPs 
around the APOA1-C3-A4 cluster have been investigated to 
enable haplotype analysis. Whilst a PstI RFLP showed no 
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association with hyperlipoproteinemia (Kessling et al., 
1985; Ferns and Galton, 1986a; Hayden et al., 1987) an 
association has been claimed with lowered HDL levels and 
premature coronary artery disease (Anderson et al., 1986; 
Ferns and Galton, 1986a). XmnI (Kessling et al., 1985; 
Hayden et al., 1987) and MspI (Ferns and Galton, 1986a) 
RFLPs in this complex show only weak association with 
hyperlipoproteinemics and MI survivors. A specific 
haplotype of SstI and MspI, Sl-M2 was significantly 
increased in Caucasoid and Japanese MI survivors (Stocks et 
al., 1987). A rare EcoRI allele has been reported to be 
more frequent in patients with clinical symptoms of CHD 
than normal controls (Buraczynska et al., 1986). A J00bp 
deletion of an Alu element 5kb upstream to the APOAl gene 
occurs with a frequency of 0.05 and 0.20 in Germans and 
North American Caucasoids respectively (Frossard et al., 
1986). This deletion is detected by a number of RFLPs and 
is associated with angiographically proven atherosclerosis 
and decreased HDL cholesterol levels (Lim et al., 1986). 
One association between low HDL levels and increased 
triglyceride levels and an MspI RFLP of APOA2 has been 
reported (Deeb et al., 1986). This report supports an 
earlier finding of altered HDL composition in homozygotes 
for the possession of the site (Scott et al., 1985). 
Presence of the APOB XbaI restriction site is reported to 
be associated with a 36% increase of triglycerides in 
normal male Caucasoids (Deeb et al., 1986; Law et al., 
1986), but this has not been verified in a study of MI 
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survivors (Ferns and Gal ton, 1986b). Homozygotes for t h e 
absence of this site have lower levels of APOB, total serum 
cholesterol, triglycerides and LDL-cholesterol (Leren et 
al., 1988). Hegele et al. (1986) examined the EcoRI and 
MspI RFLPs in addition to XbaI and found a significant 
increase of the presence of the sites in Caucasoid MI 
survivors. This finding was not repeated for XbaI in 
Japanese (Aburatani et al., 1987). Finally, Deeb et al. 
(1986) have reported associations between TaqI and PvuII 
sites, increased cholesterol levels, and decreased HDL 
levels. 
A TaqI RFLP of APOC2 appears associated with increased 
cholesterol levels (Deeb et al., 1986) although in a review 
(Breslow, 1988) it is claimed that neither the TaqI RFLP, 
nor a closely linked BglI RFLP, show any association with 
clinical abnormalities. 
The presence of the PvuII site in LDLR has been found to be 
associated with decreased cholesterol, LDL-cholesterol and 
triglyceride levels (Brink et al., 1986; Humphries et al., 
1991). Homozygosity for the presence of a PvuII site in LPL 
has been found to be associated with decreased triglyceride 
levels (Chamberlain et al., 1989). 
Comparisons between studies of this type are often hampered 
by the number of alternate classifications for the disease 
states and the method of selecting the "control" 
individuals. These may be randomly chosen from the general 
population or actively chosen to exclude the disease state. 
Many minor allele frequencies differ greatly among races; 
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controls and patients must be racially matched. In 
addition, the delineation of plasma lipid concentrations 
into normal and hyperlipoproteimemic classes is arbitrary. 
It may be more appropriate to determine the average allelic 
effect on continuous phenotypic variation in plasma 
lipoprotein levels (Boerwinkle and Utermann, 1988) than to 
attempt to establish allelic associations with 
heterogeneous clinical subtypes. 
The above listed difficulties in the planning and 
interpretation of this type of study have led to many 
contradictory and non-repeatable associations being 
presented in the literature. For example associations cited 
in Table 1.5 (from Breslow, 1988) are in part contradicted 
in other reviews (Deeb et al., 1986; Cooper and Clayton, 
1988). A great deal more work is required before there is 
agreement on the extent and effects of RFLP disease 
associations in this field. 
1.3.4 Genetics of non-insulin dependent diabetes mellitus 
Concordance for NIDDM in monozygotic twins approaches 100% 
(Barnett et al., 1981; Kuzuya et al., 1988). Family 
clustering of NIDDM is evident with more than 30% of the 
siblings of individuals with NIDDM having abnormal glucose 
tolerance (Kobberling and Tillil, 1982; O'Rahilly et al., 
1987). It is therefore accepted that NIDDM has a strong 
genetic component. 
Indirect evidence for genetic component in NIDDM is 
provided by admixture studies in North Dakota Amerindians, 
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Nauruans, and Mexican Americans (Brosseau et al., 1979; 
Serjeantson et al., 1983; Chakraborty et al., 1986). These 
studies reveal a decrease in prevalence of NIDDM with 
increasing foreign admixture. Bimodality of glucose 
tolerance distributions among Nauruans and Pima Indians has 
also been interpreted as indirect evidence for the presence 
of a genetic component in the aetiology of NIDDM (Rushforth 
et al., 1971; Zimmet and Whitehouse, 1978). 
A major gene has been implicated in NIDDM in the Nauruan 
population. Only 5% of 20 offspring from non-diabetic 
parents where hyperglycaemic, compared with 79% of 43 
offspring from diabetic parents (Serjeantson and Zimmet, 
1984). Segregation analysis of age adjusted fasting glucose 
and post-load glucose levels favours a dominant autosomal 
mode of inheritance but is also compatible with a 
codominant mode of inheritance (Serjeantson and Zimmet, 
1989). 
Candidate genes that have been examined in relation to 
NIDDM include the insulin gene, the insulin receptor gene, 
the family of glucose transporter genes, lipoprotein genes, 
and the amylin gene. Possible associations between blood 
group markers, HLA, and serum protein markers and NIDDM 
have also been investigated (Serjeantson and Zimmet, 1991). 
The adenosine deaminase locus, recently reported to be in 
linkage with MODY (maturity-onset diabetes of the young) 
(Bell et al., 1991) has not been implicated in NIDDM. Many 
studies have reported associations with NIDDM, with 
subsequent reports refuting these findings. There are as 
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yet no established RFLP markers for NIDDM (Serjeantson and 
Zimmet, 1991). 
1.3.5 Altered lipoprotein metabolism in non-insulin 
dependent diabetes mellitus 
Non-insulin dependent diabetes is accompanied by 
alterations in lipoprotein metabolism (Brunzell et al., 
1985; Howard, 1987; Assmann and Schulte, 1988). LDL 
particles contain approximately 70% of total plasma 
cholesterol and tend to be raised in poorly controlled 
diabetic patients (Betteridge, 1989). As insulin increases 
the number of LDL receptors (Mazzone et al., 1984), chronic 
insulin deficiency might be associated with a diminished 
number of LDL receptors which would result in a decrease in 
the clearance of LDL. In addition, glucosylation of lysine 
residues on the LDL apolipoprotein B occurs in diabetic 
patients at three to four times the rate seen in normal 
individuals (Curtiss and Witztum, 1983, 1985). It has not 
been established whether this amount of glucosylation 
affects LDL binding (Steinbrecher and Witztum, 1984; 
Schleicher et al., 1985). NIDDM LDL has been found to be 
enriched with triglycerides (Schonfeld et al., 1974) and 
LDL from patients with NIDDM and hypertriglyceridemia has 
shown reduced binding to cultured skin fibroblasts 
(Hiramatsu et al., 1985). 
High density lipoprotein metabolism is also altered in 
NIDDM. HDL cholesterol concentrations tend to be low in 
NIDDM patients (Nikkila, 1978), and there is a stronger 
association of HDL with vascular disease in NIDDM patients 
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(Reckless et al., 1978). These alterations may be the 
result of a decrease in the rate transfer of surface 
triglycerides to HDL, brought about by the lowering of 
lipoprotein lipase activity in the presence of insulin 
deficiency (Nikkila and Hormila, 1978). Other factors must 
also influence HDL metabolism in NIDDM as HDL levels often 
remain low even after hypertriglyceridemia and 
hyperglycaemia have been corrected (Betteridge, 1989). 
The production of VLDL is increased in NIDDM (Abrams et 
al., 1982). It is possible that hyperinsulinemia associated 
with insulin resistance stimulates VLDL production. 
Alternatively, it is proposed that it is insulin deficiency 
at the cellular level that leads to the over-production of 
VLDL (Gibbons, 1986). 
Changes in lipid and lipoprotein levels in NIDDM patients 
can be moderated by improving glycaemic control. However, 
in patients with moderate to poor glycaemic control, and 
associated obesity, HDL levels will often be low and 
triglyceride, and possibly cholesterol levels, will be high 
(Betteridge, 1989). 
1.3.6 Restriction fragment length polymorphism associations 
of the lipoprotein genes with non-insulin dependent 
diabetes mellitus 
A relatively small number of studies have been undertaken 
examining lipoprotein RFLPs in NIDDM. The SstI RFLP of 
APOA1-C3 revealed no differences in frequency between NIDDM 
and normal Caucasoids (Jowett et al., 1984). In contrast, 
Trembath (1987) has found an association between the S2 
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allele in NIDDM subjects with concurrent cardiac heart 
disease versus normals (no ethnicity cited). An earlier 
study by Buraczynska et al. (1985), of a 2.5kb EcoRI 
fragment in the APOAl region, revealed no association with 
atherosclerosis, but did show an association with NIDDM. 
Xiang et al. (1989) have investigated RFLPs at the APOA2, 
APOB and APOA1/C3/A4 locus and report a significant 
association with NIDDM of the APOB Xbal RFLP in individuals 
of lean/normal weight. Significant differences in the 
distribution of MspI/PstI/SstI haplotypes at the 
APOA1/C3/A4 locus are also reported between overweight 
diabetic and non-diabetic groups. Most of this difference 
is observed with the MspI RFLP. 
An increased frequency of APOE*2 homozygotes among NIDDM 
patients has been observed by Vogelberg and Maucy (1988). 
The APOE*2 and APOE*4 alleles have also been reported to be 
more frequent in diabetics with hyperlipoproteinemia 
(Parhofer et al., 1990). 
1.4 STUDY POPULATION - THE WESTERN PACIFIC REPUBLIC OF 
NAURU 
The island of the Republic of Nauru is situated in the 
Central Pacific just south of the equator, at longitude 
160°55' east and latitude 0°32'. The island is 
approximately 20 miles in circumference with an area of 
6263 acres and is positioned at the intersection of the 
three Pacific ethnic regions of Melanesia, Micronesia and 
Polynesia (Figure 1.3) (Zimmet et al., 1977). There is an 
indigenous population of Micronesian ancestry of 
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approximately 5500 persons. Extensive mining of phosphate 
deposits on the island has resulted in Nauru having one of 
the highest per capita incomes in the world and the 
lifestyle of the Nauruans has consequently changed, 
resulting in obesity and reduced physical activity and a 
diet of imported processed Western food, (Zimmet et al., 
1990). 
Diabetes prevalence was found to be extremely high in the 
adult Nauruan population; in a population based study the 
prevalence in over 20 year olds was 30.3% (Zimmet et al., 
1977), some 13 times higher than in the Australian 
population (Welborn et al., 1968). This high prevalence of 
diabetes, which was exclusively of the non-insulin 
dependent type, has only been exceeded in the American Pima 
Indians (Knowler et al., 1978). Diabetic prevalence was 
rare in the first half of the century, with mortality rates 
due to diabetes showing an exponential increase since the 
1950s (Schooneveldt et al., 1988). This high prevalence of 
NIDDM has been confirmed in a larger study and the annual 
incidence estimated to be 1.6% (Zimmet et al., 1984; Balkau 
et al., 1985). Age standardized prevalence of NIDDM has 
remained constant (24.0% in 1987), but the incidence of 
impaired glucose tolerance has decreased from 21.1% in 
1975/1976 to 8.7% in 1987 (Dowse et al., 1991). 
An analysis of the risk factors for NIDDM in this 
population has been undertaken (Balkau et al., 1985). The 
2hr post glucose load plasma glucose level was found to be 
the strongest determinant of diabetes in both sexes. In 
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females obesity, 2hr plasma insulin, fasting plasma glucos e 
and uric acid were also found to be predictors for 
diabetes. Among males the predictors were age and plasma 
triglyceride levels, with obesity having marginal 
significance. 
There is evidence for a heightened susceptibility to NIDDM 
in the Nauruan population. Foreign admixture lowers the 
occurrence of NIDDM (Serjeantson et al., 1983). Bimodality 
exists in plasma glucose distributions (Zimmet and 
Whitehouse, 1978) and the prevalence of NIDDM in Nauru, 
after adjustment for age and obesity, is three times higher 
than that seen in a neighbouring Micronesian population 
(King et al., 1984). 
In addition the population exhibits a high rate of obesity , 
which has long been considered a risk factor for NIDDM (WHO 
Expert Committee, 1980). Body mass index has been shown to 
be a predictor of NIDDM in Nauruans and Japanese (Kadowaki 
et al., 1984; Sicree et al., 1987) although this is not the 
case for the Pima Indians (Saad et al., 1988). The 
influence of obesity on the occurrence of NIDDM remains 
undefined, and it is now suggested that the duration of 
obesity, and the degree of central adiposity, may be more 
important factors in determining the predisposition of an 
individual to diabetes (Modan et al., 1986; Zimmet et al., 
1990). 
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Figure 1.3 Map of the Pacific region illustrating maJor 
geographical and ethnic divisions. The island of Nauru is 
situated close to the intersection of Micronesia, Melanesia 
and Polynesia. From Zimmet et al., 1990 , Figure 1. 
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1.5 CONCLUSIONS 
Whilst many studies have investigated the role of the 
apolipoproteins, lipoprotein lipase and the low density 
lipoprotein receptor with respect to rare lipid disorders, 
sometimes producing definite correlations with disease 
states, many of the associations claimed for the more 
common mixed and familial hyperlipoproteinemias, or for 
raised lipoprotein levels in general, are yet to be 
conclusively proven. The work on lipoprotein RFLPs in the 
study of NIDDM is in its infancy and presents added 
difficulties to those mentioned above for association with 
atherosclerosis. This is due in part to the heterogeneous 
nature of NIDDM itself and to the occurrence of 
lipoproteinemias and obesity in association with diabetes. 
The Micronesian population of Nauru represent a group in 
which the influence of the lipoprotein genes on 
hyperlipoproteinemia, obesity and non-insulin diabetes 
mellitus can be examined. A high prevalence of NIDDM and 
obesity occurring against a relatively homogeneous ethnic 
and environmental background provides an opportunity to 
investigate the relative contribution of the lipoprotein 
genes to these multifactorial disorders. 
1.6 AIMS 
The aim of this study is to explore the influence of 
lipoprotein gene variation on non-insulin dependent 
diabetes mellitus, hyperlipoproteinemia and obesity in the 
Micronesian population of Nauru. The degree of variability 
of a number of lipoprotein gene fragment length 
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polymorphisms will be established and compared with that 
seen in other ethnic groups. The suitability of these genes 
as candidate genes for non-insulin dependent diabetes 
mellitus and hyperlipoproteinemia will be investigated. The 
effect of the variability present at these loci on diabetic 
status, plasma cholesterol and plasma triglyceride levels, 
and on measures of obesity, will be determined in both 
univariate and multivariate analyses. Linkage studies will 
be undertaken to examine the possibility of linkage between 
the lipoprotein loci and non-insulin dependent diabetes 
rnellitus or hyperlipoproteinernia in the Micronesian 
population. 
SECTION 2 
MATERIALS AND METHODS 
2.1 THE WESTERN PACIFIC REPUBLIC OF NAURU 1982 AND 1987 
SURVEYS 
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In January of 1982 83% (n=l583) of adult Micronesians over 
the age 20yrs took part in a comprehensive baseline 
cardiovascular and diabetic survey on the Western Pacific 
Republic of Nauru (Zimmet et al., 1984). In February 1987 
all subjects were invited to participate in a follow-up 
survey and a sample of n=ll84 (72.7% of the eligible 
sample) was obtained (Collins et al., 1989). These surveys 
were undertaken by the World Health Organization 
Collaborating Centre for the Epidemiology of Diabetes 
Mellitus, Royal Southern Memorial Hospital, Melbourne. 
survey data were collected with the co-operation and 
assistance of the Department of Health, Nauru, and the 
people of Nauru. Blood samples and survey data were made 
available to the Human Genetics Group, John Curtin School 
of Medical Research, Canberra, as part of a collaborative 
research project with the World Health Organization 
Collaborating Centre for the Epidemiology of Diabetes 
Mellitus. 
2.1.1 Pedigree data 
Participants in the 1982 survey provided the names of their 
parents allowing pedigrees for the populations to be 
constructed. Prospective pedigrees were subsequently 
checked by Nauruan informants. All two parent pedigrees 
were checked for veracity with genetic markers (Serjeantson 
and Zimmet, 1984). 
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2.1.2 Diabetic status 
Plasma glucose concentrations were measured in both surv e ys 
following an overnight fast and again two hours after an 
oral 75g glucose load. Plasma glucose levels were measured 
on site with a glucose analyser (YSI, Yellow Springs, OH, 
USA) which uses a glucose oxidative method. Diabetic status 
was ascertained based on World Health Organization (WHO) 
recommendations (WHO Expert Committee, 1980; WHO Study 
Group, 1982) and following the criteria of the National 
Diabetes Data Group (1979). All subjects with a previous 
classification of diabetes mellitus were classified as 
such. A 2hr plasma glucose reading of ~11.1 mM, or if no 
2hr reading was available, a fasting glucose level of 
~7.8mM led to a diagnosis of diabetes mellitus. Impaired 
glucose tolerance was indicated by a 2hr glucose level of 
~7.8 mM and <11.1 mM. Subjects with fasting and 2hr glucose 
levels below 7.8mM were classified as having normal glucose 
tolerance. 
2.1.3 Morphometric data and lipid levels 
Body mass index was calculated in both surveys as weight 
over height squared (kg/m2). Waist and hip measurements 
were collected at the 1987 survey only and a waist/hip 
ratio was calculated for each individual. Fasting plasma 
cholesterol and triglyceride levels were obtained in both 
surveys using a SMAC autoanalyser (Technicon, Tarrytown, 
NY, USA) (Zimmet et al., 1984; Collins et al., 1989). 
2.2 REAGENTS AND LABORATORY MATERIALS 
2.2.1 Reagents 
The following list itemizes reagents of particular 
importance and the associated company of supply:-
[a-32PJdATP (3000 mCi/mM); Amersham, Amersham, UK 
acrylamide; Sigma Chemical Co., St Louis, MO, USA 
agar; Difeo Laboratories, Detroit, MI, USA 
agarose; Type II, Sigma 
ampicillin; Sigma 
bacto-tryptone; Difeo Laboratories 
bacto-yeast extract; Difeo Laboratories 
44 
black and white instant film (T55, T57); Polaroid Co., 
Cambridge, MA, USA 
chloramphenicol; Sigma 
dextran sulfate; Pharmacia, Uppsala, Sweden 
ethidium bromide; Sigma 
Nick translation kit (Code N.5500); Amersham 
N,N'-methylene-bis-acrylamide; Bio-Rad Laboratories, 
Richmond, CA, USA 
N,N,N' ,N' tetramethylethylene diamine (TEMED); Sigma 
nylon hybridization membranes:- GeneScreen Plus; Du 
Pont, Boston, MA, USA or BioTrace HP; Gelmen 
Sciences, Ann Arbor, MI, USA 
Multiprime DNA labelling system (Code RPN.1600Z); 
Amersham 
salmon sperm DNA; Sigma 
sodium dodecyl sulphate (SOS):- ultrapure for DNA 
extractions; BDH Chemicals, Poole, England or low 
grade for washing solutions; Sigma 
tetracycline; Sigma 
X-ray film (Fuji-RX and Fuji-NC) ;Fuji Photo Film Co., 
Tokyo, Japan 
All other standard laboratory reagents were purchased from 
Sigma, BDH or Ajax Chemicals, Auburn, Australia and were of 
A grade or analytical quality. 
2.2.2 Enzymes 
The following restriction endonucleases were used:-
1) BamHI; Pharmacia 
2) CfoI; Promega, Madison, WI, USA 
3) DraI; New England Biolabs, Beverly, MA, USA 
4) MspI; Boehringer, Mannheim, West Germany 
5) TaqI; New England Biolabs, Promega 
6) PstI; Pharmacia 
7) PvuII; Pharmacia 
8) SalI; Boehringer 
9) XbaI; Pharmacia 
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other enzymes used in the preparation of genomic DNA and in 
the radioactive labelling of plasmid DNA were as follows;-
1) Proteinase K; Sigma (12.2 U/mg) or Applied 
Biosystems (130U/ml) 
2) Escherichia coli DNA polymerase I (0.5U/µl); 
Amersham 
3) E. coli 'Klenow' fragment of DNA polymerase I 
(1.0U/µl); Amersham 
4) Thermus aquaticus (Taq) DNA polymerase; Perkin Elmer 
Cetus (5U/µl), Norwalk, CT, USA or Promega 
(4.5U/µl) 
2.2.3 Bacterial growth media 
E.coli strains were grown in either LB (Luria-Bertani) 
medium (per litre): bacto-tryptone l0g; bacto-yeast extract 
5g; NaCl l0g; pH 7.5 (Maniatis et al., 1982) or TB 
(Terrific Broth) medium (per litre): 900ml containing 4ml 
glycerol; 12g bacto-tryptone; 24g bacto-yeast extract; 
100ml of 0.17M KH2P0 4 and 0.72M K2HPO4 (Tartof and Hobbs, 
1987). 
2.2.4 Bacterial strains and plasmids 
The majority of plasmids used in the preparation of cDNA 
probes were supplied by the American Type Culture 
Collection. These included pAI-113 (Apolipoprotein Al; 
APOAl) in pKT218 (Breslow et al., 1982b); pAII-E9 
(Apolipoprotein A2; APOA2) in pKT218 (Knott et al., 1984a; 
Knott et al., 1984b); pUCI-A4 (Apolipoprotein Cl; APOCl) 
(Knott et al., 1984a; Knott et al., 1984c); pCII-711 
(Apolipoprotein C2; APOC2) in pKT218 (Jackson et al., 1984) 
and pLDLR3 (Low Density Lipoprotein Receptor; LDLR) in 
pcDVl (Yamamoto et al., 1984; Hobbs et al., 1985; Hobbs et 
al., 1987). 
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pAPOD.6 (Apolipoprotein D; APOD) in pUC18 was the gift of 
Dr D. Drayna, Genentech, CA, USA (Drayna et al., 1986; 
Drayna et al., 1987b). LPL35 (Lipoprotein Lipase; LPL) was 
the gift of Dr M. C. Schatz, Lipid Research, UCLA, CA, USA 
(Wion et al., 1987). 
pB8 and pB24 (Apolipoprotein B; APOB; ATCC; Huang et al., 
1985) and Probes IV and V (Apolipoprotein; APOA4; a gift 
from Dr. S.K. Karathanasis; Karathanasis, 1985) were used 
in preliminary testing on Nauruan samples. A decision was 
made to limit the number of lipoprotein genes investigated 
to eight, and these probes were not used in further 
experiments. 
2.3 BLOOD SAMPLES 
2.3.1 Micronesian samples 
Peripheral blood samples from patients with NIDDM, 
individuals with impaired glucose tolerance and individuals 
with normal glucose tolerance were collected during the 
1982 and 1987 Nauru Island Surveys (Zimmet et al., 1984; 
Collins et al., 1989; refer Section 2.1 for Survey 
details). The blood samples collected in the 1982 survey 
were centrifuged and separated into plasma, buffy coat and 
packed red cells. These samples were frozen and transported 
to the Lions-International Diabetes Institute and/or the 
John Curtin School of Medical Research, where they were 
stored in liquid nitrogen until required. Blood samples 
from the 1987 survey were centrifuged and the plasma 
separated from the red cells and buffy coat. Approximately 
4-6ml of the mixed red blood cells and buffy coats were 
transported frozen to the John Curtin School of Medical 
Research and stored at -20°c until required. 
2.3.2 Caucasoid control samples 
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Peripheral blood was collected from healthy laboratory 
staff, centrifuged and the buffy coats removed. Buffy coat 
samples were either used immediately for DNA extraction or 
stored at -20°c until required. 
2.4 LABORATORY METHODS 
2.4.1 Routine laboratory procedures 
All solutions and plastic disposable labware requiring 
sterilization were autoclaved at 121°C/l00kPa for 15min. 
Glassware was baked at 180°C for at least four hours. Heat 
labile compounds, such as antibiotics (ampicillin, 
tetraclycline and chloamphenicol) 2-mercapto-ethanol and 
2-dimethyl sulphate were added to solutions after 
autoclaving. Distilled and deionized water (ddH20) was used 
for all solutions. 
Nucleic acids were purified by successive extractions with 
equal volumes of phenol (saturated with TE buffer: l0mM 
Tris-HCl; lmM EDTA; pH 8.0) followed by equal volumes of 
phenol/chloroform/isoamyl alcohol (25:24:1) followed by 
equal volumes of chloroform/isoamyl alcohol (24:1) 
(modified after Maniatis et al., 1982). Ethanol 
precipitations were carried out with the addition of 0.1 
volumes of SM NaCl or 3M NaOAc and 2 volumes of absolute 
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alcohol and incubation at -20°C overnight or with the 
addition of 0.5 volumes of 7.5M NH4OAc and 2.5 volumes of 
absolute ethanol and immediate precipitation (Crouse and 
Amorese, 1987). DNA concentrations and purities were 
quantified by measuring the optical density of solutions at 
260nm and 280nm (1 OD 260 unit = 50µg/ml for double stranded 
DNA and 33µg/ml for single stranded DNA; estimates of 
purity given by 1.8~OD260 /OD280~2.0) (Maniatis et al., 1982). 
2.4.2 Biological containment and radiation safety 
All recombinant DNA techniques were performed under Cl 
biological containment conditions and according to the 
Australian Recombinant DNA Monitoring Committee. 
Radioactive procedures were performed, and wastes disposed 
of, under standards set by the Australian National 
University Radiation Safety Handbook. 
2.4.3 Genomic DNA extraction 
Genomic DNA was extracted manually from frozen pure buffy 
coats (1982 samples) and mixed red blood cells and huffy 
coats (1987 samples) following the method of Grunebaum et 
al. (1984). The 1982 huffy coat samples were thawed for 
four hours on ice (or overnight at 4°C}, washed three times 
with T20E5 (20mM Tris-HCl; 5mM EDTA; pH 7.5) and incubated 
at 3 7 ° C overnight in 4ml T20E5 in the presence of 2 00µl 10% 
ultrapure SOS and 400µ1 Proteinase K (lmg/ml). Phenol 
extraction and ethanol precipitation methods have been 
described elsewhere (Section 2.4.1). 
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Mixed red blood cell and buffy coat samples collected in 
the 1987 survey were persistently difficult to extract due 
primarily to the high proportion of red blood cells 
present. As many as eight initial T20E5 washes were required 
and the amount of Proteinase Kin the overnight incubation 
was at times increased twofold. The most intractable 
samples required up to three phenol, three 
phenol/chloroform/isoamyl alcohol and three 
chloroform/isoamyl alcohol extractions. As a consequence 
yields were sometimes poor. 
The Applied Biosytems 340A Nucleic Acid Extractor was used 
to extract DNA from approximately half of the 1987 survey 
samples. The Standard Buffy Coat Protocol for 30ml vessels 
was used with the following modifications implemented to 
overcome problems caused by the high proportion of red 
cells:-
1) Half the recommended original sample volume was used 
2) Samples were washed five times (instead of twice) in 
T20 E5 before application to the extractor 
3) An additional phenol extraction stage was added to 
the protocol 
Buffy coat samples from Caucasoid controls were extracted 
using the standard procedures described for the 1982 
Micronesian samples. 
All DNA extracted on the automated extractor was 
resuspended from precipitate papers in an original volume 
of 300µ1 TE with overnight incubation at 55°C. All samples 
extracted by hand were resuspended in volumes of 50-200µ1 
TE with overnight incubation at 4°C. All samples were 
finally suspended at concentrations of 0.3-2.0µg / µl and 
stored in sealed eppendorf tubes at 4°C. 
2.4.4 Polymerase chain reaction amplification 
Genomic DNA was amplified by polymerase chain reaction 
(Saiki et al., 1985) in an Innovonics Gene Machine 
(Victoria, Australia) thermocycler. A 234bp fragment of 
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APOE exon 4 was amplified using two primers of 22 and 20 bp 
respectively. The sequence for primer one (designated APOE3 
5' -GGC ACG GCT GTC CAA GGA GC- 3') was taken from primer 
PCRE2 of Weisgraber et al. (1988) and for primer two 
(designated SSl0 5' -TCG CGG GCC CCG GCC TGG TAC A- 3') was 
modified after primer F4 of Emi et al. (1988). 
The protocol set out by Hixson and Vernier (1990) was 
followed with some modifications. A 100µ1 reaction 
contained 1.0 µg of genomic DNA, 7.5ng/µl of each primer, 
10% dimethyl sulphate (DMSO), 2.5U Tag DNA polymerase, 0.2M 
of each dNTP and either Cetus Recommended Buffer (CRB:-
50mM KCl; l0mM Tris-HCl, pH 8.3; 1.5mM MgC1 2 ; 0.01% (w/v) 
gelatin) or Promega supplied Taq DNA polymerase buffer (as 
for CRB with 0.1% Triton X-100 and Tris-HCl at pH 9.0). The 
inclusion of DMSO in the reaction mix was crucial for 
amplification of the Ge-rich APOE exon 4. Each reaction mix 
was overlaid with 75µ1 mineral oil to prevent evaporation 
and subjected to an initial denaturation of 5min at 95°C, 
followed by 30 cycles of amplification by primer annealing 
at 60°C for lmin, extension at 70°C for lmin and 
denaturation at 95°C for 2min. The protocol was further 
modified in the course of the study by decreasing the 
amount of Taq to lU, raising the extension temperature to 
72°c and shortening the extension time to lmin. 
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Following amplification 1/l0th of the PCR product was 
removed from beneath the mineral oil and visualized on 2% 
agarose (refer Section 2.4.6). The remainder of the product 
was frozen at -20°c until required for amplified fragment 
length polymorphism (AFLP} typing. The presence of 
contamination was monitored by the inclusion of a negative 
control in every set of amplifications. This control 
contained all reaction components excluding genomic DNA. 
2.4.5 Restriction endonuclease digestion 
For restriction fragment length polymorphism (RFLP} 
analyses genomic samples containing 8-12µ1 of DNA were 
digested with between 40 and SOU of the appropriate enzyme 
(DraI, MspI, TaqI or PvuII) according to the manufacturers 
recommendations. One fifth of each PCR product was digested 
with SU of CfoI for AFLP typing. Stock l0X buffers were 
used as supplied by the manufacturer or prepared according 
to the suppliers specifications. All digestions were 
incubated overnight at 37°C, with the exception of TaqI 
digestions which were incubated for 2hrs at 65°C. 
Digestions were terminated at completion by immediate 
ethanol precipitation at room temperature. In the event of 
overnight (-20°C} precipitation EDTA was added at 25mM/µl 
reaction volume. All samples were air dried or desiccated 
and resuspended in 15µ1 TE. 
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2.4.6 Agarose gel electrophoresis 
Digested genomic DNA was fractionated in 200x200x7mm 0. 8 -
1.0% (w/v) agarose gels in TAE or TBE buffers (TAE: 0.04M 
Tris-Acetate; 0.001M EDTA; pH 8.0. TBE: 0.089M Tris-borate; 
0.089M boric acid; 0.002M EDTA pH 8.0 (Maniatis et al., 
1982). Prior to electrophoresis 15% Ficoll loading buffer 
containing bromophenol blue (0.25%) and xylene cyanol 
(0.25%) (Maniatis et al., 1982) was added at 3µ1 per 15µ1 
sample. Immediately before loading the samples were heated 
at 65°C for l0min and quick-chilled to dissociate annealed 
compatible ends. These large agarose gels were run using a 
submarine apparatus (GNA-200, Pharmacia) at 90V for 30min, 
to run the DNA samples out of the wells, and then set to 
run at 25V for at least a further 16hrs. 
Small mini-gels (100x65x5mm) were used to visualize both 
PCR product DNA and plasmid DNA. Submarine agarose gels 
(from 1.0-2.0% (w/v)) were run on a Miniphor Submarine 
Electrophoresis Unit (LKB 2013, Hoefer, San Francisco, CA, 
USA) at l00V for 1-2hrs. Samples were treated prior to 
loading as outlined in the previous paragraph. 
Gels were stained in a lµg/ml ethidium bromide/buffer 
solution for 15-30min, visualised and photographed under UV 
light (Sharp et al., 1973). 
2.4.7 Southern transfer 
Fragmented genomic DNA was transferred from the agarose 
gels to nylon membranes (GeneScreen Plus or BioTrace HP) 
following the method of Southern (1975) as modified by Reed 
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and Mann (1985). Gels were depurinated prior to trans f er in 
0.25M HCl for 8-15min to aid in the transfer of large 
fragments. BioTrace HP membranes were saturated in methanol 
prior to application to the gel; GeneScreen Plus membranes 
were saturated in ddH20. All gels were blotted overnight 
and restained with ethidium bromide after blotting to check 
for adequate transfer of fragments. Membranes were rinsed 
after blotting in 0.2M Tris-HCl pH 7.5, 2XSSC (lXSSC = 
150mM NaCl; 15mM trisodium citrate) for 30sec and air 
dried. The re-hybridization potential of the membrane was 
improved by baking for 2hr at 80°C and exposure to UV 
(254nm) for 5min. Nylon membranes were stored in Glad Wrap, 
in the dark at room temperature. 
2.4.8 Polyacrylamide gel electrophoresis 
All CfoI digested APOE PCR products pretreated as above 
(Section 2.4.6) were fractionated on 160x160xl.5mm 10% 
polyacrylamide gels using Hoefer supplied plates and tank 
apparatus (Vertical Slab Gel Electrophoresis Unit, SE 600, 
Hoefer). The 10% gels were prepared as follows:-
10ml 
5ml 
34ml 
500µ1 
50µ1 
40% polyacrylamide 
l0xTBE stock buffer 
ddH20 
10% ammonium persulphate 
99% TEMED 
Stock solutions of 40% polyacrylimide (acrylamide/N,N'-
methylene-bis-acrylamide (38/2, w/w) were prepared, 
deionized, filtered, de-gased and stored at 4°C in the 
dark. Ammonium persulphate (10%) was made weekly and stored 
at 4°C. Gels were run in TBE, at J0mA/gel for approximately 
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3hr before staining in ethidium bromide (lµg/ml buffer ) for 
J0min and visualization under UV (Maniatis et al., 1982 ) . 
2.4.9 Transformation of competent cells 
Competent cells were prepared using the method of Dagert 
and Ehrlich (1977), snap frozen and stored at -70°C. 
Transformations of E. coli strains with plasmid were 
performed according to Yanisch-Perron et al. (1985) and 
grown in LB. 
2.4.10 Preparation of plasmid DNA 
Plasmid DNA was prepared according to the alkaline lysis 
method (Ish-Horowicz and Burke, 1981; Maniatis et al., 
1982). Large scale preparations were made in 500ml cultures 
of LB or TB with ampicillin (50µg/ml) or tetraclycline 
(15µg/ml) and amplification overnight with chloramphenicol 
(136µg/ml) after reaching an OD600 of 0.7. Small 
preparations were made from 1ml of 5ml overnight LB 
cultures without amplification. Plasmid DNA was resuspended 
after CsCl purification (Maniatis et al., 1982) in TE to a 
final stock concentration of ~lµg/µl and stored at -70°C in 
50µ1 aliquots. Working solutions of 0.25µg/µl were stored 
at 4°C. 
2.4.11 Recovery of DNA from agarose gels 
A number of the cDNA probes used labelled and hybridized 
more efficiently when the insert was removed from the host 
plasmid. Plasmid DNA was digested and the fragments run on 
agarose gels. A maximum agarose fragment of 7x5x5mm 
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containing the appropriate insert was cut from the gel 
after staining and the DNA electo-eluted at l00V for 40min 
using a IBI Model UEA Electroeluter (Bromma, Sweden). 
Inserts were ethanol precipitated and resuspended in TE. 
2.4.12 Radioactive labelling of plasmid DNA 
cDNA probes were prepared from whole plasmids or inserts by 
nick translation (Kelly et al., 1970) or random priming 
(Feinberg and Vogelstein, 1983, 1984) respectively. Nick 
translation and random priming reactions were performed 
using the Amersham Nick Translation Kit and the Amersham 
Multiprime DNA Labelling Systems according to the suppliers 
specifications. The reaction mixes were as follows:-
Nick translation 
0.25µg plasmid DNA 
10.0µl mixed dNTP buffers 
(dCTP, dGTP, dTTP each at J00µM) 
2. 5µ1 [ a-32P] dATP 
5.0µl DNA polymerase I (2.5U) 
xµl ddH20 to 50µ1 
Random priming 
0.25µg insert DNA 
(pre-boiled for 2min and kept on ice) 
4.0µl each of dCTP, dGTP, dTTP as supplied 
2. 5µ1 [ a-32 p] dATP 
5.0µ1 l0x supplied reaction buffer 
5.0µl l0x supplied hexanucleotide primer buffer 
2.0µl DNA polymerase I 'Klenow' fragment (2U) 
xµl ddH20 to 50µ1 
The reactions were incubated at 15°C for 1hr and 37°C for 
30min respectively. The labelled probes were ethanol 
precipitated, resuspended in at least 200µ1 TE and stored 
on ice until required. 
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2.4.13 Hybridizations 
The protocol of Nasmyth (1982) was followed to hybridize 
labelled cDNA probes to the nylon membranes. Two membranes 
were placed, DNA side out, in plastic bags and 
prehybridized at room temperature for at least 2hr in a 
prehybridization mix of 0.46 volumes ddH2O containing 
S0µg/ml preboiled sonicated salmon sperm DNA and Nasmyth 
Solution to a total volume of 20ml. The Nasmyth solution 
(1.lM NaCl; 0.333M NA2HPO4 ; 0.111M EDTA, pH 6.2; 1.85% N-
lauroylsarcosine and 18.5% dextran sulphate) was made 
weekly in small quantities and stored at 4°C. 
Hybridizations solutions were identical to prehybridization 
solutions but also included 0.0Sµg (lx10 8 cpm/µg) of 
labelled probe per 100cm2 of membrane (and per 5ml 
hybridization solution). The sonicated salmon sperm DNA and 
the labelled probe were boiled for l0min and chilled on ice 
before addition to the hybridization bag. Membranes were 
incubated at 65°C for 16-48hr in a shaking water bath. 
Membranes were put through a series of washes after 
hybridization with the aim of removing non-specific 
hybridization and lowering background radioactivity. An 
initial room temperature wash of Smin in 2xSSC, 0.1% SOS 
was followed by consecutive washes of 30min in 0.1% SOS and 
an increasing stringency of lxSSC, 0.SxSSC and 0.lxSSC. 
Membranes were checked after each wash, air dried for 
5-l0min and wrapped in Glad Wrap when they had reached 
3-15cps. Fuji Xray film was exposed to the membranes for 3-
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10 days at -70°C, in the presence of Lighting Plus 
intensifying screens (Du Pont) and developed automatically. 
Membranes were stripped in 0.4M NaOH at 42°C for J0min and 
0.lxSSC, 0.1% SOS, 0.2M Tris-HCl pH 7.5 at 42°C for J0min. 
Both GeneScreen Plus and BioTrace HP membranes were reused 
several times and were stored moist between use. 
2.5 STATISTICS AND COMPUTING METHODS 
Data management and statistical analyses were carried out 
on a VAX 8700 supported by the Australian National 
University Computer Service Centre, and on a NEC PowerMate 
386/20 (NEC Inc, Tokyo, Japan). The following software 
packages were used:- SPSSx Statistical Package for the 
Social Sciences (SPSS Inc., 1986) for general data 
manipulation, descriptive statistics, comparison of means 
(both t-test and ANOVA), multiple linear regressions; GLIM 
Generalized Linear Interactive Modelling (Payne, 1986; 
Healy, 1988); LIPED for linkage analysis (Ott, 1974); 
INSTAT (GraphPAD Software, San Diego, CA, USA) for chi-
square tests and Fisher's exact probabilities; PC/GENE 
(IntelliGenetics Inc., Mountain View, CA, USA) for sequence 
analysis; BIOSYS (Swofford and Selander, 1981) for gene 
frequency calculations and tests of Hardy-Weinberg 
equilibrium. 
SECTION 3 
LIPOPROTEIN GENE VARIATION 
IN MICRONESIANS: 
COMPARISONS WITH OTHER 
ETHNIC GROUPS 
3.1 AIMS 
1) To establish the frequencies of seven lipoprotein 
gene RFLPs and of the common apolipoprotein E 
functional alleles in a Micronesian population. 
2) To compare these allele frequencies with known 
frequencies in other ethnic groups. 
3) To estimate the information content of these 
polymorphisms and their suitability as candidate 
markers for NIDDM and lipoproteinemia. 
3.2 INTRODUCTION 
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The characterization, localization and sequencing of the 
genes involved in lipoprotein transport and metabolism has 
led to many studies of the potential role of these genes in 
lipoproteinemias and atherosclerosis. As a corollary there 
is now information available on the frequencies of protein 
variants and RFLPs for lipoprotein genes in different 
ethnic groups. However, these data are limited in some 
cases to Caucasoid populations, and are more extensive for 
the lipoproteins genes which have been more heavily 
implicated in the aetiology of lipoproteinemia and 
atherosclerosis. In particular the APOAl, APOC2 and APOE 
genes have been examined in a range of ethnic groups whilst 
there is a paucity of ethnic information for APOA2, APOCl, 
APOD, LDLR and LPL. 
This chapter reports specific RFLP and AFLP frequencies for 
sites within these eight lipoprotein genes in a Micronesian 
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population and compares them with allele frequencies in 
other ethnic groups. In this chapter, and the remainder of 
the thesis, the APOE alleles will be referred to as APOE*2, 
APOE*3 and APOE*4, according to convention, while a code of 
gene name-enzyme initial will be used to distinguish 
between the different RFLPs. The number 1 will always be 
used within the enzyme abbreviation of this code to refer 
to the presence of the polymorphic site and consequently 
identifies the smallest polymorphic fragment sizes 
associated with each RFLP. For example APOAl-Tl refers to 
the presence of the Taql restriction site in APOAl. 
3.2.1 Lipoprotein genes in different ethnic groups 
3.2.1.1 Apolipoprotein Al 
The MspI site within the third intron of APOAl was first 
reported by Seilhamer et al. (1984). This Mspl site has 
been examined extensively (Table 3.1), as it falls within 
the APOA1-C3-A4 lipoprotein gene cluster of chromosome 
llq23-qter, and has been used, along with a range of other 
sites, most commonly PstI and SstI, to establish haplotype 
frequencies in lipoproteinemia and heart disease studies 
(Anderson et al., 1986; Humphries et al., 1987; Antonarakis 
et al., 1988; Paulweber et al., 1988; Cole et al., 1989). 
There is sufficient variability in allele frequencies 
within ethnic groups at this locus to make pooling of 
results from the different reports inappropriate. 
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Table 3.1 APOAl Mspl allele frequenc i es in non-
Micronesians. 
Ethnicityt APOAl-Ml 
African 0.74 
African American 0.87 
African American 0.96 
Asian Indian 0.54 
Caucasoid 0.88 
Caucasoid 0.89 
Caucasoid 0.90 
Caucasoid 0.93 
Caucasoid 0.94 
Caucasoid 0.95 
Caucasoid 0.97 
Japanese 0.44 
Japanese 0.44 
Japanese 0.60 
N 
27 
62 
67 
23 
70 
231 
92 
142 
100 
129 
52 
27 
68 
82 
Reference 
Paul et al., 1987 
Thompson et al., 1988 
Antonarakis et al., 198 8 
Paul et al., 1987 
Coleman et al., 1986 
Thompson et al., 1988 
Ferns and Galton, 1986a 
Hegele et al., 1989 
Frossard et al., 1986 
Antonarakis et al., 198 8 
Paul et al., 1987 
Paul et al., 1987 
Thompson et al., 1988 
Hamaguchi et al., 1987 
t Heterogeneity tests:- African x2=19.62, d.f.=2, p<0.001; 
Caucasoid x2=16.23, d.f.=6, p=0.012; Japanese x2=8.52, 
d.f.=2, p=0.014. 
3.2.1.2 Apolipoprotein A2 
Another MspI site is found within an Alu sequence 3' to the 
APOA2 gene on chromosome lq21-q23 (Scott et al., 1985). 
Reports of frequencies for this site are limited to 
Caucasoid populations (Table 3.2), among which significant 
differences in allele frequencies are found. 
Table 3.2 APOA2 MspI allele frequencies in non-
Micronesians. 
Ethnicityt APOA2-Ml N Reference 
Caucasoid 0.81 87 Scott et al. , 1985 
Caucasoid 0.81 59 Ferns et al. , 1986b 
Caucasoid 0.85 163 Deeb et al. , 1986 
Caucasoid 0.85 85 Raj put-Williams 
et al. , 1989 
Caucasoid 0.90 160 Hegele et al. , 1989 
t Heterogeneity test:- Caucasoid x2=9.72, d.f.=4, p=0.045. 
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3.2.1.3 Apolipoprotein Cl 
Apolipoprotein Cl is situated within the apolipoprotein 
gene cluster at 19q12-q13.2. A DraI polymorphic site has 
been reported at this locus in one Caucasoid sample with a 
frequency of 0.786 (APOCl-O1, N=378, Frossard et al., 
1987) . 
3.2.1.4 Apolipoprotein C2 
A TaqI polymorphic site is present some 2kb 3' of the 
apolipoprotein C2 gene in the chromosome 19 cluster 
(Humphries et al., 1983). The site has been examined in a 
number of different ethnic groups, as presented in Table 
3.3. APOC2-Tl frequencies for the four Caucasoid 
populations do not differ significantly from each other and 
have been pooled. 
Table 3.3 APOC2 TaqI allele frequencies in non-
Micronesians. 
Ethnicityt APOC2-Tl N Reference 
African 0.48 46 Williams et 
Asian Indian 0.50 50 Williams et 
Caucasoid 0.35 103 Deeb et al. , 
Caucasoid 0.40 114 Williams et 
Caucasoid 0.44 100 Frossard et 
Caucasoid 0.44 90 Humphries et 
Pooled Caucasoid 0.41 407 
Chinese 0.58 38 Williams et 
Japanese 0.56 40 Williams et 
West Indian 0.52 52 Williams et 
al. , 1985 
al. , 1985 
1986 
al. , 1985 
al. , 1987 
al. , 1983 
al. , 1985 
al. , 1985 
al. , 1985 
t Heterogeneity test:-Caucasoid x2=4.54, d.f.=3, p=0.210. 
3.2.1.5 Apolipoprotein D 
A TaqI polymorphic site has been reported for 
apolipoprotein D (Drayna et al., 1987b). The frequency of 
APOD-Tl in Caucasoids was 0.18 (N=l0J, Drayna et al., 
1987b). 
3.2.1.6 Apolipoprotein E 
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Apolipoprotein E gene and protein polymorphisms have been 
extensively examined. Three common alleles for APOE, 
APOE*2, APOE*3 and APOE*4, are co-dominantly inherited and 
code for three apolipoprotein E isoforms. These isoforms 
differ at amino acid residues 112 and 158. Isoform APOE*2 
has cysteine residues at both 112 and 158, APOE*3 has a 
cysteine at 112 and an arginine at 158, whilst APOE*4 has 
arginine residues at both sites (Rall et al., 1982). In 
addition to producing charge differences, these 
substitutions alter two recognition sites for CfoI and its 
isoschizomer HhaI (Hixson and Vernier, 1990). 
The relationships between APOE isoforms and 
hyperlipoproteinemias or atherosclerosis are now well 
established (Davignon et al., 1988). The apolipoprotein E 
isoforms APOE*2, APOE*3 and APOE*4 can be detected by two-
dimensional gel electrophoresis (Zannis and Breslow, 1981) 
or isoelectric focussing (Utermann et al., 1982) with 
immunoblotting (Kamboh et al., 1988b). The corresponding 
DNA polymorphisms can be detected using a range of 
techniques utilizing the polymerase chain reaction and 
either allele specific oligonucleotide probing (Emi et al., 
1988; Smeets et al., 1988; Weisgraber et al., 1988; Kontula 
et al., 1990), oligonucleotide "melting" (Funke et al., 
1986), post-amplification cleavage with Hhal (or its 
isoschizomer CfoI) (Hixson and Vernier, 1990; Kontula et 
al., 1990), allele specific priming (Wenham et al., 1991) 
or primer guided incorporation assays (Syvanen et al., 
1990). 
63 
Allele frequencies are known for a number of different 
ethnic groups (Table 3.4). Although APOE allele frequencies 
do not differ significantly between the two African samples 
there is within ethnic group variability in both Caucasoids 
and Japanese. 
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Table 3.4 APOE allele frequencies in non-Micronesians. 
E*2 E*3 E*4 
Africant 
0.027 0.677 0.296 
0.034 0.706 0.260 
Pooled African 
N 
365 
194 
0.029 0.687 0.284 559 
Amerindian 
0.000 0.816 0.184 
Caucasoidt 
0.039 0.767 
0.041 0.733 
0.076 0.788 
0.077 
0.078 
0.079 
0.080 
0.082 
0.082 
0.12 
0.120 
0.130 
0.773 
0.770 
0.784 
0.770 
0.751 
0.782 
0.72 
0.764 
0.742 
Chinese 
0.084 0.852 
Japaneset 
0.023 0.891 
0.035 0.872 
0.037 0.846 
0.044 0.863 
0.082 0.850 
Mayan 
0.194 
0.227 
0.136 
0.150 
0.152 
0.136 
0.150 
0.168 
0.136 
0.16 
0.116 
0.128 
0.064 
0.086 
0.093 
0.117 
0.093 
0.068 
0.000 0.911 0.089 
Mexican 
0.039 0.859 0.102 
New Guinean 
Pawaia 
0.138 0.603 0.259 
Huli 
0.154 0.356 0.490 
95 
1157 
615 
1209 
1031 
102 
624 
400 
2000 
1557 
426 
303 
223 
196 
110 
188 
576 
91 
319 
135 
963 
58 
52 
Reference 
Sepehrnia et al., 1988a 
Kamboh et al., 1989 
Asakawa et al., 1985 
Lehtimaki et al., 1990 
Ehnholm et al., 1986 
Ordovas et al., 1987 
Utermann et al., 1982 
Sing and Davignon, 1985 
Lenzen et al., 1986 
Cumming and Robertson, 1984 
Klasen et al., 1987 
Assmann et al., 1984 
Wardell et al., 1982 
Gueguen et al., 1989 
Boerwinkle et al., 1987 
Davignon et al., 1988 
Asakawa et al., 1985 
Kobori et al., 1988 
Eto et al., 1986a 
Imari et al., 1988 
Utermann, 1987 
Kamboh et al., 1991 
Hanis et al., 1991 
Kamboh et al., 1990 
Kamboh et al., 1990 
t Heterogeneity testing:- African x2=1.77, d.f.=2, p=0.412; 
Caucasoid high~against lo~;E*2 x2=67.19, d.f.=2, p <0.001; 
Caucasoid high~ against lo~+E*3 x2=60.37, d.f.=2, p <0.001; 
Caucasoid high~ ~gainst lo~ E*4 x2=114.81, d.f.=2, p<0.001; 
Japanese x2=34.00, d.f.=8, p<0.001. 
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3.2.1.7 Low density lipoprotein receptor 
The most commonly investigated RFLP at the LDLR locus is 
the result of a PvuII site in intron 15 (Hobbs et al., 
1985). This PvuII site has been studied in the general 
population (Berg, 1990; Humphries et al., 1991) and in 
pedigrees segregating for familial hypercholesterolemia. In 
some families affected with familial hypercholesterolemia 
the PvuII RFLP, along with others (NcoI and StuI) were used 
as genetic markers for identification of at risk 
individuals ( Kotze et al., 1987; Daga et al., 1988; Kotze 
et al., 1989; Schuster et al., 1989). Reports of allele 
frequencies for this site have been restricted to Caucasoid 
populations (Table 3.5). There is a significant difference 
between the lowest and highest allele frequencies reported 
for this site. 
Table 3.5 LDLR PvuII allele frequencies in non-
Micronesians. 
Ethnicityt LDLR-Pl N Reference 
Caucasoid 0.18 239 Pedersen and Berg, 1990 
Caucasoid 0.226 96 Humphries et al. , 1985 
Caucasoid 0.23 324 Schuster et al., 1990 
Caucasoid 0.236 19 Hobbs et al. , 1985 
Caucasoid 0.29 85 Hegele et al. , 1990 
Caucasoid 0.32 289 Humphries et al. , 1991 
Caucasoid 0.32 60 Kotze et al. , 1987 
Caucasoid 0.402 112 Daga et al. , 1988 
t Heterogeneity test: Caucasoid high~~gainst loJs x2=38.80, 
d.f.=l, p<0.001. 
3.2.1.8 Lipoprotein lipase 
Lesions in the LPL gene have been found in pedigrees 
segregating for lipoprotein lipase deficiency (Devlin et 
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al., 1990; Emi et al., 1990a, 1990b; Hata et al., 1990b). 
However the lipoprotein lipase locus has not been studied 
extensively with regard to lipoprotein variation in the 
general population. Allele frequency estimation of the 
PvuII site in intron 6 (Fisher et al., 1987) is limited to 
Caucasoid populations (Table 3.6). The frequency of LPL-Pl 
does not differ significantly among the three Caucasoid 
populations. 
Table 3.6 LPL PvuII allele frequencies in non-Micronesians. 
Ethnicityt 
Caucasoid 
Caucasoid 
Caucasoid 
Pooled Caucasoid 
LPL-Pl 
0.541 
0.554 
0.59 
0.552 
N 
186 
122 
49 
357 
Reference 
Chamberlain et al., 1989 
Thorn et al., 1990 
Fisher et al., 1987 
t Heterogeneity test: Caucasoid x2=0.84, d.f.=2, p=0.659. 
3.3 MATERIALS AND METHODS 
3.3.l sample selection 
A series of samples, unrelated by surname, were selected 
randomly from the 1987 Nauru Survey blood sample 
collections without reference to diabetic status. Only 
respondents claiming Nauruan ethnicity were included, 
although this does not preclude the possibility of 
ancestral foreign admixture. Caucasoid samples, to be used 
as experimental controls on hybridization filters, were 
obtained from healthy laboratory staff. 
3.3.2 Sample description 
A total sample of 119 was obtained comprising 67 females 
and 52 males, with a mean age of 40.59 years (SE 1.25). 
Mean age did not differ significantly between females and 
males (Female mean 39.55 years, SE 1.64; Male mean 41.92, 
SE 1.93; t=0.94, d.f.=117, p=0.348). 
3.3.3 APOAl, APOA2, APOCl, APOC2, APOD, LDLR and LPL RFLP 
typing 
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Genomic DNA was prepared from the samples, digested with 
DraI, MspI, PvuII and TaqI and transferred to nylon 
membranes as described in Chapter 2. The cut DNA was 
hybridized to plasmids containing the cDNA probes discussed 
in Section 2.2.4 (Table 3.7). 
3.3.4 APOE AFLP typing 
A 234bp fragment of APOE exon 4 was amplified from each 
sample and digested with CfoI according to the methods 
described in Chapter 2. 
3.3.5 statistical methods 
Sample allele frequencies were calculated by counting and 
standard errors for these frequencies calculated using the 
normal approximation to the binomial distribution, where 
SE= jpq/2n (p = frequency of allele 1, q = frequency of 
allele 2, n = number of individuals) (Li, 1955). All 2x2 x2 
goodness of fit tests were performed with continuity 
correction. In 2x2 comparisons, where cell sizes were less 
than five, Fisher's exact test was used (Snedecor and 
Cochran, 1980). In tests of Hardy-Weinberg equilibrium 
exact significance probabilites (analagous to Fisher's 
test) were calculated when cell sizes were less than five 
(Swofford and Selander, 1981). No adjustments were made for 
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information content (PIC) for each polymorphism detected in 
the Micronesian population, and for the polymorphisms 
reviewed in Section 3.2, were calculated according to 
Botstein et al. (1980). 
Table 3.7 Probe descriptions, enzyme combinations and 
fragment sizes. 
Gene 
APOAl 
APOA2 
APOCl 
APOC2 
APOD 
LDLR 
LPL 
Probet 
pAI-113 
pAII-E9 
pUCI-A4 
pCII-711 
pAPOD.6 
pLDLR-2HHI 
pLPL35 
Size 
(bp) 
600 
430 
420 
500 
740 
1900 
2413 
Vector 
pKT218 
pKT218 
unknown 
pKT218 
pUC18 
§ 
unknown 
Enzyme Fragment 
(kb) 
Mspl Ml 1.0 
M2 1.7 
Mspl Ml 3.0 
M2 3.7 
DraI Dl 2.6/7.6 
D2 10.2 
TaqI Tl 3.5 
T2 3.8 
Taql Tl 2.2 
PvuII 
PvuII 
T2 2.7 
Pl 14.0 
P2 16.5 
Pl 2.7/4.9 
P2 7.6 
t Refer to Sections 2.2.4 and 3.2 for probe source and 
references. 
§ pLDLR-2HHI cut from pLDLR3 (5.3kb probe in pcDVl). 
3.4 RESULTS 
3.4.1 APOAl, APOA2, APOCl, APOC2, APOD, LDLR and LPL RFLP 
typing 
Hybridization of Mspl digested genomic DNA with the 600bp 
plasmid probe pAI-113 resulted in a 1.7kb fragment in the 
presence of the MspI site, and a 1.0kb fragment in its 
absence (Figures 3.la and 3.2). These alleles will be 
referred to as APOAl-Ml (1.0kb) and APOA1-M2 (1.7kb). 
Digestion with Mspl and hybridization with the 600bp 
plasmid pAII-E9 yielded a 3.0kb fragment (APOA2-Ml) in the 
presence of the APOA2 MspI site and a 3.7kb fragment 
(APOA2-M2) in its absence (Figures 3.lb and 3.3). 
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After DraI digestion of genomic DNA, hybridization with the 
pUCl-A4 probe for APOCl detected monomorphic fragments of 
3.5 and 7.0kb and a single two-allele polymorphism with 
bands at 2.6 and 7.6kb (APOCl-Dl) or 10.2kb (APOC1-D2) 
(Figure 3.4). 
The diallelic TaqI site in APOC2 resulted in bands of 
either 3.5kb (APOC2-Tl) or 3.8kb (APOC2-T2) when TaqI 
digested genomic DNA was probed with pUCII-117 (Figures 
3.lc and 3.5). Digestion of genomic DNA with TaqI and 
subsequent probing with pAPOD.6 detected a monomorphic 
fragment of 3.2kb and diallelic bands at 2.2kb (APOD-Tl) 
and 2. 7kb (APOD-T2) ( Figure 3. 6) . 
When PvuII digested genomic DNA was probed with pLDLR-2HHI 
(a 1.9kb BamHI fragment of pLDLR3) the presence of the 
PvuII site was revealed by a 14.0kb fragment (LDLR-Pl), and 
its absence by a 16.5kb fragment (LDLR-Pl). pLDLR-2HHI also 
detected an invariant band of 3.6kb (Figures 3.ld and 3.7). 
Invariant bands at 0.8, 1.9, 2.9, 3.2 and 6.6kb, and a 
diallelic polymorphism of 7.6kb (LPL-P2) or 2.7 and 4.9kb 
(LPL-Pl) were detected after hybridization of PvuII 
digested genomic DNA to pLPL35 (Figures 3.le and 3.8). 
3.4.2 APOE AFLP typing 
Six CfoI restriction sites were present in the amplified 
APOE*4 sequence. One of these sites was absent in APOE*3 
and two were absent in APOE*2 (Figure 3.9a). Consequently 
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unique combinations of CfoI fragment sizes were present in 
the digested amplification products of all six genotypes 
(Figure 3.9a). The fragments revealed upon digestion of the 
amplification products of homozygotes are presented in 
Figure 3.9b. 
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Figure 3.1 Restriction maps of apolipoprotein and 
lipoprotein restriction fragment length polymorphisms. 
a APOAl; b APOA2; c APOC2, d LDLR; e LPL. Solid bars= 
exons; open bars= intrans; *=polymorphic site; M = MspI; 
T = TaqI; P = PvuII. 
a APOA1 b APOA2 
1 2 3 4 1 2 3 4 
5' --I i 3' 5' 
-- -
3' 
M M* M M M* M 
i i i i i i 
1.0 3.0 
• • • • 
1.7 3.7 
• • • • 
1kb • 1kb 
• • • 
C APOC2 
3 4 
5' = 3' 
T T*T 
+ ii 
3.5 
• • 
3.8 
• • 
1kb 
• • 
d LDLR e LPL 
10 1112 1314 15 1617 5 6 7 8 
5' - • • • iM I • • : 3' 5' = -
I • I : 3' 
-
p P* p p P* p 
i i i i i i 
14.0 2.7 4.9 
• • • • •• 
16.5 7.6 
• • • • 
4kb 2kb 
• • • • 
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Figure 3.2 APOAl(pAI-113) hybridization of Mspl digested 
genomic DNA. Lane 1 heterozygote (1.0 and 1.7kb); lane 2 
APOA1-M2 homozygote (1.7kb); lane 3 APOAl-Ml homozygote 
( 1. 0kb) . 
APOA 1 (pA 1-113)xMsp I 
1.7kb-
1.0-
1 2 3 
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Figure 3.3 APOA2(pAII-E9) hybridization of Mspl digested 
genomic DNA. Lane 1 APOA2-Ml homozygote (3.0kb); lane 2 
heterozygote (3.0 and 3.7kb); lane 3 APOA2-M2 homozygote 
(3.7kb). 
APOA2(pAII-E9)xMsp I 
1 2 3 
-3.7kb 
-3.0 
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Figure 3.4 APOCl(pUCI-A4) hybridization of DraI digested 
genomic DNA. Lane 1 heterozygote (2.6/7.6 and 10.2kb); 
lanes 2 and 3 APOCl-O1 homozygotes (2.6/7.6kb); lane 4 
APOCl-O2 homozygote (10.2kb). 
APOC 1 (pUCI-A4)xDra I 
7.0kb-
3.5 -
1 2 3 4 
-10.2 
- 7.6 
- 2.6 
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Figure 3.5 APOC2(pCII-711) hybridization of TaqI digested 
genomic DNA. Lane 1 APOC2-Tl homozygote (3.5kb); lane 2 
APOC2-T2 homozygote (3.8kb); lane 3 heterozygote (3.5 and 
3.8kb). 
APOC2(pCll-711 )x Taq I 
1 2 3 
,--3.8kb 
..___ 3.5 
76 
Figure 3.6 APOD(pAPOD.6) hybridization of TaqI digested 
genomic DNA. Lane 1 APOD-T2 homozygote (2.7kb); lanes 2 and 
3 heterozygotes (2.2 and 2.7kb); lane 4 APOD-Tl homozygote 
( 2 . 2 kb) . 
APOD(pAPOD.6)x Taq I 
1 2 3 4 
3.2kb -
- 2.7 
-2.2 
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Figure 3.7 LDLR(pLDLR-2HHI) hybridization of PvuII digested 
genomic DNA. Lane 1 heterozygote (14.0 and 16.5kb); lane 2 
LDLR-Pl homozygote (14.0kb); lane 3 LDLR-P2 homozygote 
( 16 . 5 kb) . 
LDLR(pLDLR-2HHl)xPvu II 
16.5kb, 
14------
3.6-
1 2 3 
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Figure 3.8 LPL(pLPLJS) hybridization of PvuII digested 
genomic DNA. Lane 1 LPL-Pl homozygote (2.7/4.9kb); lane 2 
heterozygote (2.7/4.9 and 7.6kb); lane 3 LPL-P2 homozygote 
( 7 . 6kb) . 
LPL(pLPL35)xPvu II 
6.6kb -
3.2 --.. 
2.9 ---
1.9 -
0.8 -
1 2 3 
- 7.6 
-4_9 
- 2.7 
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Figure 3.9 Amplified fragment length polymorphism typing of 
common APOE isoforms. a CfoI cleavage map of amplified APOE 
exon 4 234bp fragment for six the most common APOE 
phenotypes. Sizes in bp; arrows= cleavage sites; * 
polymorphic cleavage sites. b Polyacrylamide gel after 
electrophoresis of uncut 234bp amplification product (lane 
1) and CfoI fragments from an APOE*2/APOE*2 homozygote 
(lane 2), APOE*3/APOE*3 homozygote (lane 3), and 
APOE*4/APOE*4 homozygote (lane 4). The fragment sizes (in 
bp) of a DNA standard (HaeIII digested pBR322) are shown in 
lane 5. 
a 
b 
E*2/E*2 
E*3/E*3 
E*4/E*4 
E*2/E*3 
E*2/E*4 
E*3/E*4 
234-
91 -
78-
72-
48-
31> 
30 
~ 
31 
31 
31 
31 
31 
31 
* 
, ~ r H 
16 91 
16 91 
16 19 72 
16 91 
16 91 
19 72 
91 
16 
19 72 
1 2 
* 
~ ' ~ , + 
~8 78 
18 48 30 
18 48 30 
18 78 
48 30 
18 78 
48 30 
18 48 30 
3 4 5 
-267 
-184 
-124 
-104 
- 89 
- 80 
- 64 
- 57 
- 51 
3.4.3 Micronesian lipoprotein genotype distributions and 
allele frequencies 
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Reliable typings were obtained for samples of between 74 
and 101 for the eight lipoprotein genes under study. The 
genotype distributions are presented in Table 3.8. All of 
the distributions were consistent with expections based on 
Hardy-Weinberg equilibrium. 
Frequencies for the presence of any one site for the 
diallelic systems ranged from a low of 0.230 ± 0.035 in 
LDLR-Pl to a high of 0.839 ± 0.027 for APOCl-O1 (Table 
3.9). Direct-count heterozygosity ranged from 0.233 for 
APOCl to 0.564 for APOC2, with an average of 0.395 (SE 
0.040). Seven of the eight loci examined were "reasonably 
informative" (0.25<PIC<0.50), while APOCl was only 
"slightly informative" (PIC<0.25), according to the 
criteria of Botstein et al. (1980). 
Table 3.8 Micronesian genotype frequencies for APOAl, 
APOA2, APOCl, APOC2, APOD, APOE, LDLR and LPL. 
Locus Genotype Observed 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(Dr a I) 
APOC2 
(TaqI) 
APOD 
(Taql) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
( PvuII) 
Ml-Ml 
Ml-M2 
M2-M2 
N 
13 
49 
30 
Total 92 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
D1-O1 
01-02 
02-02 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
50 
41 
10 
101 
65 
21 
4 
90 
25 
57 
19 
Total 101 
Tl-Tl 
Tl-T2 
T2-T2 
13 
35 
36 
Total 84 
E*2/E*2 
E*2/E*3 
E*2/E*4 
E*3/E*3 
E*3/E*4 
E*4/E*4 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
0 
7 
1 
56 
20 
0 
84 
3 
28 
43 
74 
49 
22 
3 
74 
14.1 
53.3 
32.6 
49.5 
40.6 
9.9 
72.2 
23.3 
4.5 
24.8 
56.4 
18.8 
15.5 
41.7 
42.8 
0.0 
8.3 
1.2 
66.7 
23.8 
0.0 
4.1 
37.8 
58.1 
66.2 
29.7 
4.1 
Expected 
N 
15.3 
44.4 
32.3 
49.2 
42.6 
9.2 
63.4 
24.3 
2.3 
28.4 
50.3 
22.3 
11.1 
38.8 
34.1 
0.2 
6.6 
1.0 
57.5 
17.4 
1.3 
3.9 
26.2 
43.9 
48.7 
22.7 
2.6 
xz 
0.97 
0.14 
1.78 
0.83 
• • • • 
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p 
value t 
0.324 
0.709 
0.231 
0.182 
0.364 
1.000 
0.747 
0.713 
t Testing Hardy-Weinberg equilibrium contingency x2 with 
d.f.=1, or exact probability. 
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Table 3.9 Micronesian allele frequencies for APOAl, APOA2, 
APOCl, APOC2, APOD, APOE, LDLR and LPL. 
Locus 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
Allele 
Ml 
M2 
N 
Ml 
M2 
N 
D1 
D2 
N 
Tl 
T2 
N 
Tl 
T2 
N 
E*2 
E*3 
E*4 
N 
Pl 
P2 
N 
Pl 
P2 
N 
Frequency SE 
0.408 0.036 
0.592 0.036 
92 
0.698 0.032 
0.302 0.032 
101 
0.839 0.027 
0.161 0.027 
90 
0.530 0.035 
0.470 0.035 
101 
0.363 0.037 
0.637 0.037 
84 
0.048 0.016 
0.827 0.029 
0.125 0.026 
84 
0.230 0.035 
0.770 0.035 
74 
0.811 0.032 
0.189 0.032 
74 
Hetero-
zygosityt 
0.533 
0.406 
0.233 
0.564 
0.417 
0.333 
0.378 
0.297 
t Heterozygosity calculated by direct counting. 
3.4.4 Comparisons with other ethnic groups 
PIC 
value 
0.366 
0.333 
0.234 
0.374 
0.356 
0.273 
0.291 
0.260 
The APOA-Ml allele (0.408 ± 0.036, PIC 0.366) was less 
common, and with a frequency closer to 0.5, more 
informative, in Micronesians than in either Caucasoids or 
Africans (Table 3.1). Comparisons with the Caucasoid and 
African populations with the closest allele frequencies 
(0.88 ± 0.03, PIC 0.220 and 0.74 ± 0.06, PIC 0.318 
respectively, Coleman et al., 1986; Paul et al., 1987) 
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indicate that the differences in allele frequencies were 
significant (Caucasoid x2=72.24, d.f.=l, p=<0.001; African 
x2=17.24, d.f.=l, p<0.001). The Micronesian APOAl allele 
frequencies were not dissimilar from those most recently 
reported for Japanese (0.44 ± 0.04, Thompson et al., 1988) 
or from Asian Indians (0.54 ± 0.07, Paul et al., 1987) 
(Japanese x2=0.24, d.f.=1, p=0.627; Asian Indians x2=2.24, 
d.f.=l, p=0.136). 
Caucasoid allele frequencies for APOA2-Ml were variable 
(Table 3.2), yet the lowest of the reported frequencies 
(0.81 ± 0.03, PIC 0.260, Scott et al., 1985) was 
significantly higher than that found in Micronesians (0.698 
± 0.032, PIC 0.333) (X 2=5.71, d.f.=l, p=0.017). The only 
reported Caucasoid APOCl-O1 frequency of 0.786 ± 0.015 (PIC 
0.280, Frossard et al., 1987) was similar to that found in 
the Micronesian sample (0.839 ± 0.027, PIC 0.234; x2=2.21, 
d.f.=1, p=0.137). 
The frequency of the presence of the APOC2 TaqI site in 
Micronesians (0.530 ± 0.035, PIC 0.374) was similar to that 
in both African and Asian groups (Williams et al., 1985 
African 0.48 ± 0.05; West Indian African 0.52 ± 0.05; Asian 
Indian 0.50 ± 0.05; Chinese 0.58 ± 0.06; Japanese 0.56 ± 
0.06; p values for comparisons between 0.489 and 0.958). 
The frequency of the APOC2-Tl allele was, however, 
significantly increased over that found in pooled Caucasoid 
samples (0.41 ± 0.02, PIC 0.367, Table 3.3; x2=8.91, d.f.=l, 
p=0.003). 
The frequency of the APOD Taql site was significantly 
increased, and more informative in Micronesians (0.363 + 
0.037, PIC 0.356), than in Caucasoids (0.18 ± 0.03, PIC 
0.252, Drayna et al., 1987b; x2=15.18, d.f.=l, p<0.001). 
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Both the APOE*2 and APOE*4 (0.048 ± 0.016 and 0.125 ± 0.026) 
frequencies fall within the range of those reported for 
Caucasoid populations (APOE*2 0.039 ± 0.004 to 0.130 ± 
0.016; APOE*4 0.116 ± 0.013 to 0.227 ± 0.012; Table 3.4). 
The APOE*3 frequency (0.827 ± 0.029) was slightly higher 
than in Caucasoids, but not significantly different 
(x2=1.25, d.f.=l, p=0.263) from the highest reported 
frequency of 0.788 ± 0.008 (Ordovas et al., 1987). 
The frequencies for all three APOE alleles differed from 
those found in two African populations, and from Chinese 
and New Guinean samples (African x2=19.86, d.f.=2, p<0.001; 
Chinese x2=7.60, d.f.=2, p=0.022; New Guinean x2=47.75, 
d.f.=2, p<0.001; Table 3.4; Davignon et al., 1988; Kamboh 
et al., 1990). The larger of the Japanese surveys (Eto et 
al., 1986a) and the Mexican sample (Hanis et al., 1991) 
report APOE allele frequencies which were similar to those 
found in Micronesians (Japanese x2=0.54, d.f.=2, p=0.763; 
Mexican x2=1.28, d.f.=2, p=0.528). Mayans and Amerindians 
did not possess the APOE*2 allele (Asakawa et al., 1985; 
Kamboh et al., 1991). Although it is possible that the 
sporadic occurrence (5%) of APOE*2 in Micronesians is a 
consequence of ancestral foreign admixture, this seems 
unlikely because Melanesians from Papua New Guinea have the 
highest frequency of APOE*2 yet reported (Kamboh et a l ., 
1990). 
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The LDLR-Pl frequency of 0.230 ± 0.035 was within the 
reported range for Caucasoids (0.18 ± 0.02 to 0.402 ± 0.0 33 ; 
Table 3.5). The presence of the LPL PvuII site was more 
common (x2=33.09, d.f.=1, p<0.001) and less informative, i n 
Micronesians (0.811 ± 0.032, PIC 0.260) than in a pooled 
sample of Caucasoids (0.552 ± 0.017, PIC 0.372; Table 3.6). 
3.5 DISCUSSION 
3.5.1 Comparisons with other ethnic groups 
All seven RFLPs and the APOE polymorphism, chosen on the 
basis of reported polymorphism in Caucasoids, were found to 
be informative and polymorphic in Micronesians. This is 
fortuitous, if not a little surprising, as the same 
polymorphisms need not necessarily be expected to occur in 
different ethnic groups. The erythrocyte-type glucose 
transporter (GLUTl) gene was found to be associated with 
Bglll RFLPs in Micronesians (Serjeantson et al., 1989), but 
not in Caucasoids (Shows et al., 1987). Conversely many HLA 
Class I antigens found in Caucasoids were not present in 
Micronesians (Serjeantson et al., 1983). Three HLA DPa/DP~ 
RFLP defined haplotypes, present in Caucasoids were 
reported absent in Micronesians, whilst two haplotypes, 
present in Micronesians, were reported absent in Caucasoids 
(Easteal et al., 1989). There is then, no precedent for 
expecting equivalent polymorphisms to occur in Micronesians 
and Caucasoids. 
No consistent pattern of difference was found between 
lipoprotein allele frequencies in Micronesians and other 
ethnicities. Of the eight loci examined, five had allele 
frequencies significantly different from Caucasoids. Of 
these APOAl and LPL differed most markedly (by 0.472 and 
0.259 respectively). APOC2 presented the most consistent 
allele frequencies across ethnic groups, and although 
significant, the difference between Micronesians and 
Caucasoids at this locus was only 0.120. Micronesian and 
Caucasoid allele frequencies did not differ at the APOCl, 
APOE or LDLR loci. 
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The small number of studies in other ethnicities 
necessitates caution in drawing conclusions, but 
preliminary comparisons indicate that the Micronesian 
lipoprotein allele frequencies are dissimilar to those of 
Caucasoids and Africans and closer to those of Orientals. 
Similarities existed at four of five loci compared for 
Orientals, but at only two of the five compared for 
Africans. 
3.5.2 Heterozygosity in Micronesian lipoprotein genes 
Nauru supported a population of about 1000 to 1400 in pre-
European times (Simpson, 1844). Availability of water on 
the island was unpredictable, with rainfall known to vary 
between 13 to 460cm a year (Viviani, 1970). It is therefore 
likely that the Nauruans were exposed to times of drought 
and famine, with consequent fluctuations in population 
size. Flint et al. (1989) suggest that such circumstances 
of potential bottleneck effects, or the maintenance of a 
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small population size over many generations may result in 
lowered heterozygosity. However, Maruyama and Fuerst ( 1985) 
make the suggestion, based on theoretical observations, 
that after a bottleneck event, allelic loss may occur more 
rapidly than loss of genie heterozygosity. The average 
heterozygosity of 0.395 ± 0.040 in the Micronesian 
population is not low relative to the maximum 
heterozygosity for a diallelic system of 0.5. 
Polynesians, traditionally existing, at times, under 
similar conditions as the Nauruans, have been found to have 
low diversity as revealed by examination of a-globin 
haplotypes and tandem repetitive highly variable loci 
(Flint et al., 1989; Hertzberg et al., 1988). The extent of 
this low diversity had not previously been realised in 
studies of less polymorphic systems, perhaps because the 
ability to detect only electrophoretic variation had masked 
a sizable proportion of the diversity present in a given 
population. This may also be true of the lipoprotein loci 
in Micronesians; the RFLP and AFLP data presented here may 
suggest relatively high heterozygosity, but this can only 
be verified using more polymorphic markers. Variability, 
measured at the level of RFLP and AFLP data, has however 
been maintained at these eight loci in the Micronesian 
population. 
3.5.3 Micronesian lipoprotein genes as candidate markers 
for disease studies 
The prerequisites for using RFLPs and AFLPs as genetic 
markers are twofold. First these markers must be 
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polymorphic in the study population. This criterion is met 
by the eight lipoprotein fragment length polymorphisms 
under study. Second, given the presence of variability, the 
information content of the polymorphisms must be such as to 
maximize the probability of detection of linkage to the 
disease locus. The polymorphic information content is 
calculated as the probability that a given offspring of a 
parent carrying the predisposing allele at the disease 
locus will allow deduction of the genotype at the marker 
locus. For any marker this is evaluated by multiplying the 
frequencies of all possible parental matings by the 
probability that an offspring will be informative (Botstein 
et al . , 19 8 O) • 
High PIC values result when the marker locus has a high 
number of alleles and equitable allele frequencies. 
Consequently maximum PIC values of 0.375, for a two allele 
system, and 0.602 for a three allele system, are obtained 
where p q = 0.50 and p = q = r = 0.33 respectively (where 
p, q, and rare the allele frequencies for alleles 1, 2, 
and 3 respectively). These PIC values may be as high as 
those of multiple allele systems where one or two alleles 
predominate and the remaining alleles are rare. 
The average PIC for the seven RFLPs examined was 0.316, or 
84.2% (with a range of 62.4% to 99.7%) of the maximum for 
diallelic systems. The APOE locus had a relatively low PIC 
value, being only 0.273 or 45% of the maximum for a three 
allele system. The APOAl, APOA2 and APOD RFLPs had PIC 
values markedly higher than in Caucasoids (increased by 
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38.9%, 19.5% and 27.7% respectively). The converse was true 
for APOCl and LPL (decreased by 12.3% and 29.9 % 
respectively). Overall, the loci examined, except APOCl, 
were reasonably informative on the PIC scale of zero to 
one, and, except APOE, highly informative within the limits 
set by the number of alleles. 
The apolipoprotein and lipoprotein genes are known to be 
involved in the monogenic determination of hypo- or 
hyperlipoproteinemias (Falus and Ramies, 1988; Assmann et 
al., 1990; Hata et al., 1990b). They are also strongly 
implicated in the aetiology of polygenic variation in 
lipoprotein levels (Galton et al., 1990; Pedersen and Berg, 
1990). The eight genes examined here therefore meet the 
criteria for consideration as candidate genes for the 
lipoproteinemias. As lipoprotein metabolism is altered in 
diabetes mellitus (Brunzell et al., 1985; Assmann and 
Schulte, 1988) they can also be regarded as candidate genes 
for NIDDM. 
3.6 CONCLUSIONS 
1) The lipoprotein genes APOAl, APOA2, APOCl, APOC2, 
APOD, APOE, LDLR and LPL have been examined in a 
Micronesian population and either RFLP or 
functional allele frequencies estimated. All eight 
loci were polymorphic. Frequencies for the presence 
of restriction sites ranged from 0.230 ± 0.035 to 
0.839 ± 0.027. APOE allele frequencies were APOE*2 
0.048 ± 0.016, APOE*3 0.827 ± 0.029 and APOE*4 0.125 
± 0.00.026. 
2) The allele frequencies for Micronesians have been 
compared with those for other ethnic groups. 
Micronesian lipoprotein allele frequencies were 
found to be dissimilar to those of Caucasoids and 
Africans and closer to those of Orientals. 
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3) The seven RFLPs had a heterozygosity of 0.395 ± 
0.040 and were highly informative, given that they 
were dimorphic. The APOE polymorphism was found to 
be reasonably informative. The lipoprotein gene 
polymorphisms under study meet the criteria 
required for use as candidate disease markers in 
NIDDM and the lipoproteinemias. 
SECTION 4 
ASSOCIATIONS OF MICRONESIAN 
LIPOPROTEIN GENES WITH 
LIPOPROTEINEMIA, OBESITY 
AND DIABETIC STATUS 
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4.1 AIMS 
General aims:- To investigate the genetic contribution of 
lipoprotein genes to lipoproteinemia, obesity and non-
insulin diabetes mellitus in Micronesians. 
Specific aims:-
1) To investigate the influence of lipoprotein gene 
RFLP frequencies and apolipoprotein E allele 
frequencies on plasma cholesterol and triglyceride 
concentrations in a Micronesian population. 
2) To investigate the influence of lipoprotein gene 
RFLP frequencies and apolipoprotein E allele 
frequencies on obesity, as measured by body mass 
index, and on degree of central adiposity, as 
measured by waist-to-hip ratio in a Micronesian 
population. 
3) To investigate the influence of lipoprotein gene 
RFLP frequencies and apolipoprotein E allele 
frequencies on non-insulin dependent diabetes 
mellitus in a Micronesian population. 
4.2 INTRODUCTION 
4.2.1 Lipoprotein genes in lipoproteinemia - population 
studies 
Several associations have been documented between 
apolipoprotein and lipoprotein RFLPs and 
hyperlipoproteinemias or atherosclerosis (Section 1.3.3). 
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The following discussion will be restricted to include on ly 
reported investigations of the RFLPs and the APOE AFLPs 
examined in this study. 
RFLP variation at the chromosome 11 apolipoprotein gene 
cluster has been shown to be associated with both 
angiographically defined atherosclerosis and the occurrence 
of myocardial infarct (Section 1.3.3 and Galton, 1990). The 
situation regarding associations of variation at this locus 
with hyperlipoproteinemia is less clear. The APOAl Mspl 
site has been found in weak association with 
hyperlipoproteinemia in Caucasoids (Ferns and Galton, 
1986a) but not Japanese (Rees et al., 1986). Freeman et al. 
(1990) found a significant difference in plasma LCAT 
activity between APOAl-Ml homozygotes and heterozygotes. As 
LCAT is responsible for the formation of nearly all plasma 
cholesteryl esters in normal individuals (Glomset, 1968), 
differences in its activity are expected to affect plasma 
cholesterol levels. 
The MspI site at the APOA2 locus has been the subject of 
five published studies concerning hyperlipoproteinemia. 
APOA2-Ml was significantly associated with lowered HDL 
levels and increased triglycerides in Caucasoids (Deeb et 
al., 1986). This finding was in agreement with a previous 
report of altered HDL composition (apolipoprotein 
Al/apolipoprotein A2 ratio) in APOA2-M2 homozygotes (Scott 
et al., 1985) and with the results of Ferns et al. (1986b) 
who found the APOA2-Ml allele to be more common in 
hypertriglyceridemics. However, an absence of association 
between the MspI site and a range of plasma lipoprotein 
levels, including triglycerides and HDL-cholesterol has 
recently contradicted these earlier findings (Rajput-
Williams et al., 1989). 
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Whilst the APOC2 TaqI site has been used to establish 
linkage to apolipoprotein C2 deficiency phenotypes in type 
I hyperlipoproteinemia (Humphries et al., 1984), no 
associations have been reported between allele frequencies 
and hypertriglyceridemia. There is a reported absence of 
association between this TaqI RFLP and types Ila, IIb, III, 
IV and V hyperlipoproteinemia (Humphries et al., 1983). The 
APOC2-Tl allele was, however, found to be associated with 
increased cholesterol levels (Deeb et al., 1986). 
The apolipoprotein E polymorphism has been well studied. In 
addition to being associated with differences in plasma 
triglyceride levels this polymorphism also explains a 
consistent, but small proportion of inter-individual 
variability in plasma cholesterol levels (Section 1.3.2.6; 
Robertson and Cumming, 1985; Sing and Davignon, 1985; 
Boerwinkle and Utermann, 1988; Davignon et al., 1988). 
In general, APOE*2 has been associated with lower plasma 
cholesterol concentrations, APOE*4 with the higher, and 
APOE*3 with intermediate levels. APOE*2 has also been shown 
to be associated with higher levels of plasma triglycerides 
(Assmann et al., 1984; Sing and Davignon, 1985; Ehnholm et 
al., 1986). One exception to this pattern of association is 
seen in type III hyperlipoproteinemia, where 90% of 
patients possess the APOE*2/APOE*2 phenotype (Utermann et 
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al., 1979; Breslow et al., 1982a). Type III 
hyperlipoproteinemia is characterized by elevated levels of 
plasma cholesterol and triglycerides, and premature heart 
disease (Refer Table 1.3). As the APOE*2/APOE*2 phenotype 
is present in 1 per 100 Caucasoids, and type III 
hyperlipoproteinemia has a prevalence of only 1 per 10,000, 
it is generally accepted that other factors are required 
before the disease is expressed (Utermann, 1985). The 
situation is further complicated as Ghiselli et al. (1982) 
and Utermann et al., (1984) report an association of APOE*4 
with hypertriglyceridemia (types IIb and V 
hyperlipoproteinemia). 
The PvuII site in LDLR has been used alone, or in concert 
with other polymorphic sites, to establish disease 
genotypes or haplotypes in familial hypercholesterolemia 
(Kotze et al., 1987; Daga et al., 1988; Kotze et al., 1989; 
Schuster et al., 1989). The presence of the site has also 
been found to be associated with decreased total 
cholesterol (Brink et al., 1986; Humphries et al., 1991) 
and LDL-cholesterol (Humphries et al., 1991), and it has 
recently been shown that the presence of the site 
eliminates the effect of APOE*4 on cholesterol levels 
(Berg, 1990). The PvuII site is thought to account for 3% 
of the sample variance in total cholesterol levels 
(Schuster et al., 1990) and 9.6% of LDL-cholesterol 
variability (Humphries et al., 1991). Individuals 
homozygous for the presence of the PvuII site in LPL have 
lowered triglycerides levels (Chamberlain et al., 1989). 
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The APOAl MspI, APOA2 MspI, APOCl DraI and APOC2 Taql RFLPs 
have recently been examined in a study analyzing 
associations of apolipoprotein RFLPs with lipid 
abnormalities. Myklebost et al. (1990) report a lack of 
association between RFLP variation at these sites and 
variation in plasma lipoprotein levels. 
4.2.2 Lipoprotein genes in non-insulin dependent diabetes 
mellitus - population studies 
Relatively few studies have examined associations of 
lipoprotein genes with NIOOM. In a small study of 45 
Caucasoid hypertriglyceridemics, 15 of whom had NIOOM, an 
association was found between the SstI site in the APOA1-
C3-A4 cluster and triglyceridemia but not NIOOM (Jowett et 
al., 1984). The frequency of the S2 allele at this site 
was, however, increased in patients with NIOOM and 
concurrent coronary heart disease (CHO) (14%, N=47) when 
compared with non-diabetic controls (2%, N=35) (Trembath et 
al., 1987). Normotriglyceridemic diabetics without CHO did 
not show the increase in S2 frequency which was observed in 
those with CHO. It was concluded that there was no 
association between diabetes alone and the SstI site. 
Within the same apolipoprotein cluster a 2.5kb EcoRI 
fragment was significantly associated with NIODM in a 
Polish population. In a sample of 100 patients with 
diabetes, five were homozygous for the fragment and eight 
heterozygous, compared with only one homozygote and one 
heterozygote in a sample of 100 controls. Both controls 
with the 2.5kb fragment had a family history of diabetes 
(Buraczynska et al., 1985). 
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The APOA2, APOB and APOA1-C3-A4 loci have been examined in 
Chinese Americans with NIDDM (Xiang et al., 1989). The APOB 
XbaI RFLP appeared to contribute to the development of 
NIDDM in individuals of lean/normal weight. Significant 
differences in the distribution of the MspI alleles alone, 
and of MspI/PstI/SstI haplotypes at the APOA1-C3-A4 locus 
were reported between overweight diabetic and non-diabetic 
groups. Most of the difference was observed at the MspI 
site, with the Ml allele having an increased frequency in 
overweight patients with diabetes. 
The common APOE genetic variants are known to contribute to 
normal plasma lipoprotein variation (Boerwinkle and 
Utermann, 1988), with the APOE*2 and APOE*4 alleles being 
more frequent in hypertriglyceridemia and 
hypercholesterolemia respectively (Sections 1.3.2.6 and 
4.2.1; Assmann et al., 1984; Utermann et al., 1984). In 
addition, the VLDL of NIDDM patients contains more 
apolipoprotein Ethan does that of hyperlipoproteinemics 
(Black et al., 1990). The APOE*2 variant in particular is 
implicated a priori in the pathogenesis of NIDDM due to the 
presence of hypertriglyceridemia in NIDDM. 
The phenotype distributions of APOE were similar in NIDDM 
and control groups in both Japanese and Caucasoid 
populations (Eto et al., 1986b; Imari et al., 1988; Snowden 
et al., 1991). However, Vogelberg and Maucy (1988) have 
detected an increase in APOE*2 containing phenotypes in 
NIDDM, due to an increase in the frequency of APOE*2 
homozygotes in the diabetics. 
When the degree of lipoproteinemia, but not obesity, 
NIDDM patients is considered associations previously 
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reported for non-NIDDM hyperlipoproteinemic individuals 
were maintained. Both APOE*4 containing phenotypes and 
APOE*4 allele frequencies were increased in Japanese 
hypercholesterolemics (type Ila and IIb) with NIDDM (Eta et 
al., 1987) and the APOE*2 allele was found more often in 
Japanese hypertriglyceridemic patients with NIDDM than in 
normolipidemics (Imari et al., 1988}. In a population of 
unstated ethnicity, the APOE*2/APOE*3 and APOE*3/APOE*4 
phenotypes were more common in hyperlipoproteinemics with 
NIDDM than normolipidemics. In this population the APOE*2 
allele was associated with hypertriglyceridemia, and the 
APOE*4 with mixed lipoproteinemias and hypercholesterolemia 
(Parhofer et al., 1990). 
4.2.3 Lipoprotein genes, obesity and non-insulin dependent 
diabetes mellitus 
Obesity has been recognised as an important risk factor for 
NIDDM (WHO Expert Committee, 1980). It is now thought that 
obesity itself is less of a cause of NIDDM than the 
duration of the obesity, and the degree of associated 
central adiposity. These factors may act to precipitate the 
onset of NIDDM in genetically susceptible individuals 
(Zimmet et al., 1989). Consequently it may prove 
informative to investigate patterns of obesity (as measured 
by BMI) and degree of central adiposity (as measured by 
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WHR) in relation to genetic variation in the lipoprotein 
genes since they are candidate genes for NIDDM. This 
approach has proven fruitful in the case of APOB and the 
APOA1-C3-A4 loci (Section 4.2.2) which showed associations 
with NIDDM, mediated by the degree of obesity. 
The relationship between APOE alleles and obesity or 
central adiposity may be of particular interest as 
triglycerides are raised in both APOE*2 carriers and in 
NIDDM patients. Two reports indicate that obese subjects 
with APOE*2 or APOE*4 were not significantly more 
susceptible to hyperlipoproteinemia than obese subjects 
with the common APOE*3/APOE*3 phenotype (Eto et al., 1989; 
Gueguen et al., 1989), although Gueguen et al., (1989) did 
find an interactive effect between APOE*4 and weight change 
on triglyceride levels. In support of the latter finding 
Fumeron et al. (1988) claimed that the APOE*4 carrying 
phenotypes were indeed more often associated with 
hypertriglyceridemia in obesity than were the APOE*3 
phenotypes. The effect of APOE*4 in increasing 
triglycerides in obese subjects in general was also present 
in obese subjects with NIDDM (Eto et al., 1986b, 1987). 
This finding appears in conflict with the general rule of 
associations in the general population. The association 
which has been cited between APOE*4 and 
hypertriglyceridemia in the general population (Ghiselli et 
al., 1982) may be artifactual since this study claims the 
association with type V hyperlipoproteinemia without 
excluding subjects with obesity, which is frequent in this 
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disorder. The relationships between NIDDM, apolipoprotein E 
phenotypes, hyperlipoproteinemia and obesity remain 
unclear. However, Fumeron et al. (1988) suggest that in the 
non-obese population APOE*4 is associated with 
hypercholesterolemia, and that this association is 
augmented in NIDDM. In the obese population they propose 
that, even in the presence of NIDDM, the main association 
is between APOE*4 and hypertriglyceridemia. 
4.3 MATERIALS AND METHODS 
4.3.1 Sample selection 
The series of samples referred to in Section 3.3.1 were 
used in the analysis of allele and genotype distribution 
frequencies in relation to plasma cholesterol 
concentrations (CHO), plasma triglyceride concentrations 
(TG), body mass index (BMI) and waist-to-hip ratio (WHR). 
Measurements of CHO, TG, BMI and WHR were obtained as 
described in Section 2.1.3. 
Further individuals with NIDDM were selected from the 1987 
Nauru Survey blood sample collections with the aim of 
increasing the proportion of NIDDM patients in the series. 
Where additional NIDDM individuals were found to have a 
non-NIDDM first degree relative represented in the original 
series this relative was excluded. This extended series was 
used in the analysis of allele and genotype distribution in 
relation to NIDDM. 
4.3.2 APOAl, APOA2, APOCl, APOC2, APOD, LDLR and LPL RFLP 
typing 
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Genomic DNA was prepared from the samples, digested with 
Dral, Mspl, PvuII and Taql and transferred to nylon 
membranes as described in Chapter 2. The cut DNA was 
hybridized to plasmids containing the cDNA probes discussed 
in Section 2.2.4 (refer also Table 3.7). 
4.3.3 APOE AFLP typing 
A 234bp fragment of APOE exon 4 was amplified from each 
sample and digested with CfoI according to the methods 
described in Chapter 2. 
4.3.4 Statistical methods 
Sample allele frequencies were calculated and contingency 
testing performed as described in Section 3.3.5. Equality 
of variance was tested before t-tests were performed and 
either separate variance or pooled variance estimators used 
accordingly (Snedecor and Cochran, 1980). Pearson's 
correlation coefficients are reported at a significance 
level of p~0.05. 
Multiple regression and loglinear modelling were carried 
out in a stepwise manner, with the significance of removal 
of established independent variables being tested with the 
entry of each new independent variable. The degree of 
impact of each independent variable on the dependent 
variable is reported as fi, the standardized regression 
coefficient. fi represents the effect that one standard 
deviation difference in the independent variable would have 
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on the standardized scores of the dependent variable. The 
explanatory power of each new independent variable is 
reported as the change in R2 (ChR2) and is the proportion 
of variance in the dependent variable explained by 
variability in the independent variable. The level of 
significance for all tests carried out in association with 
the multiple regression and loglinear analyses, unless 
otherwise stated, was 5%. The reported significance test 
for entry of an independent variable into the regression is 
the change in F (FCh), the ratio of the change in sum of 
squares over the residual sum of squares, with associated 
probability SigFCh. As the distribution of plasma 
triglycerides was skewed, triglyceride values were 
transformed by the function:- transformed TG (tranTG) 
log10 (TG + 1) before entry into either multiple regression 
or loglinear analyses. 
Generalized linear modelling, with a binomial error term, 
was used to model the effect of continuous and binary 
independent variables on the binary dependent variable of 
diabetic status (Healy, 1988). In this situation each 
individual x was treated as a group of size one, with 
either zero or one successes in the group relating to the 
presence or absence of diabetes. The change in deviance 
(ChDev) upon the addition or removal of dependent variables 
in this case is distributed as a x2 (with associated 
degrees of freedom). An estimate of the proportion of 
variation (% Var) in the dependent variable due to the 
addition of a new independent variable is given by the 
associated change in deviance over the total deviance. 
Because large sample approximations break down when the 
sample at each set of x-values is only of size one, the 
residual deviance could not be used as a measure of the 
goodness of fit of the model. 
4.3.5 sample description 
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The total sample of 119 described in Section 3.3.2 was used 
in the analysis of CHO, TG, BMI and WHR and is referred to 
as the random series. Three individuals were of unknown 
diabetic status, while one had unknown CHO and TG, and two 
had unknown WHR. These individuals were not excluded from 
the series. Descriptives for this series, as a whole, by 
sex, and subgrouped into high and low categories for each 
of the four test variables are presented in Tables 4.1 and 
4.2. The top quartile of the sample for each variable was 
assigned to the high group, whilst those below the top 
quartile were assigned to the low group. The cut off values 
for the sample were as follows:- plasma cholesterol 5.86 
mM; plasma triglycerides 1.59 mM; body mass index 39.20 
kg/m2; waist-to-hip ratio 0.91. 
A total sample of 140 was obtained in the extended NIDDM 
series. Individuals with missing values for CHO, TG, BMI or 
WHR were not excluded from the series. Descriptive 
statistics for this series are presented in Tables 4.1 and 
4 • 2 • 
4.3.6 Within sample correlations 
A number of correlations existed within the data set which 
affect the interpretation of results as presented in the 
following sections. Plasma CHO and TG levels were 
positively correlated (p~0.05) in the random series 
(r=0.504), in both females (r=0.565) and males (r=0.428) 
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and in the control sample (r=0.538), but not the NIDDM 
sample (r=0.046, p=0.360). Examination of partial 
correlation coefficients revealed that the relationship 
between CHO levels and TG levels in the random series was 
retained after controlling for age (partial r=0.530), sex 
(partial r=0.531), or diabetic status (partial r=0.516). 
There were significant, but relatively minor positive 
correlations, between both plasma CHO level and diabetic 
status (r=0.164), and plasma TG level and diabetic status 
(r=0.147). Both of these associations held after 
controlling for sex (partial r=0.168 and partial r=0.152 
respectively), and the CHO and diabetic status association 
was maintained after controlling for age (partial r=0.153). 
The correlation between TG levels and diabetic status was, 
however, lost after controlling for age (partial r=0.117, 
p=0.111). 
Age and diabetic status were correlated (r=0.355) 
regardless of sex (partial r=0.390). Another important 
association was seen between WHR and sex (r=0.447), with 
higher waist-to-hip ratios being found in men. This 
correlation was retained even after controlling for age 
(partial r=0.473) and diabetic status (partial r=0.483). 
WHR was also positively related to plasma TG levels 
(r=0.277) regardless of age (partial r=0.295), sex (partial 
r=0.264), or diabetes (partial r=0.260). 
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Several secondary correlations were also evident in the 
data set. For example the positive correlation between WHR 
and age (r=0.310), whilst maintained across the sexes 
(partial r=0.318), lost substantial magnitude after 
controlling for the presence of diabetes (partial r=0.213). 
The same pattern was true for the correlation of high WHR 
with presence of diabetes (r=0.301), which was strengthened 
marginally after controlling for sex (partial r=0.338), but 
weakened by controlling for age (partial r=0.219). These 
results would indicate that the primary association within 
the triad of diabetic status, WHR and age was between age 
and diabetic status. 
Table 4.1 Micronesian series sample descriptives:- age, sex, diabetic status. 
Random seriest 
Sex 
CHO 
TG 
BMI 
WHR 
female 
male 
low§ 
high 
low 
high 
low 
high 
low 
high 
NIDDM series 
Sex female 
male 
NIDDM yes 
no 
Age (years) 
-X SE N 
40.59 
39.55 
41.92 
1.25 119 
1.64 
1.93 
39.38 1.34 
43.32 2.82 
40.19 1.44 
40.69 2.37 
41.32 1.48 
38.31 2.23 
* 38.01 1.31 
48.14 2.68 
67 
52 
90 
28 
89 
29 
90 
29 
88 
29 
42.11 
41.24 
43.12 
1.17 140 
1.57 
1.76 
* 47.05 1.63 
37.96 1.52 
75 
65 
64 
76 
Female 
N ~ 0 
67 56.3 
50 74.6 
17 25.4 
56# 83.6 
11 16.4 
49 73.1 
18 26.9 
54# 83.1 
11 16.9 
75 53.6 
N 
52 
40 
11 
33 
18 
41 
11 
34 
18 
65 
Male 
~ 0 
43.7 
78.4 
21.6 
64.7 
35.3 
78.8 
21.2 
65.4 
34.6 
45.4 
NIDDM 
N 
36 
19 
17 
~ 0 
31.0 
52.8 
47.2 
23# 63.9 
13 36.1 
24 66.7 
12 33.3 
26 72.2 
10 27.8 
24 66.7 
12 33.3 
64 
32 
32 
45.7 
50.0 
50.0 
non-NI DOM 
N 
80 
45 
35 
66 
13 
62 
17 
62 
18 
62 
16 
76 
43 
33 
~ 0 
69.0 
56.2 
43.8 
83.5 
16.5 
78.5 
21.5 
77.5 
22.5 
79.5 
20.5 
54.3 
56.6 
43.4 
~ Within the random series status was unknown for NIDDM n=3, CHO n=l, TG n=l and WHR n = 2. 
# The top quartile was classified as 'high', the remainder as 'low'. 
* Two by two contingency x2 , d.f.=l, 0.0lsps0.05. 6 
Two tailed t-test, p s 0.01. ~ 
Table 4.2 Micronesian series sample descriptives:- plasma cholesterol and triglyceride levels, body 
mass index and waist-to-hip ratio. 
Random seriest 
Sex 
CHO 
TG 
BMI 
WHR 
female 
male 
low§ 
high 
low 
high 
low 
high 
low 
high 
NIDDMtt series 
Sex female 
male 
NIDDM yes 
no 
CHO (mM) 
x SE N 
5.23 0.10 118 
5.25 0.15 
5.20 0.14 
* 4.75 0.08 
6.76 0.14 
* 4.97 0.11 
6.00 0.19 
5.26 0.12 
5.12 0.19 
5.19 0.11 
5.31 0.27 
67 
51 
90 
28 
89 
29 
89 
29 
88 
28 
5.29 0.10 139 
5.19 0.14 
5.41 0.14 
* 5.59 0.15 
5.04 0.12 
75 
64 
64 
75 
TG (mM) 
X SE N 
1.37 0.09 118 
1.26 0.12 
1.51 0.14 
* 1.16 0.07 
2.03 0.27 
* 0.95 0.03 
2.66 0.22 
* 1.45 0.11 
1.12 0.10 
1.21 0.08 
1.83 0.27 
67 
51 
90 
28 
89 
29 
89 
29 
88 
28 
1.51 0.12 139 
1.28 0.11 
1.79 0.22 
* 1.83 0.23 
1.24 0.09 
75 
64 
64 
75 
BMI (kg/m2 ) 
-X SE N 
34.65 0.70 119 
35.14 0.98 
34.02 1.00 
34.57 0.76 
35.06 1.73 
34.39 0.87 
35.58 1.09 
* 31.19 0.49 
45.39 0.85 
34.94 0.85 
33.94 1.31 
67 
52 
90 
28 
89 
29 
90 
29 
88 
29 
34.96 
35.76 
34.01 
0.63 138 
35.17 
34.80 
0.87 
0.89 
1.04 
0.77 
75 
63 
62 
76 
WHR 
-X SE N 
0.86 0.01 117 
* 0.84 0.01 
0.89 0.01 
0.86 0.01 
0.88 0.01 
0.85 0.01 
0.89 0.01 
0.86 0.01 
0.87 0.01 
* 0.84 0.01 
0.94 0.01 
65 
52 
88 
28 
88 
28 
88 
29 
88 
29 
0.87 0.01 137 
* 0.84 0.01 
0.90 0.01 
* 0.90 0.01 
0.85 0.01 
74 
63 
6 2 
7 5 
t Within the random series status was unknown for CHO n = l, TG n = l and WHR n = 2. 
§tt Within the NIDDM series status was 
unknown for CHO n= l, TG n = l, BMI n = 2 and WHR n = 3. 
The top quartile was classified as 'high', the remainder as 'low'. 
* Two tailed t-test, p ~0.01. 
~ 
0 
(j\ 
107 
4.4 RESULTS 
4.4.1 Micronesian lipoprotein genes in lipoproteinemia and 
obesity - population study 
4.4.1.1 Allele frequencies and genotype distributions in 
low and high plasma cholesterol groups 
Genotype frequencies and allele frequencies in low and high 
CHO groups for the seven RFLPs and the APOE polymorphism 
are presented in Tables 4.3 and 4.4 respectively. Sample 
sizes ranged from 55 to 76 for the low CHO group and 19 to 
26 for the high CHO group. All of the distributions were 
consistent with expectations under Hardy-Weinberg 
equilibrium. 
There was a significant difference between the allele 
counts for APOD in the low and high groups with the 
frequency of APOD-T2 increasing from 0.586 ± 0.044 in the 
low CHO group to 0.800 ± 0.063 in the high CHO group (Table 
4.4). There was a significant absence of APOD-Tl 
homozygotes from the high CHO group, whilst these 
homozygotes comprised over 20% of the low CHO group 
(Fisher's exact test p=0.032). Other comparisons indicated 
that the allele frequencies for the remaining sites were 
similar in low and high CHO groups. 
Table 4.3 Micronesian lipoprotein genotype frequenc i es in 
low and high cholesterol groups. 
Locus Genotype 
(Enzyme) 
APOAl Ml-Ml 
(MspI) Ml-M2 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE§ 
( CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
M2-M2 
Total 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
D1-D1 
D1-D2 
D2-D2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
E*2/E*2 
E*2/E*3 
E*2/E*4 
E*3/E*3 
E*3/E*4 
E*4/E*4 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Low 
9 13.0 0.426 
37 53.6 
23 33.4 
69 
37 49.3 
29 38.7 
9 12.0 
75 
45 70.3 
15 23.4 
4 6.3 
64 
18 23.7 
43 56.6 
15 19.7 
76 
13 20.3 
27 42.2 
24 37.5 
64 
0 0.0 
5 7.9 
1 1.6 
43 68.3 
14 22.2 
0 0.0 
63 
3 5.4 
20 36.4 
32 58.2 
55 
35 63.7 
18 32.7 
2 3.6 
55 
0.502 
0.101 
0.321 
0.394 
1.000 
1.000 
1.000 
High 
4 17.4 1.000 
12 52.2 
7 30.4 
23 
13 52.0 
12 48.0 
0 0.0 
25 
20 76.9 
6 23.1 
0 0.0 
26 
7 29.2 
13 54.2 
4 16.6 
24 
0 0.0 
8 40.0 
12 60.0 
20 
0 0.0 
2 9.5 
0 0.0 
13 61.9 
6 28.6 
0 0.0 
21 
0 0.0 
8 42.1 
11 57.9 
19 
14 73.7 
4 21.0 
1 5.3 
19 
0.276 
1.000 
1.000 
0.548 
1.000 
0.538 
0.371 
t Testing Hardy-Weinberg equilibrium, x2 p value, d.f.=1, 
or exact probability. 
§ APOE genotypes pooled into three classes for testing:-
common homozygotes; common/rare heterozygotes; rare 
homozygotes and other heterozygotes. 
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Table 4.4 Micronesian lipoprotein allele frequencies in low 
and high cholesterol groups. 
Locus Allele 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOO 
(TaqI) 
APOE 
(CfoI) 
LOLR 
(PvuII) 
LPL 
(PvuII) 
Ml 
M2 
N 
Ml 
M2 
N 
01 
02 
N 
Tl 
T2 
N 
Tl 
T2 
N 
E*2 
E*3 
E*4 
N 
Pl 
P2 
N 
Pl 
P2 
N 
Low 
Freq. SE 
0.399 0.042 
0.601 0.042 
69 
0.687 0.038 
0.313 0.038 
75 
0.820 0.034 
0.180 0.034 
64 
0.520 0.041 
0.480 0.041 
76 
0.414 0.044 
0.586 0.044 
64 
0.048 0.019 
0.833 0.033 
0.119 0.029 
63 
0.236 0.040 
0.764 0.040 
55 
0.800 0.038 
0.200 0.038 
55 
High 
Freq. SE 
0.435 0.073 
0.565 0.073 
23 
0.760 0.060 
0.240 0.060 
25 
0.885 0.044 
0.155 0.044 
26 
0.563 0.072 
0.438 0.072 
24 
0.200 0.063 
0.800 0.063 
20 
0.048 0.033 
0.810 0.061 
0.143 0.054 
21 
0.211 0.066 
0.789 0.066 
19 
0.842 0.059 
0. 158 0. 059 
19 
t Contingency x2 of allele counts, d.f.=1. 
p 
value 
0.19 0.665 
0.97 0.325 
1.13 0.288 
0.27 0.605 
6.04 0.014 
§ 
0.11 0.744 
0.33 0.568 
§ Pooled allele count tests for APOE:- E*2 vs E*3 and E*4, 
p=0.681; E*3 vs E*2 and E*4, p=0.906; E*4 vs E*2 and E*3, 
p=0.893. 
4.4.1.2 Allele frequencies and genotype distributions in 
low and high plasma triglyceride groups 
110 
The distributions of genotypes in high (sample sizes from 
54 to 74) and low (sample sizes from 20 to 26) TG groups 
were consistent with Hardy-Weinberg expectations {Table 
4.5). There was a similarity in allele frequencies between 
the two groups in the majority of sites examined {Table 
4.6). However, there was a tendency towards an increase in 
the frequency of the APOC2-Tl allele in the high TG group, 
with the frequency of APOC2-Tl homozygotes rising from 
21.6% in low TG to 34.6% in high TG. A corresponding fall 
in the frequency of APOC1-T2 homozygotes was seen from 
21.6% in the low TG group to 11.5% in the high TG group. 
The differences in homozygote frequencies between the two 
groups were not significant (for APOC2-Tl/APOC2-Tl, 
xz=l.11, d.f.=1, p=0.292; for APOC2-T2/APOC2-T2, Fisher's 
exact test p=0.385). 
Table 4.5 Micronesian lipoprotein genotype frequencies in 
low and high triglyceride groups. 
Locus 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE§ 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
Genotype 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
D1-D1 
D1-D2 
D2-D2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
E*2/E*2 
E*2/E*3 
E*2/E*4 
E*3/E*3 
E*3/E*4 
E*4/E*4 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Low 
10 14.9 0.504 
36 53.7 
21 31.4 
67 
36 48.6 1.000 
31 41.9 
7 9.5 
74 
48 75.0 0.595 
14 21.9 
2 3.1 
64 
16 21.6 0.322 
42 56.8 
16 21.6 
74 
9 15.0 0.355 
23 38.3 
28 46.7 
60 
0 0.0 0.336 
5 7.9 
0 0.0 
43 68.3 
15 23.8 
0 0.0 
63 
3 5.6 1.000 
20 37.0 
31 57.4 
54 
35 64.8 0.671 
16 29.6 
3 5.6 
54 
High 
3 12.0 1.000 
13 52.0 
9 36.0 
25 
14 53.8 1.000 
10 38.5 
2 7.7 
26 
17 65.4 0.288 
7 26.9 
2 7.7 
26 
9 34.6 0.686 
14 53.9 
3 11.5 
26 
4 16.7 1.000 
12 50.0 
8 33.3 
24 
0 0.0 1.000 
2 9.5 
1 4.8 
13 61.9 
5 23.8 
0 0.0 
21 
0 0.0 0.548 
8 40.0 
12 60.0 
20 
14 70.0 1.000 
6 30.0 
0 0.0 
20 
t Testing Hardy-Weinberg equilibrium, x2 p value, d.f.=1, 
or exact probability. 
§ APOE genotypes pooled into three classes for testing:-
common homozygotes; common/rare heterozygotes; rare 
homozygotes and other heterozygotes. 
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Table 4.6 Micronesian lipoprotein allele frequenc i es in low 
and high triglyceride groups. 
Locus Allele 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(Dr a I) 
APOC2 
(TaqI) 
APOO 
(TaqI) 
APOE 
(CfoI) 
LOLR 
(PvuII) 
LPL 
(PvuII) 
Ml 
M2 
N 
Ml 
M2 
N 
01 
02 
N 
Tl 
T2 
N 
Tl 
T2 
N 
E*2 
E*3 
E*4 
N 
Pl 
P2 
N 
Pl 
P2 
N 
Low 
Freq. SE 
0.418 0.043 
0.582 0.043 
67 
0.696 0.038 
0.304 0.038 
74 
0.859 0.031 
0.141 0.031 
64 
0.500 0.041 
0.500 0.041 
74 
0.342 0.043 
0.658 0.043 
60 
0.040 
0.841 
0.119 
63 
0.017 
0.033 
0.029 
0.241 0.041 
0.759 0.041 
54 
0.796 0.039 
0.204 0.039 
54 
High 
Freq. SE 
0.380 0.069 
0.620 0.069 
25 
0.731 0.061 
0.269 0.061 
26 
0.788 0.057 
0.212 0.057 
26 
0.615 0.067 
0.385 0.067 
26 
0.417 0.071 
0.583 0.071 
24 
0.071 0.040 
0.786 0.063 
0.143 0.054 
21 
0.200 0.063 
0.800 0.063 
20 
0.850 0.056 
0.150 0.056 
20 
p 
value 
0.22 0.642 
0.22 0.636 
1.37 0.241 
2.06 0.152 
0.83 0.361 
§ 
0.27 0.601 
0.55 0.459 
t Contingency x2 of allele counts, d.f.=1, excluding APOE, 
d.f.=2. 
§ Pooled allele count tests for APOE:- E*2 vs E*3 and E*4, 
p=0.681; E*3 vs E*2 and E*4, p=0.556; E*4 vs E*2 and E*J, 
p=0.893. 
4.4.1.3 Allele frequencies and genotype distributions in 
low and high body mass index groups 
113 
Genotype distributions and allele frequencies for low and 
high BMI groups are presented in Tables 4.7 and 4.8. No 
deviations from Hardy-Weinberg expectations were evident in 
the data and no significant differences existed between the 
allele frequencies of the low and high BMI groups. There 
was a significant decline in the frequency of LDLR-P2 
homozygotes from 64.1% in the low BMI group to 42.9% in the 
high BMI group (X2=6.97, d.f.=1, p=0.008). The 
corresponding decline in LDLR-P2 allele frequency from 
0.802 ± 0.039 in low BMI to 0.690 ± 0.071 approached 
significance (Refer Table 4.8). 
Table 4.7 Micronesian lipoprotein genotype frequencies in 
low and high body mass index groups. 
Locus 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE§ 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
Genotype 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
D1-D1 
D1-D2 
D2-D2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
E*2/E*2 
E*2/E*3 
E*2/E*4 
E*3/E*3 
E*3/E*4 
E*4/E*4 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Low 
8 11.8 0.422 
36 52.9 
24 35.3 
68 
35 46.7 0.968 
33 44.0 
7 9.3 
75 
52 76.5 0.107 
13 19.1 
3 4.4 
68 
18 23.7 0.602 
41 53.9 
17 22.4 
76 
11 17.8 0.475 
26 41.9 
25 40.3 
62 
0 0.0 0.673 
6 9.4 
1 1.5 
43 67.2 
14 21.9 
0 0.0 
64 
2 3.8 1.000 
17 32.1 
34 64.1 
53 
35 66.0 1.000 
16 30.2 
2 3.8 
53 
High 
% pt 
5 20.8 0.880 
13 54.2 
6 25.0 
24 
15 57.7 0.318 
8 30.8 
3 11.5 
26 
13 59.1 1.000 
8 36.4 
1 4.5 
22 
7 28.0 0.208 
16 64.0 
2 8.0 
25 
2 9.1 1.000 
9 40.9 
11 50.0 
22 
0 0.0 1.000 
1 5.0 
0 0.0 
13 65.0 
6 30.0 
0 0.0 
20 
1 4.7 0.611 
11 52.4 
9 42.9 
21 
14 66.7 1.000 
6 28.6 
1 4.7 
21 
t Testing Hardy-Weinberg equilibrium, x2 p value, d.f.=1, 
or exact probability. 
§ APOE genotypes pooled into three classes for testing:-
common homozygotes; common/rare heterozygotes; rare 
homozygotes and other heterozygotes. 
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Table 4.8 Micronesian lipoprotein allele frequencies in low 
and high body mass index groups. 
Locus Allele 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(Dr a I) 
APOC2 
(TaqI) 
APOO 
(TaqI) 
APOE 
(CfoI) 
LOLR 
(PvuII) 
LPL 
(PvuII) 
Ml 
M2 
N 
Ml 
M2 
N 
01 
02 
N 
Tl 
T2 
N 
Tl 
T2 
N 
E*2 
E*3 
E*4 
N 
Pl 
P2 
N 
Pl 
P2 
N 
Low 
Freq. SE 
0.382 0.042 
0.618 0.042 
68 
0.687 0.038 
0.313 0.038 
75 
0.860 0.030 
0.140 0.030 
68 
0.507 0.041 
0.493 0.041 
76 
0.387 0.044 
0.613 0.044 
62 
0.055 0.020 
0.828 0.033 
0.117 0.028 
64 
0.198 0.039 
0.802 0.039 
53 
0.811 0.038 
0.189 0.038 
53 
High 
Freq. SE 
0.479 0.072 
0.521 0.072 
24 
0.731 0.061 
0.269 0.061 
26 
0.773 0.063 
0.227 0.063 
22 
0.600 0.069 
0.400 0.069 
25 
0.295 0.069 
0.705 0.069 
22 
0.025 0.025 
0.825 0.060 
0.150 0.056 
20 
0.310 0.071 
0.690 0.071 
21 
0.810 0.061 
0.190 0.061 
21 
p 
value 
1.38 0.241 
0.36 0.551 
1.89 0.170 
1.32 0.251 
1.18 0.278 
§ 
2.11 0.146 
0.00 1.000 
t Contingency x2 of allele counts, d.f.=1, excluding APOE, 
d.f.=2. 
§ Pooled allele count tests for APOE:- E*2 vs E*3 and E*4, 
p=0.682; E*3 vs E*2 and E*4, p=0.846; E*4 vs E*2 and E*3, 
p=0.784. 
4.4.1.4 Allele frequencies and genotype distr i bu t ions in 
low and high waist-to-hip ratio groups 
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Three of the genotype distributions examined in relation to 
high or low waist-to-hip ratio differed significantly from 
Hardy-Weinberg expectations (Table 4.9). APOD heterozygotes 
(32.8%) were under-represented in comparison to an 
expectation of 46.1% in the low WHR group. The reverse was 
true for the high WHR group where the frequency of APOD 
heterozygotes (68.2%) exceeded that expected (44.9%) by 
some 23.3%. There was an excess of 13.0% over expectation 
in the observed frequency of heterozygotes for APOC2 in the 
low WHR group with a concomitant deficit in both homozygote 
classes. 
An increase in the frequency of the APOC2-Tl allele from 
0.493 ± 0.041 in the low WHR group to 0.635 ± 0.073 in the 
high WHR group was evident (Table 4.10). Although this 
increase itself bordered on significance, the changes in 
APOC2-Tl homozygote frequencies from 17.8% in the low group 
to 46.2% in the high group and in APOC2 heterozygote 
frequencies from 63.0% in the low group to 34.6% in the 
high group were both significant (x2=6.73, d.f.=1, p=0.009 
and x2=5.16, d.f.=1, p=0.023 respectively). The frequency 
of the APOE*2 allele was 0.032 ± 0.016 in the low WHR group 
and 0.105 ± 0.050 in the high WHR group. This increase 
approached significance at p=0.085. 
Table 4.9 Micronesian lipoprotein genotype frequenc i es in 
low and high waist-to-hip ratio groups. 
Locus 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOO 
(TaqI) 
APOE§ 
(CfoI) 
LOLR 
(PvuII) 
LPL 
(PvuII) 
Genotype 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
D1-D1 
01-02 
02-02 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
E*2/E*2 
E*2/E*3 
E*2/E*4 
E*3/E*3 
E*3/E*4 
E*4/E*4 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Low 
10 14.7 0.705 
35 51.5 
23 33.8 
68 
36 48.7 0.916 
32 43.2 
6 8.1 
74 
47 70.1 0.387 
17 25.4 
3 4.5 
67 
13 17.8 
46 63.0 
14 19.2 
73 
12 19.7 
20 32.8 
29 47.5 
61 
0 0.0 
4 6.3 
0 0.0 
42 66.7 
17 27.0 
0 0.0 
63 
3 5.6 
18 34.0 
32 60.4 
53 
37 69.8 
15 28.3 
1 1.9 
53 
0.040 
0.041 
0.189 
0.712 
1.000 
High 
3 13.6 0.682 
12 54.6 
7 31.8 
22 
13 52.0 0.631 
9 36.0 
3 12.0 
25 
17 77.3 0.324 
4 18.2 
1 4.5 
22 
12 46.2 
9 34.6 
5 19.2 
26 
0 0.0 
15 68.2 
7 31.8 
22 
0 0.0 
3 15.8 
1 5.2 
12 63.2 
3 15.8 
0 0.0 
19 
0 0.0 
10 50.0 
10 50.0 
20 
11 55.0 
7 35.0 
2 10.0 
20 
0.330 
0.048 
1.000 
0.277 
0.591 
t Testing Hardy-Weinberg equilibrium, x2 p value, d.f.=1, 
or exact probability. 
§ APOE genotypes pooled into three classes for testing:-
common homozygotes; common/rare heterozygotes; rare 
homozygotes and other heterozygotes. 
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Table 4.10 Micronesian lipoprotein allele frequencies in 
low and high waist-to-hip ratio groups. 
Locus Allele 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
Ml 
M2 
N 
Ml 
M2 
N 
D1 
D2 
N 
Tl 
T2 
N 
Tl 
T2 
N 
E*2 
E*3 
E*4 
N 
Pl 
P2 
N 
Pl 
P2 
N 
Low 
Freq. SE 
0.404 0.042 
0.596 0.042 
68 
0.703 0.038 
0.297 0.038 
74 
0.828 0.033 
0.172 0.033 
67 
0.493 0.041 
0.507 0.041 
73 
0.361 0.043 
0.639 0.043 
61 
0.032 0.016 
0.833 0.033 
0.135 0.030 
63 
0.226 0.041 
0.774 0.041 
53 
0.840 0.036 
0.160 0.036 
53 
High 
Freq. SE 
0.409 0.074 
0.591 0.074 
22 
0.700 0.065 
0.300 0.065 
25 
0.864 0.052 
0.136 0.052 
22 
0.635 0.073 
0.365 0.073 
26 
0.341 0.071 
0.659 0.071 
22 
0.105 0.050 
0.789 0.066 
0.105 0.050 
19 
0.250 0.068 
0.750 0.068 
20 
0.725 0.071 
0.275 0.071 
20 
p 
value 
0.00 0.956 
0.00 0.971 
0.30 0.583 
3.08 0.079 
0.06 0.815 
§ 
0.09 0.764 
2.46 0.117 
t Contingency x2 of allele counts, d.f.=1, excluding APOE, 
d.f.=2. 
§ Pooled allele count tests for APOE:- E*2 vs E*3 and E*4, 
p=0.085; E*3 vs E*2 and E*4, p=0.705; E*4 vs E*2 and E*3, 
p=0.785. 
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4.4.1.5 Phenotypic and allelic means 
The phenotypic means for CHO, TG, BMI and WHR have been 
calculated for all eight polymorphic sites and are 
presented in Tables 4.11, 4.12 and 4.13. Also displayed in 
these tables are the p values for one way analysis of 
variance between phenotypic means, and p values fort-tests 
between the means for the presence or absence of an allele. 
In the case of APOE the allelic means are also presented in 
tabulated form (Table 4.14). 
At the APOAl locus the presence of the APOAl-Ml was 
significantly associated with an increase in BMI of 3.35 + 
1.70 kg/m2 • This increase equated to 9.7% of the average 
BMI for the sample. No significant correlations of BMI with 
other variables were evident after multiple regression 
analysis. 
The presence of the APOC2-T2 allele was significantly 
associated with decreased plasma triglyceride levels. The 
mean plasma triglyceride concentration was 1.26 ± 0.09 mM 
in the presence of the T2 allele and increased to 1.85 ± 
0.29 mM in its absence (p=0.058). This increase of 0.59 ± 
0.22 was equivalent to 43.1% of the average plasma 
triglyceride concentration in the sample. The differences 
across phenotypic means for this RFLP were also significant 
(p=0.032 and refer Table 4.11). 
Plasma triglyceride levels were strongly correlated with 
plasma cholesterol levels and correlated to a lesser extent 
with diabetic status and WHR in the sample population 
(Section 4.3.6). To examine the strength of the plasma 
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triglyceride to APOC2 association, transformed triglyceride 
values were regressed on cholesterol levels, age, sex, BMI, 
WHR, and diabetic status (Table 4.15). The plasma 
cholesterol levels and WHR had a significant effect on 
transformed plasma triglyceride levels (CHO ~=0.514, 
ChR2=0.290; WHR ~=0.262, ChR2=0.068). When plasma 
triglyceride levels were adjusted for cholesterol level and 
WHR the association between TG levels and APOC2 was no 
longer significant. When plasma cholesterol levels were 
adjusted for the effect of plasma triglyceride levels 
(Table 4.15, ~=0.538, ChR2=0.290) a significant association 
between the presence of the APOC2-T2 allele and decreased 
plasma cholesterol concentrations was observed (p=0.035). 
The effect of the presence of APOC2-T2 was to lower the 
adjusted cholesterol level 6.2% from 5.47 ± 0.14 mM to 5.13 
± 0.07 mM. This association results from the strong 
correlation seen between triglyceride levels and 
cholesterol levels within the sample; there was no primary 
relationship between APOC2 and cholesterol as allele 
frequencies for APOC2 did not differ between low and high 
cholesterol groups. 
The APOC2 polymorphism also had an affect on waist-to-hip 
ratios. A marginal association of APOC2 phenotype to mean 
WHR was evident (p=0.075 and refer Table 4.11). The 
majority of this difference was due to the fall in WHR in 
the presence of the APOC2-T2 allele. The allelic mean in 
the presence of APOC2-T2 was 0.86 ± 0.01 and 0.89 ± 0.01 in 
its absence (p=0.025). This increase represented 3.5% of 
the mean WHR measurement for the total sample. 
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Waist-to-hip ratios were also increased in the presence of 
APOD-T2 (p=0.033). This increase was marginally significant 
across phenotypes (p=0.074, Table 4.12) and represented 
4.7% of the mean WHR for the sample as a whole. 
As WHR was correlated with age, diabetic status, sex and 
plasma triglycerides in the total sample (Section 4.3.6) a 
multiple regression was performed in order to adjust the 
WHR measurements for the sample for these covariates (Table 
4.15). Other variables, including plasma CHO levels and BMI 
were presented for entry, but only those already known to 
be correlated with WHR entered the regression equation 
(sex, diabetes, tranTG and age). After adjustment for these 
variables the associations between WHR and APOC2, and WHR 
and APOD were no longer significant. 
The presence of the APOE*2 and APOE*4 alleles did not 
significantly affect the mean values for CHO, TG, BMI or 
WHR (Table 4.14). 
Table 4.11 Plasma cholesterol, plasma triglycerides, body mass index and waist-to-hip ratio 
phenotypic means for APOAl, APOA2, APOCl and APOC2. 
Phenotype 1-1 1-2 2-2 p valuest 
x# SE N -X SE N -X SE N Phen.§ Pres. 1 Pres. 2 
APO Al ( Ms pl) 
CHO 
TG 
BMI 
WHR 
APOA2 (MspI) 
CHO 
TG 
BMI 
WHR 
APOCl (DraI) 
CHO 
TG 
BMI 
WHR 
APOC2 ( TaqI) 
CHO 
TG 
BMI 
WHR 
5.03 
1.09 
37.93 
0.87 
5.24 
1.39 
35.49 
0.87 
5.30 
1.50 
34.26 
0.86 
5.25 
1.85 
35.54 
0.89 
0.29 
0.19 
2.13 
0.02 
0.14 
0.14 
1.09 
0.01 
0.14 
0.14 
0.89 
0.01 
0.26 
0.29 
1.59 
0.01 
13 
13 
13 
13 
50 
50 
50 
49 
65 
65 
65 
64 
25 
25 
25 
25 
5.17 
1.41 
35.57 
0.86 
5.29 
1.44 
34.23 
0.85 
5.61 
1.36 
36.21 
0.87 
5.25 
1.28 
35.23 
0.86 
t Significance tests not valid where N<5. 
0.17 
0.13 
1.18 
0.01 
0.19 
0.17 
1.08 
0.01 
0.22 
0.19 
1.96 
0.01 
0.12 
0.10 
1.07 
0.01 
49 
49 
49 
47 
41 
41 
41 
41 
21 
21 
21 
21 
56 
56 
57 
55 
5.36 
1.58 
32.71 
0.87 
4.82 
1.35 
36.02 
0.86 
5.15 
1.94 
35.80 
0.85 
4.99 
1.19 
32.54 
0.85 
0.18 
0.24 
1.18 
0.01 
0.23 
0.30 
2.61 
0.02 
0.29 
0.17 
1.01 
0.02 
30 
30 
30 
30 
9 
9 
10 
9 
4 
4 
4 
4 
19 
19 
19 
19 
0.676 
0.355 
0.093 
0.779 
0.497 
0.964 
0.656 
0.217 
0.639 
0.032 
0.350 
0.075 
0.433 
0.364 
0.051 
0.744 
0.242 
0.863 
0.659 
0.896 
0.342 
0.317 
0.054 
0.305 
0.536 
0.216 
0.138 
0.612 
0.855 
0.887 
0.538 
0.089 
0.356 
0.838 
0.298 
0.662 
0.807 
0.058 
0.574 
0.02 5 
§ Abbreviations for p values:- Phen. = ANOVA between phenotypic 
for presence of allele 1 against absence of allele 1; Pres. 2 -
allele 2 against absence of allele 2. 
means; Pres. 1 = t-test between means 
t-test between means for presence of 
# CHO (mM), TG {mM), BMI (kg/m2). f-' 
N 
N 
Table 4.12 Plasma cholesterol, plasma triglycerides, body mass index and waist-to-hip ratio 
phenotypic means for APOD, LDLR and LPL. 
Phenotype 1-1 1-2 2-2 p valuest 
-# X SE N X SE N -X SE N Phen.§ Pres. 1 Pres. 2 
APOD (TaqI) 
CHO 
TG 
BMI 
WHR 
LDLR (PvuII) 
CHO 
TG 
BMI 
WHR 
LPL (PvuII) 
CHO 
TG 
BMI 
WHR 
4.89 
1.44 
33.75 
0.83 
4.79 
0.71 
33.47 
0.79 
5.28 
1.59 
34.62 
0.86 
0.17 
0.27 
1.42 
0.02 
0.17 
0.18 
1.21 
0.01 
13 
13 
13 
12 
3 
3 
3 
3 
49 
49 
49 
48 
5.14 
1.48 
34.44 
0.88 
5.34 
1.52 
36.87 
0.88 
4.91 
1.25 
35.83 
0.86 
t Significance tests not valid where N<5. 
0.16 
0.16 
1.38 
0.01 
0.24 
0.24 
1.68 
0.01 
0.26 
0.17 
1.46 
0.02 
35 
35 
35 
35 
28 
28 
28 
28 
22 
22 
22 
22 
5.24 
1.38 
36.12 
0.86 
5.11 
1.45 
33.84 
0.85 
5.66 
1.01 
34.40 
0.91 
0.22 
0.20 
1.44 
0.01 
0.19 
0.16 
1.09 
0.01 
36 
36 
36 
36 
43 
43 
43 
42 
3 
3 
3 
3 
0.619 
0.918 
0.553 
0.074 
0.520 
0.696 
0.290 
0.991 
0.544 
0.876 
0.149 
0.220 
. . . . . 
0.190 
0.988 
0.523 
0.033 
0.349 
0.118 
0.597 
0.514 
§ Abbreviations for p values:- Phen. = ANOVA between phenotypic means; Pres. 1 = t-test between means 
for presence of allele 1 against absence of allele 1; Pres. 2 = t-test between means for presence of 
allele 2 against absence of allele 2. 
# CHO (mM), TG (mM), BMI (kg/m2). 
I-' 
t\J 
w 
Table 4.13 Plasma cholesterol, plasma triglycerides, body mass index and waist-to-hip ratio 
phenotypic means for APOE. 
Pheno- APOE*2/APOE*3 APOE*2/APOE*4 APOE*3/APOE*3 APOE*3/APOE*4 
typet 
-§ - -
X SE N X SE N X SE N X SE N 
CHO 5.01 0.81 7 5.31 . . . . 1 5.15 0.12 56 5.31 0.22 20 
TG 1.81 0.80 7 3.25 . . . . 1 1.35 0.12 56 1.24 0.16 20 
BMI 33.63 2.29 7 27.80 . . . . 1 34.81 0.95 56 35.96 1.81 20 
WHR 0.89 0.22 7 0.91 .... 1 0.86 0.01 56 0.86 0.02 20 
t Phenotypes APOE*2/APOE*2 and APOE*4/APOE*4 not represented in the sample. 
§ CHO (mM) ' TG (mM) ' BMI (kg/m2). 
I-' 
N 
~ 
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Table 4.14 Plasma cholesterol, plasma triglycerides, body 
mass index and waist-to-hip ratio allelic means for APOE. 
Allele present Allele absent 
APOE*2 
CHO 
TG 
BMI 
WHR 
APOE*3 
CHO 
TG 
BMI 
WHR 
APOE*4 
CHO 
TG 
BMI 
WHR 
5.05 
1.99 
32.90 
0.89 
5.17 
1. 3 6 
35.00 
0.86 
5.31 
1.34 
35.60 
0.86 
SE 
0.70 
0.72 
2.11 
0.02 
0.12 
0.11 
0.79 
0.01 
0.21 
0.18 
1.77 
0.01 
N 
8 
8 
8 
8 
83 
83 
73 
81 
21 
21 
21 
21 
X 
5.19 
1.32 
35.12 
0.86 
5.31 
3.25 
27.80 
0.91 
5.13 
1.40 
34.68 
0.86 
SE 
0.11 
0.20 
0.84 
0.01 
0.14 
0.14 
0.88 
0.01 
t CHO (mM), TG (mM), BMI (kg/m2). 
§ Two-tailed t-test, not valid where N<5. 
N 
76 
76 
76 
74 
1 
1 
1 
1 
63 
63 
63 
61 
p value§ 
0.849 
0.385 
0.412 
0.144 
0.491 
0.805 
0.615 
0.919 
Table 4.15 Multiple regression of plasma triglyceride, 
plasma cholesterol levels, and waist-to-hip ratios. 
Independent 
variable 
/3 SE SigFCh 
Dependent 
N=113 
variable transformed plasma triglyceride level 
CHO 
WHR 
0.514 
0.262 
0.077 
0.077 
45.23 
11.64 
Dependent variable plasma cholesterol level 
N=113 
tranTG 0.538 0.080 45.23 
Dependent variable waist-to-hip ratio 
N=113 
Sex 
Diabetes 
tranTG 
Age 
0.415 
0.190 
0.199 
0.201 
0.077 
0.083 
0.078 
0.083 
31.00 
14.19 
5.86 
5.89 
0.000 
0.001 
0.000 
0.000 
0.000 
0.017 
0.017 
0.290 
0.068 
0.290 
0.218 
0.089 
0.035 
0.034 
; Change in F upon addition of new independent variable. 
Proportion of variance explained by each independent 
variable. 
4.4.2 Micronesian lipoprotein genes in non-insulin 
dependent diabetes mellitus - population study 
4.4.2.1 Genotype distributions and allele frequencies 
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Genotype distributions and allele frequencies for the eight 
loci under study are given in Tables 4.16 and 4.17. All of 
the genotype distributions examined in relation to NIDDM 
were consistent with expectations under Hardy-Weinberg 
equilibrium except APOC2. The expected frequency of APOC2 
heterozygotes in the patient group was 49.1% and the 
observed frequency was some 13.6% higher at 62.7%. This 
increase mirrored the increase seen in observed over 
expected heterozygote frequencies in the low WHR group and 
reported in Section 4.4.1.4. 
APOE allele frequencies differed marginally between patient 
and control groups. The rare alleles APOE*2 and APOE*4 were 
present in 17 of 36 patients (47.2%) and only 15 of 54 
controls (27.8%) (x2=2.77, d.f.=1, p=0.096). The larger 
portion of this difference was due to an increase in the 
frequency of the APOE*2 allele from 0.028 ± 0.016 
. in 
controls to 0.097 ± 0.035 in patients. There was an 
attendant marginally significant decline in APOE*3 
frequencies from 0.861 ± 0.033 in the control group to 
0.750 ± 0.051 in the patients (x2=2.86, d.f.=l, p=0.091). 
The presence of the APOD-T2 allele was significantly 
associated with NIDDM. The frequency of this allele 
increased from 0.594 ± 0.048 in the control group to 0.777 
± 0.039 in the patient group (x2=8.45, d.f.=1, p=0.004). 
The corresponding decline in the APOD-Tl homozygote 
--
127 
frequency from 20.8% in controls to 3.6% in patients was 
highly significant (Fisher's exact test p=0.007). There was 
also marginal significance in the increase in APOD-T2 
homozygosity from 39.6% in controls to 58.9% in patients 
(X2=3.32, d.f.=l, p=0.068). 
--
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Table 4.16 Micronesian lipoprotein genotype frequencies in 
diabetes patients and control populations. 
Locus Genotype 
(Enzyme) 
APOAl 
(Mspl) 
APOA2 
(Mspl) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOO 
(TaqI) 
APOE§ 
(CfoI) 
LOLR 
(PvuII) 
LPL 
(PvuII) 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
Ml-Ml 
Ml-M2 
M2-M2 
Total 
01-01 
01-02 
02-02 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
Tl-Tl 
Tl-T2 
T2-T2 
Total 
E*2/E*2 
E*2/E*3 
E*2/E*4 
E*3/E*3 
E*3/E*4 
E*4/E*4 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Pl-Pl 
Pl-P2 
P2-P2 
Total 
Patients 
11 20.0 
27 49.1 
17 30.9 
55 
27 47.4 
25 43.8 
5 8.8 
57 
40 72.7 
13 23.7 
2 3.6 
55 
15 25.4 
37 62.7 
7 11.9 
59 
2 3.6 
21 37.5 
33 58.9 
56 
0 0.0 
6 16.6 
1 2.8 
19 52.8 
10 27.8 
0 0.0 
36 
2 5.3 
17 44.7 
19 50.0 
38 
30 63.8 
13 27.7 
4 8.5 
47 
1.000 
0.960 
0.596 
0.053 
0.714 
0.403 
0.691 
0.200 
Controls 
8 13.6 
31 52.5 
20 33.9 
59 
30 46.9 
26 40.6 
8 12.5 
64 
43 75.4 
12 21.1 
2 3.5 
57 
16 25.4 
32 50.8 
15 23.8 
63 
11 20.8 
21 39.6 
21 39.6 
53 
0 0.0 
3 5.6 
0 0.0 
39 72.2 
12 22.2 
0 0.0 
54 
2 4.2 
15 31.2 
31 64.6 
48 
30 62.5 
16 33.3 
2 4.2 
48 
0.591 
0.679 
0.285 
0.999 
0.278 
0.575 
1.000 
1.000 
t Testing Hardy-Weinberg equilibrium, x2 p value, d.f.=1, 
or exact probability. 
§ APOE genotypes pooled into three classes for testing:-
comrnon homozygotes; common/rare heterozygotes; rare 
hornozygotes and other heterozygotes. 
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Table 4.17 Micronesian lipoprotein allele frequencies in 
diabetes patients and control populations. 
Locus Allele 
(Enzyme) 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
Ml 
M2 
N 
Ml 
M2 
N 
D1 
D2 
N 
Tl 
T2 
N 
Tl 
T2 
N 
E*2 
E*3 
E*4 
N 
Pl 
P2 
N 
Pl 
P2 
N 
Patients 
Freq. SE 
0.445 0.047 
0.555 0.047 
55 
0.693 0.043 
0.307 0.043 
57 
0.845 0.035 
0.155 0.035 
55 
0.568 0.046 
0.432 0.046 
59 
0.223 0.039 
0.777 0.039 
56 
0.097 0.035 
0.750 0.051 
0.153 0.042 
36 
0.276 0.051 
0.724 0.051 
38 
0.777 0.043 
0.223 0.043 
47 
Controls 
Freq. SE 
0.398 0.045 
0.602 0.045 
59 
0.672 0.041 
0.328 0.041 
64 
0.860 0.032 
0.140 0.032 
57 
0.508 0.045 
0.492 0.045 
63 
0.406 0.048 
0.594 0.048 
53 
0.028 0.016 
0.861 0.033 
0.111 0.030 
54 
0.198 0.041 
0.802 0.041 
48 
0.792 0.041 
0.208 0.041 
48 
p 
value 
0.52 0.471 
0.12 0.725 
0.09 0.764 
0.88 0.349 
8.45 0.004 
§ 
1.46 0.227 
0.06 0.801 
t Contingency x2 of allele counts, d.f.=1, excluding APOE, 
d.f.=2. 
§ Pooled allele count tests for APOE:- E*2 vs E*3 and E*4, 
p=0.092; E*3 vs E*2 and E*4, p=0.091; E*4 vs E*2 and E*3, 
p=0.554. 
4.4.3 Multivariate analysis of Micronesian lipoprotein 
genes in non-insulin dependent diabetes mellitus, 
lipoproteinemia and obesity 
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4.4.3.1 Lipoprotein genes in obesity and lipoproteinemia -
multiple regression 
Four sets of multiple regression analyses were undertaken 
with transformed plasma triglyceride concentrations, plasma 
cholesterol, body mass index and waist-to-hip ratios as 
successive dependent variables. The analyses were performed 
on the random series data set with the sample size limited 
to the number of individuals genotyped at each of the eight 
loci examined. In each analysis the variables listed below 
(excluding the dependent variable under examination) were 
presented for entry to the regression as independent 
variables:-
age (years) 
sex 
diabetic status 
transformed plasma triglyceride level (mM) 
plasma cholesterol level (mM) 
body mass index (kg/m2) 
waist-to-hip ratio 
There are known correlations between some of these 
variables (CHO and TG, WHR and sex for example, refer 
Section 4.3.6). It was therefore expected that collinearity 
would be present between some of the independent variables. 
However all independent variables were subject to a 
tolerance test before entry to the regression, and none 
were rejected on the basis of collinearity alone. 
In addition to the variables listed above, dummy variables 
for the presence of each allele of the eight lipoprotein 
genes under study were presented in successive runs of the 
analyses. The individual presentation of the loci was 
--
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necessary to ensure that the same cases were used to 
estimate all coefficients within one analysis, and because 
significance levels obtained from pairwise matrices may be 
unreliable (SPSS Inc., 1986). An interactive term for age 
and diabetic status was examined, but the significance of 
this interaction did not reach the inclusion threshold of 
5% in any of the preliminary analyses and so was not 
considered further. 
In the analysis of CHO and BMI none of the loci tested were 
found to have a significant effect on the dependent 
variable. The presence of APOC2-T2 had a significant effect 
on transformed plasma triglyceride levels (~=-0.177, 
ChR2=0.029, Table 4.18). This effect was less than that of 
either plasma cholesterol concentrations, or WHR. The 
proportion of triglyceride variance explained by the model 
was 40.2%, with the proportion explained by CHO levels, WHR 
and the presence of APOC2-T2 being 30.3%, 7.0% and 2.9% 
respectively. 
The APOC2-T2 allele also had a marginally significant 
effect on WHR (Table 4.18). With the sample size limited by 
the number of individuals genotyped for APOC2 (N=95) 
diabetic status was no longer a significant independent 
variable for WHR (~=0.132, ChR2=0.085, p=0.149 for entry, 
compare with Section 4.4.1.5, Table 4.15). The effect of 
the APOC2-T2 allele on WHR was minor (~=-0.147, ChR2=0.020) 
in comparison to the effects of age, sex and plasma 
triglyceride level (Table 4.18). 
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Table 4.18 Multiple regression of plasma triglyceride, a nd 
waist-to-hip ratios - effect of APOC2-T2. 
Independent 
variable 
/3 SE SigFCh 
Dependent 
N=95 
variable transformed plasma triglyceride level 
CHO 
WHR 
APOC2-T2 
0.492 
0.226 
-0.177 
0.083 
0.086 
0.084 
40.40 
10.29 
4.45 
Dependent variable waist-to-hip ratio 
N=95 
Age 
Sex 
tranTG 
APOC2-T2 
0.350 
0.329 
0.226 
-0.147 
0.082 
0.084 
0.086 
0.085 
21.03 
19.07 
9.95 
3.04 
0.000 
0.002 
0.038 
0.000 
0.000 
0.002 
0.085 
0.303 
0.070 
0.029 
0.184 
0.140 
0.067 
0.020 
§t Change in F upon addition of new independent variable. Proportion of variance explained by each independent 
variable. 
4.4.3.2 Lipoprotein genes in non-insulin dependent diabetes 
mellitus - loglinear analysis 
The independent variables of age, sex, transformed plasma 
triglyceride concentration, plasma cholesterol 
concentration, BMI and WHR were tested for successive 
significant entry to a loglinear model with diabetic status 
as a binary dependent variable. Interactive terms between 
the variables listed above were also tested for entry. 
These analyses were performed on the NIDDM series data set. 
The total sample size in each analysis was limited to the 
number of individuals genotyped for the locus under 
investigation. 
An initial deviance of 187.48 (d.f.=136) was reduced to 
148.51 (d.f.=133) with the successive addition of WHR 
(% Var=12.03), age (% Var=5.68) and a WHR*age interaction 
term(% Var=J.08) to the model (Table 4.19). This model 
accounted for 20.79% of the variability in diabetic status. 
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Transformed triglyceride plasma levels, while being a 
significant predictor of diabetic status when presented 
alone, did not enter the model after the predictors of WHR, 
age and WHR*age had been entered. 
Table 4.19 Log linear model of diabetic 
Independent Model Change . in 
variable deviance deviance 
Dependent variable diabetic status 
Empty model 
Successive entry 
WHR 
Age 
WHR*age 
Combined entry 
WHR, age 
and WHR*age 
187.48 
164.92 
154.28 
148.51 
148.51 
. . . . . 
22.56 
10.64 
5.77 
38.97 
status. 
d.f. 
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1 
1 
1 
3 
pt 
. . . . . 
<0.001 
0.001 
0.016 
<0.001 
9e-0 Var§ 
. . . . 
12.0 
5.7 
3.1 
20.8 
t p value for change in deviance, distributed as x2 with 
associated degrees of freedom. 
§%of variance= change in deviance over empty model 
deviance. 
Genotypes, or the presence of alleles for the eight loci 
were first presented individually for entry to the model; 
if the genotype or allele presence was found to be a 
significant predictor for diabetic status they were 
presented to a model which already included WHR, age and 
WHR*age and the results were re-examined. 
The genotypes and the presence of either allele for APOD 
was found to be a significant predictor of diabetic status 
(Table 4.20; APOD genotype% Var.=5.5; APOD-Tl % Var.=2.6; 
APO-T2 % Var=4.7). Once the more powerful predictors of 
diabetic status were included in the model the effect of 
the APOD locus could no longer be detected (Table 4.20). 
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Table 4.20 Loglinear model of diabetic status - effect of 
APOD genotypes and alleles. 
Independent Model Change in 
variable deviance deviance 
Dependent variable diabetic status 
Empty model 
Lone entry 
APOD genotype 
APOD-Tl 
APOD-T2 
Combined entry 
WHR, age 
and WHR*age 
Lone entry after 
APOD genotype 
APOD-Tl 
APOD-T2 
146.91 
138.80 
143.11 
140.06 
117.64 
WHR, age 
114.62 
115.12 
116.25 
. . . . 
8.11 
3.80 
6.85 
29.27 
and WHR*age 
3.02 
2.52 
1.39 
d.f. 
105 
2 
1 
1 
3 
2 
1 
1 
pt 
. . . . . 
0.017 
0.051 
0.009 
<0.001 
0.221 
0.112 
- 0.238 
9c-0 Var§ 
. . . 
5.5 
2 . 6 
4.7 
19.9 
2.1 
1.7 
1.0 
t p value for change in deviance, distributed as x2 with 
associated degrees of freedom. 
§%of variance - change in deviance over empty model 
deviance. 
APOC2-Tl was found to have a marginal effect on diabetic 
status (Table 4.21; % Var=l.8), the significance of which 
was lowered further when the model included WHR, age and 
WHR*age. The presence of APOE*2 allele was a significant 
predictor of diabetic status (Table 4.21; % Var=3.8), but 
not after the stronger predictors of WHR, age and WHR*age 
had been entered into the model. 
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Table 4.21 Loglinear model of diabetic status - effect o f 
APOC2-Tl and APOE*2. 
Independent 
variable 
Model 
deviance 
Change in 
deviance 
Dependent variable diabetic status 
Empty model 163.45 . . . . 
Lone entry 
APOC2-Tl 160.44 3.01 
Combined entry 
WHR, age 129.86 33.59 
and WHR*age 
Lone entry after WHR, age and WHR*age 
APOC2-Tl 127.80 2.06 
Dependent variable diabetic status 
Empty mode 1 116 . 4 2 . . . . 
Lone entry 
APOE*2 111.99 4.43 
Combined entry 
WHR, age 85.55 30.88 
and WHR*age 
Lone entry after WHR, age and WHR*age 
APOE*2 82.93 2.62 
d. f. 
117 . . . . . 
1 0.083 1.8 
3 <0.001 20.6 
1 0.150 1.3 
86 
1 0.035 3.8 
3 <0.001 26.5 
1 0.106 2.3 
t p value for change in deviance, distributed as x2 with 
associated degrees of freedom. 
§%of variance= change in deviance over empty model 
deviance. 
4.5 DISCUSSION 
4.5.l APOC2 in non-insulin dependent diabetes mellitus and 
hypertriglyceridemia 
A significant association was found between plasma 
triglyceride levels and the TaqI polymorphic site of APOC2. 
A dosage effect was apparent with the presence of the 
APOC2-T2 allele (3.8kb) being associated with a 31.9% 
decrease in plasma triglyceride concentrations. Once 
transformed triglyceride levels were adjusted for plasma 
cholesterol concentrations and WHR this dosage effect was 
no longer significant. However, it is more appropriate to 
I: 
' 
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evaluate the confounding effects of cholesterol and wa i st-
to-hip ratios on the APOC2 triglyceride association by 
means of multivariate analysis. These analyses showed that 
the APOC2-T2 allele had an influence on triglyceride 
variability after adjustment for the influences of 
cholesterol levels and waist-to-hip ratios. The APOC2-
triglyceride relationship was also consistent with a 
tendency, although non-significant, towards an excess of 
APOC2-Tl homozygotes {3.5kb) in individuals in the upper 
quartile for plasma triglyceride levels. 
The relationship between the APOC2 TaqI RFLP and plasma 
triglyceride levels were replicated, in the main, with 
respect to waist-to-hip ratios. There was a marginally 
significant dosage effect of APOC2-T2 in lowering waist-to-
hip ratios, and a significant decrease in the waist-to-hip 
ratios of individuals who possessed the APOC2-T2 allele. 
There was an attendant increase of APOC2-Tl homozygotes in 
individuals with waist-to-hip ratios below the top quartile 
for the population. In multiple regression analyses the 
APOC2-T2 allele was seen to influence waist-to-hip ratios, 
although the significance of this influence was marginal. 
The increase of plasma triglyceride levels in NIDDM is well 
documented (Betteridge, 1986; Howard, 1987) and was evident 
in the present study (Section 4.3.6). However, the 
significance of the effect of the APOC2 locus as a 
predictor for NIDDM was marginal. It would appear then, 
that the primary association of the APOC2 locus in the 
Micronesian population is with alterations in plasma 
triglyceride concentrations and not NIDDM or WHR. 
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The apolipoprotein C2 protein is a cofactor for lipoprotein 
lipase, the enzyme responsible for hydrolysis of plasma 
triglycerides to free fatty acids and monoacylglycerols 
(Herbert et al., 1983). Individuals with an apolipoprotein 
C2 deficiency often present clinically with a massive 
accumulation of chylomicrons and triglycerides, the 
classical symptoms of lipoprotein lipase deficiency (type I 
hyperlipoproteinemia) (Yamamura et al., 1979). It is 
possible that alterations in the efficiency of action of 
apolipoprotein C2, rather than its complete absence, could 
also impair LPL function and lead to increases in plasma 
triglycerides. 
The APOC2-Tl allele is reported by Deeb et al. {1986) to be 
associated with increased cholesterol levels. Different 
populations with different linkage disequilibrium 
relationships may show different RFLP associations with 
triglyceride concentrations, or its correlate, cholesterol 
levels. However, the marked effect of allelic variation at 
the APOC2 locus on triglyceride levels observed in this 
study has not been reported previously. 
4.5.2 APOD in non-insulin dependent diabetes mellitus and 
hypercholesterolemia 
The presence of the APOD-T2 allele (Taql 2.7kb) was 
significantly associated with NIDDM. The allele was a 
significant lone predictor of diabetic status as indicated 
by loglinear modelling. The strength of the relationship 
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between APOD and NIDDM was minor in comparison to the 
relationships of the stronger correlates of age and WHR 
with NIDDM. Average waist-to-hip ratios were increased in 
the presence of the APOD-T2 allele, but possibly due only 
to the strong association between diabetic status and WHR. 
The observation of the association between APOD alleles and 
NIDDM is unique, and the possible contribution of the APOD 
polymorphism to NIDDM susceptibility has not been examined 
in other populations (Refer Section 4.2.2). 
As a result of the increase in plasma cholesterol 
concentrations in patients with NIDDM the APOD-T2 allele 
was also found at increased frequency in individuals with 
plasma cholesterol levels in the top quartile of the 
population. Although the presence of the APOD-T2 allele was 
associated with increased cholesterol levels in the general 
population, these increases were not substantial enough to 
gain significance. 
Lecithin-cholesterol acyltransferase catalyzes the 
esterification of free cholesterol in the plasma, forming 
cholesteryl esters. Apolipoproteins Al, Cl, A4 and E are 
known to activate LCAT to different degrees, while 
apolipoproteins A2, C2 and CJ have an inhibitory effect on 
this enzyme (Refer Table 1.2). Steyrer and Kastner, (1988) 
postulate that apolipoprotein D may have a stabilizing 
effect on LCAT. However, the degree to which this suggested 
stabilization may result in altered plasma cholesterol 
levels is unknown. 
--
11 
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The associations apparent between the APOD locus and NIDDM 
may be the result of linkage disequilibrium with another 
gene. A possible candidate is the glucose transporter gene 
(GLUT2, liver isoform) which has been localized to 3ql4.2-
q26.3 (Fukumoto et al., 1989). This locality lies within 
the range 3pl4.2-qter, so far determined for the position 
of the APOD locus (Drayna et al., 1987a). The GLUT2 gene 
has not been examined in the Micronesian population. 
4.5.3 APOE in non-insulin dependent diabetes mellitus and 
hyperlipoproteinemia 
In contradiction with generally accepted patterns of 
associations between APOE alleles and hyperlipoproteinemia 
(Assmann et al., 1984; Sing and Davignon, 1985; Ehnholm et 
al., 1986), no associations were seen in this population 
between the APOE alleles and either hypertriglyceridemia or 
hypercholesterolemia. 
The frequency of the APOE*2 allele was marginally increased 
in NIDDM and in individuals with high waist-to-hip ratios. 
This observation was in agreement with a previous report of 
increased APOE*2 containing phenotypes in NIDDM (Vogelberg 
and Maucy, 1988). Restricted sample sizes have precluded 
the division of the sample into patients or controls with 
and without obesity, or with or without increased plasma 
lipoproteins levels. However, given that the average BMI 
was high among both patients with diabetes and controls 
(35.17 ± 1.04 and 34.80 ± 0.77 respectively), and that only 
two of the diabetics and two of the controls had BMI values 
of less than 24.00, it is obvious that comparisons between 
1: 
' 
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non-obese and obese individuals per se in this population, 
would be impossible. The sample then is of obese 
individuals with and without NIDDM. There was no evidence 
to support the suggestion of Fumeron et al. (1988) that the 
APOE*4 allele is more likely to be associated with 
hypertriglyceridemia in obese individuals. 
4.6 CONCLUSIONS 
1) The presence of the APOC2 TaqI 3.8kb allele was 
significantly associated with lowered plasma 
triglyceride levels in the Micronesian population. 
2) The APOC2 TaqI 3.8kb allele was also associated with 
lower waist-to-hip ratios in the Micronesian 
population. This association, may however be 
secondary to that of the effect of APOC2 on 
triglyceride levels. 
3) The APOD TaqI 2.7kb allele was significantly 
associated with non-insulin dependent diabetes 
mellitus in the Micronesian population and was more 
common in individuals with high cholesterol levels. 
The primary association, however, appears to be 
with non-insulin dependent diabetes mellitus and 
not plasma cholesterol levels. 
4) The APOD TaqI 2.7kb allele was associated with 
increased waist-to-hip ratios. This association is 
believed to be secondary to the associations of the 
APOD RFLP with non-insulin dependent diabetes 
mellitus. 
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5) There is limited evidence for an association betwee n 
the APOE*2 allele and non-insulin dependent 
diabetes mellitus. There is, however, no support 
for the often reported associations between APOE*2 
and hypertriglyceridemia or APOE*4 and 
hypercholesterolemia. 
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SECTION 5 
LINKAGE OF MICRONESIAN 
LIPOPROTEIN GENES WITH 
LIPOPROTEINEMIA 
AND DIABETIC STATUS 
-
5.1 AIMS 
1) To test for linkage between seven lipoprotein 
restriction fragment length polymorphisms, the 
common apolipoprotein E alleles and 
a) liability for non-insulin dependent 
diabetes mellitus 
b) hypercholesterolemia 
c) hypertriglyceridemia. 
5.2 INTRODUCTION 
5.2.1 Multifactorial disorders and linkage analysis 
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Inherited diseases with clear modes of inheritance, known 
biochemical defects, early age of onset, and full 
penetrance are most amenable to genetic analysis. However, 
the genes for some age dependent single gene disorders such 
as polyposis coli, polycystic kidney disease and multiple 
endocrine neoplasia have been mapped successfully (Reeders 
et al., 1985; Bodmer et al., 1987; Simpson et al., 1987). 
In addition, several single gene disorders with unknown 
biochemical defects (e.g. Duchenne muscular dystrophy) have 
been mapped and candidate genes identified (Monaco et al., 
1986). 
Efforts have begun to focus on disorders which 1) are 
common, 2) may show only partial family clustering, 3) are 
of unknown biochemical origins, 4) have variable, generally 
late age of onset, 5) are related to environmental or 
lifestyle conditions, 6) are of heterogeneous nature, and 
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7) may be polygenic. These include diabetes, epilepsy, 
hypertension, hyperlipoproteinemia, cardiovascular disease, 
and a range of psychiatric disorders (Schull and Weiss, 
1980). 
In these complex and multifactorial disorders, where 
disease occurrence depends upon the presence and the 
biologic interactions among genetic and environmental 
factors, susceptibility genes may be neither necessary, nor 
sufficient, for the expression of the disorder. A range of 
genetic factors may interact with numerous other 
contributing factors, leading to the differential 
expression of symptoms. It is often difficult in these 
cases to classify family members as affected, unaffected, 
exposed, or unexposed. Spurious associations can occur when 
families are drawn from subpopulations that are genetically 
heterogeneous at the marker locus, or where differences in 
the disease prevalence occur among population subgroups 
(Khoury et al., 1990). 
In an attempt to minimize these confounding effects in 
analysis, certain criteria must be placed on the selection 
of the study population. The populations should be more or 
less totally ascertainable and have minimal ethnic and 
lifestyle heterogeneity (Schull and Weiss, 1980). The 
Micronesian population of Nauru meets these criteria, 
although even in this relatively homogeneous population, 
there is evidence to suggest genetic diversity in diabetes 
(Serjeantson et al., 1989). 
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The detection of associations between candidate genes and 
disease states at a population level, relies upon the 
presence of linkage disequilibrium between the polymorphic 
restriction site and the disease promoting genetic lesion. 
For large genes in regions with a high rate of 
recombination, this assumption may not hold. For instance, 
some insulin-receptor (INSR) RFLPs are not in linkage 
disequilibrium with each other (Elbein et al., 1986; 
Serjeantson et al., 1987), so that a single RFLP at INSR 
will not necessarily be associated with an INSR gene defect 
in population studies. Population studies can detect 
( ::::- O·l cl'Y'l) 
linkage up to about l00kbj whereas family studies are 
capable of detecting linkage of up to 15 000kb (Lander and 
Botstein, 1986a). Moreover genetic heterogeneity can only 
be detected using linkage analysis. 
5.2.2 Lipoproteinemias - family studies 
It has been recognized that the hyperlipoproteinemias 
comprise a heterogeneous group of disorders, and these 
disorders have subsequently been subdivided into types I 
through V (Table 1.4). Genetic defects in the lipoprotein 
lipase and apolipoprotein C2 genes are known to lead to 
type I hyperlipoproteinemia (Humphries et al., 1984; 
Langlois et al., 1989; Monsalve et al., 1990), whilst 
apolipoprotein E and low density lipoprotein receptor gene 
defects are causal factors in types III and IIa 
hyperlipoproteinemia respectively (Utermann et al., 1979; 
Breslow et al., 1982a; Leppert et al., 1986; Brink et al., 
1990). Familial combined hyperlipoproteinemia (types IIb 
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and IV hyperlipoproteinemia) has recently been found to be 
linked to the APOA1-APOC3-APOA4 gene cluster (Wojciechowski 
et al . , 19 91) . 
However, these hyperlipoproteinemia subtypes are neither 
genetically nor clinically homogeneous, and a great deal 
remains to be understood concerning possible genetic 
susceptibility to the hyperlipoproteinemias. 
Whilst it may be clinically appropriate to attempt to 
divide the hyperlipoproteinemias into meaningful subtypes, 
and given that the recognised subtypes are genetically 
heterogeneous, it may be worthwhile to ignore a priori 
classifications and "classical diagnoses" and examine 
hypercholesterolemia and hypertriglyceridemia in the 
population in general rather than in predefined disease 
groups. This approach will be taken in the present chapter 
in a linkage analysis of the lipoprotein genes and 
hypercholesterolemia or hypertriglyceridemia, where these 
"affected states" are defined as the possession of plasma 
cholesterol or triglycerides levels above the 90th 
percentile. 
5.2.3 Non-insulin dependent diabetes mellitus - family 
studies 
Formal pedigree analysis of NIDDM in Caucasoid populations 
has been difficult due to the heterogeneity of 
environmental factors to which individuals in these 
populations are exposed (Zimmet, 1982). 
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The populations of the Seminole Amerindians, Pima 
Amerindians and Nauruan Micronesians have a high prevalenc e 
of NIDDM and a relatively homogeneous environment. In these 
populations pedigree analysis has provided evidence of 
familial clustering in NIDDM, and suggests the presence of 
a major gene in the development of the disease (Elston et 
al., 1974; Serjeantson and Zimmet, 1984; Knowler et al., 
1990). Formal segregation analysis in Micronesians favours 
a dominant, but is compatible with a codominant, mode of 
inheritance for hyperglycaemia (Serjeantson and Zimmet, 
1989). 
There are as yet no known RFLP markers for NIDDM. Many 
genes have been examined, including the insulin gene, the 
insulin receptor gene, and the glucose transporter gene 
family, with claims and counter-claims of associations 
being reported in the literature (Serjeantson and Zimmet, 
1991). Most recently Bell et al. (1991) have reported a 
maximum lad score for linkage between maturity-onset 
diabetes of the young (MODY) and the adenosine deaminase 
(ADA) gene of chromosome 20q. There is a rather early age 
of onset in NIDDM among Nauruans, which suggests that some 
MODY families may be part of the NIDDM spectrum seen in 
this population (Serjeantson and Zimmet, 1991). The ADA-
related polymorphism was examined in the Nauruan 
population. The same two alleles, out of a possible five, 
were segregating in most of the families, and the lad 
scores were consequently uninformative. However, there was 
no distortion in allele frequencies in NIDDM patients of 
early onset when compared with older, unaffected contro l s 
(pers. comm. Prof. S.W. Serjeantson). 
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The confusion in the literature may have arisen as a result 
of a dependence on population studies. If NIDDM . lS 
genetically heterogeneous, or has a polygenic aetiology 
then pedigree analyses of candidate genes, such as the 
lipoprotein genes are essential (Serjeantson and Zimmet, 
1991). 
5.3 MATERIALS AND METHODS 
5.3.1 Pedigree selection and structure 
Families were selected for linkage analysis of the 
lipoprotein genes and hyperlipoproteinemia on the basis of 
having at least two first degree relatives with plasma 
cholesterol or plasma triglycerides levels over the 90th 
percentile for the population, at the time of either the 
1982 or 1987 survey. Eleven families were found to be 
segregating for high cholesterol levels, and nine for high 
triglyceride levels. Blood samples were available for 51 
adults in the high cholesterol families and 44 adults in 
the high triglyceride families. Of the individuals in the 
pedigrees, 26 and 20 respectively, had cholesterol or 
triglyceride levels in the top decile. 
Families which were segregating for NIDDM were selected 
from the 1982 Nauru Survey. Twelve families were selected 
and the diabetic status and age of the adult individuals 
examined. As the onset of NIDDM is age dependent, an age 
adjusted liability score based on measures of fasting and 
........ 
148 
2hr plasma glucose levels was calculated for each 
individual (Serjeantson and Zimmet, 1984). This liability 
score can be viewed as an estimate of the likelihood of 
progression to diabetes in younger individuals and in 
effect dichotomizes the population so that in every age 
group there is approximately the same proportion of 
individuals who are "liable to diabetes". A liability score 
of intermediate value indicates that the likelihood of 
progression to diabetes can not be determined. 
Of the 60 individuals in the selected families 14 were 
diabetic. After applying the liability score all 14 were 
classified as liable to diabetes and were therefore 
classified as affected. Forty six individuals in the 
families were not diabetic; of these, two went on to 
develop diabetes by 1987 and were consequently reclassified 
as affected; ten had liability scores of intermediate value 
and were classified as being of unknown diabetic status; 
twenty eight had low liability scores and remained 
classified as unaffected. Six of the forty six individuals 
had high liability scores, which would indicate a tendency 
towards the later development of diabetes. A conservative 
decision was made to classify five of these six individuals 
as unknown, despite their high liability. The remaining 
individual was found to have impaired glucose tolerance in 
both 1982 and 1987, and was classified as affected. 
The reassignment of "non-diabetic" to "unknown" on the 
basis of information gained by use of the liability scores 
resulted in the loss of two families from the sample. These 
........ 
-
149 
families were no longer informative for NIDDM after 
reassignment. The remaining ten families comprised 53 
adults for whom there were blood samples. Of the family 
members, 17 were classified as affected, 10 as unknown, and 
26 as unaffected. 
The samples from both the hyperlipoproteinemia and the 
NIDDM pedigrees were typed for lipoprotein fragment length 
polymorphisms (Sections 5.3.2 and 5.3.3). Difficulties were 
experienced in obtaining results using the pLDLR-2HHI 
probe, and successful typing of the LDLR PvuII site was 
limited to half of the sample. 
5.3.2 APOA1, APOA2, APOC1, APOC2, APOD, LDLR and LPL RFLP 
typing 
Genomic DNA was prepared from the samples, digested with 
DraI, MspI, PvuII and TaqI and transferred to nylon 
membranes as described in Chapter 2. The cut DNA was 
hybridized to plasmids containing the cDNA probes discussed 
in Section 2.2.4 (refer also Table 3.7). 
5.3.3 APOE AFLP typing 
A 234bp fragment of APOE exon 4 was amplified from each 
sample and digested with CfoI according to the methods 
described in Chapter 2. 
5.3.4 Linkage analysis 
Linkage analyses were performed using the LIPED computer 
programme (Ott, 1974), as modified by Dr A. Spence, and lod 
scores calculated (where lod score= log10 (probability of 
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observed offspring at given rate of recomb i nat i on / 
probability of observed offspring in absence of l inkage )) . 
All analyses were originally undertaken over a range of Sf 
= 8m from 0.00 to 0.40 (where 8f = female recombination 
rate, and 8m = male recombination rate). As recombination 
rates are known to differ between the sexes (White and 
Lalouel, 1987), lod scores of particular interest were 
recalculated over ranges of 8f i 8m from 0.05 to 0.50. 
The criteria for the interpretation of lod scores set by 
Morton (1955), and based on a type I error of a= 0.001, 
and a type II error of~= 0.01, were applied. With a lod 
score of 3 or greater, it is concluded that the frequency 
of recombination is significantly less than 0.50. If the 
lod score is -2 or less, it is concluded that the frequency 
of recombination is significantly greater than the value of 
8 for which the lads were calculated. At lod scores between 
3 and -2 judgement of the likelihood of linkage is not 
possible as the pedigrees do not contain enough 
information. 
These criteria are based upon the theorem that the expected 
value of a probability ratio is one under the null 
hypothesis, regardless of the alternative hypothesis 
(Haldane and Smith, 1947; Wald, 1947). Some workers hav e 
felt that this theorem is true only if the theorem is 
specified a priori, which is not the case, as in pract i ce 
it is based upon the sample (Chotai, 1984 ) . However, 
recently Collins and Morton ( 1991 ) have used exact 
calculation to shown that posterior specification of the 
alternative hypothesis does not bias the test. 
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Lod scores were calculated under models of both dominant 
and recessive inheritance. Under a model of reduced 
penetrance it was necessary to assume reduced penetrance, 
as one of the hypercholesterolemic and hypertriglyceridemic 
pedigrees included affected offspring from unaffected 
parents. Although the same situation did not occur in the 
pedigrees used in the diabetes linkage analysis, the same 
assumption of reduced penetrance was employed, as there are 
cases in the population where non-diabetic parents have 
diabetic offspring. 
Allele frequencies for the lipoprotein alleles were taken 
as those established in Chapter 3 (Table 3.9). Allele 
frequencies for hypercholesterolemia and 
hypertriglyceridemia were calculated on the basis of 10% of 
the population being affected and were as follows:- under a 
dominant model, p 
model, p = 0.316, q 
0.051, q = 0.949; under a recessive 
0.684; where pis the frequency of 
the "affected" allele and q is the frequency of the 
"normal" allele. The allele frequencies for NIDDM in the 
population were estimated based on the proportion of over-
forty-year-olds who had diabetes (46.9%), as no individuals 
in this age group had a liability score which classified 
them as being of unknown diabetic status. The estimated 
allele frequencies were: under a dominant model, p = 0.271, 
q = 0.729; under a recessive model, p = 0.685, q 0.315; 
·, 
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where pis the frequency of the "affected" allele and q is 
the frequency of the "normal" allele. 
5.4 RESULTS 
5.4.1 Micronesian lipoprotein genes in hypercholesterolemia 
- linkage analysis 
The eleven pedigrees used in the analysis of linkage 
between the eight lipoprotein fragment length polymorphisms 
and hypercholesterolemia are presented in Table 5.1. Lad 
scores were calculated under models of recessive 
inheritance with full penetrance, and dominant inheritance 
with 99%, 90% and 80% penetrance, at values of Sf= Sm from 
0.0 to 0.5 (Table 5.2). Under a dominant model of 
inheritance close linkage of hypercholesterolemia was 
excluded for APOAl, APOCl, APOC2, APOD, APOE and LPL at 99 % 
penetrance. Under a recessive model linkage of APOD was 
excluded, while lod scores were uninformative for the 
remaining loci. Lod scores were uninformative for LDLR, 
under both models of inheritance, and at all levels of 
penetrance tested. A small, but positive lod score of 0.97 
was obtained at Sf= Sm= 0.1 for APOA2. 
Under a dominant model with 99% penetrance the negative lod 
scores for APOCl, APOC2, APOD, APOE, LDLR and LPL were due 
largely to the influences of the minority of families, with 
between 60% and 96% of the magnitude of the lod scores 
being attributable to one or two families. 
Further lod scores for APOA2 and hypercholesterolemia were 
calculated at values where Sf f Sm to establish the effect 
of different recombination rates for females and males 
(Table 5.3). Maximum, but uninformative lad scores for 
APOA2 of 1.11 were obtained at Sf= 0.35 to 0.50 and Sm 
0.05. 
When the maximum APOA2, hypercholesterolemia lad scores 
were examined for the contribution of individual families 
(Table 5.4), three families were found to be largely 
responsible for the positive lod scores, with a combined 
lad score across these families of 1.61 and 1.55. Five 
families had lod scores extremely close to zero (-0.05 to 
0.05), whilst the remaining three had lod scores ranging 
from -0.07 to -0.25. 
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Four of the unaffected individuals in the high cholesterol 
pedigrees were found to have plasma cholesterol levels 
above the 75th percentile of 5.86 mM, which had been used 
to define high and low groups in the population in Section 
4 (Refer Table 5.1). When the status of these individuals 
was reassigned to unknown, and the linkage analysis 
repeated, the resultant lad scores precipitated an altered 
conclusion from the original analyses, under dominant 
inheritance with reduced penetrance, in only one situation. 
The lod score for linkage of the LDLR PvuII RFLP with 
hypercholesterolemia, following reassignment of the four 
individuals was -2.81 at Sf= Sm= 0.0, compared with an 
original lod score of -1.59 (Refer Table 5.2). The lod 
scores for the remaining seven loci differed from the 
original lod scores by between 0.01 and 1.69, with the 
APOA2 analysis remaining uninformative, and results from 
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the other six loci still providing evidence of exclusion to 
linkage with hypercholesterolemia. 
Table 5.1 Extreme plasma cholesterol pedigrees. 
Pedigree Ind. t Status§ Locus 
Al A2 Cl C2 D E LDLR LPL 
A 
Mo 2 AB AA AB AB BB AB BB AA 
Cl 1 AB AA AB AA AB BB AB 
C2 2 AA AA AA BB AB AB BB AA 
CJ 2 AB AA AA AB AB AB AB AB 
C4 1 AB AA AB BB AB BB AA 
B 
Cl 2 AB AB AA AA AB BB BB AB 
C2 1 AB AA AA AB AB BB AA 
CJ 1 AB AA AA AB AB BB AA 
C 
Cl 2 AB AA AB BB 
C2 2 AA AA AB AB AB BB BB AA 
CJ 1 AA BB AA BB AA BC AA 
C4 2 AA AA AB BB AA BC BB AA 
cs 1 AA AB AB AA AB BB AA 
C6 1 AB AB AA BB AB BC AA 
D 
Mo 2 AB AA AA AB BB BB BB AB 
Cl 1 AA AB AA AB BB BB BB 
C2 2 AA AA AB AB BB BC AB AB 
CJ 1# AB AB BB BC C4 2 AA AA AB AB BB BC AB AA 
cs 2 AB AA AA AB AB BB AA 
E 
2# Mo AA AB AB AB BB BB AB AB 
Fa 2 AB AB AA BB BB BB BB AA 
Cl 2 AB AB AA BB BB BB AB AA 
C2 1 AA AA AA BB BB BB AA 
CJ 2 AB AA AB AB BB BB BB AA 
C4 1 AB AB AB AB BB BB AB 
cs 1 AA AB AA BB BB BB AB 
C6 2 AA AB AA BB BB BB AA 
t Ind. Individuals:- Mo - mother; Fa= father; 
en= numbered children. 
§ status 1 = affected; status 2 = unaffected. 
Continued overleaf. 
# Plasma cholesterol level above the 75th percentile. 
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Table 5.1 Cont'd. Extreme plasma cholesterol pedigrees. 
Pedigree Ind. t Status§ Locus 
Al A2 Cl C2 D E LDLR LPL 
F 
Cl 2 AB AB AA AB BB BB AA 
C2 1 AB AB AA AA AB BB AB 
CJ 1 BB AA AA AA AB BB BB AA 
G 
Cl 1 AB BB AA BB AB BC AB 
C2 2 AB BB AA AB BB BC AB AA 
CJ 1 AB AB AA AB BB BC AA 
C4 1 AA BB AA AB BB BC AA 
cs 2 AA AB AA BB BB BC AB 
H 
Fa 2 AA AA AA AB BB 
Cl 1 AB AB AA AB BB BC AB 
C2 1 AB AB AA AB AB BC AB 
I 
2# Cl AA AA BB AB BB AB AA 
C2 1# AB AB AB BC AA 
CJ 2 BC 
C4 1 AB BB BB BB AA 
cs 2 AA AA BB AA BB BC AA 
J 
Cl 1 AA AB AA BB AB BB AB 
C2 2 AB AB AA AB AB BB AB AA 
CJ 2 AA AB BB AB BB BB AB 
C4 1 AA AB AA BB BB BB AB 
K 
Mo 2 AB AB AA AB BB BC AB 
Cl 1 AA AA AB BB BC AA 
C2 1 BB AB AB BB BB cc AA 
t Ind. Individuals:- Mo - mother; Fa= father; 
Cn = numbered children. 
§ Status 1 = affected; status 2 = unaffected. 
# Plasma cholesterol level above the 7Sth percentile. 
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Table 5.2 Lod scores for linkage of hypercholesterolemia 
with lipoprotein gene fragment length polymorphisms. 
Locus 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.99 
-0.07 
-0.31 
-0.73 
-1.40 
-2.61 
0.17 
0.52 
0.84 
0.97 
0.02 
-0.05 
-0.23 
-0.60 
-1.33 
-3.31 
-0.07 
-0.33 
-0.85 
-1.88 
-8.23 
-0.08 
-0.33 
-0.80 
-1.61 
-3.19 
-0.05 
-0.23 
-0.58 
-1.22 
-2.50 
-0.02 
-0.09 
-0.23 
-0.53 
-1.59 
0.05 
0.14 
0.08 
-0.37 
-2.07 
Dominant 
Penetrance 
0.90 
-0.06 
-0.27 
-0.64 
-1.23 
-2.29 
0.13 
0.41 
0.70 
0.88 
0.76 
-0.04 
-0.17 
-0.43 
-0.92 
-1.95 
-0.06 
-0.27 
-0.69 
-1.48 
-4.22 
-0.06 
-0.25 
-0.60 
-1.13 
-1.85 
-0.04 
-0.15 
-0.38 
-0.76 
-1.35 
-0.01 
-0.06 
-0.14 
-0.29 
-0.56 
0.05 
0.13 
0.13 
-0.10 
-0.95 
0.80 
-0.06 
-0.23 
-0.55 
-1.07 
-2.06 
0.09 
0.32 
0.56 
0.75 
0.79 
-0.03 
-0.12 
-0.33 
-0.70 
-1.46 
-0.05 
-0.22 
-0.57 
-1.21 
-3.08 
-0.05 
-0.19 
-0.46 
-0.85 
-1.37 
-0.02 
-0.09 
-0.24 
-0.51 
-0.97 
-0.01 
-0.04 
-0.08 
-0.16 
-0.28 
0.04 
0.11 
0.14 
-0.00 
-0.62 
t 8f - female recombination fraction; 8m - male 
recombination fraction. 
Recessive 
Penetrance 
1.00 
-0.09 
-0.39 
-0.97 
-2.04 
-1.89 
0.08 
0.23 
0.32 
0.15 
0.37 
0.02 
0.03 
-0.06 
-0.44 
-0.49 
-0.08 
-0.37 
-1.04 
-2.59 
-0.38 
-0.05 
-0.22 
-0.56 
-1.23 
-2.70 
0.01 
0.01 
-0.12 
-0.53 
-1.60 
-0.01 
-0.02 
-0.05 
-0.09 
-0.16 
0.05 
0.16 
0.21 
0.01 
-0.19 
Table 5.3 Lod scores for linkage of hypercholesterolemia 
with APOA2 MspI restriction fragment length polymorphism 
under a model of dominant inheritance and 99% penetrance. 
Locus 
APOA2 
(MspI) 
0.05 
0.20 
0.35 
0.50 
0.05 
0.88 
0.86 
0.63 
0.47 
0.20 
1.07 
0.84 
0.50 
0.30 
t 8f = female recombination fraction; 8m 
recombination fraction. 
0.35 
1.11 
0.76 
0.34 
0.10 
male 
0.50 
1.11 
0.72 
0.26 
0.00 
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Table 5.4 Family lod scores for linkage of 
hypercholesterolemia with APOA2 MspI restriction fragment 
length polymorphism under a model of dominant inheritance 
with 99% penetrance. 
Pedigree 
0.35 
D 0.80 
C 0.60 
B 0.21 
D, c, and B 1.61 
I 0.03 
H 0.02 
K 0.00 
A -0.02 
J -0.03 
I, H, K, A, and J 0.00 
F -0.08 
G -0.17 
E -0.25 
F, G, and E -0.50 
Total 1.11 
t 8f = female recombination fraction; 
recombination fraction= 0.05. 
8ft 
0.50 
0.80 
0.56 
0.19 
1.55 
0.03 
0.00 
0.00 
-0.02 
-0.02 
0.01 
-0.07 
-0.14 
-0.22 
-0.43 
1.11 
8m - male 
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5.4.2 Micronesian lipoprotein genes in hypertriglyceridemia 
- linkage analysis 
Pedigrees used in the linkage analysis of the eight 
lipoprotein fragment length polymorphisms and 
hypertriglyceridemia are presented in Table 5.5. Lad scores 
were calculated under models of recessive inheritance with 
full penetrance, and dominant inheritance with 99%, 90% and 
80% penetrance, at values of Sf= Sm from 0.0 to 0.5 (Table 
5.6). Under a recessive model linkage of APOC2 was 
excluded, while lod scores were uninformative for the 
remaining loci. Under a dominant model of inheritance close 
linkage of hypertriglyceridemia was excluded for APOAl, 
APOA2, APOC2, and APOD at 99% penetrance. Under the same 
model, lod scores were uninformative for APOCl, APOE, LDLR 
and LPL. 
In the case of APOCl under dominant inheritance, an 
examination of lod scores for individual families revealed 
that one family had a positive lod score of 1.19 at Sf= 8m 
= 0.0, and the remaining families had lod scores which were 
negative or close to zero. For APOA2, APOC2, and APOD, 
under dominant penetrance of 99%, one or two families were 
responsible for over 75% of the magnitude of the negative 
lod scores. 
Five of the unaffected individuals in the high triglyceride 
pedigrees were found to have plasma triglyceride levels 
above the 75th percentile of 1.59 mM, which had been used 
to define high and low groups in the population in Section 
4 (Refer Table 5.5). When the status of these individuals 
was reassigned to unknown, and the linkage analysis 
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repeated, the resultant lad scores, under a model of 
dominant inheritance with 99% penetrance, and at Hf= Sm 
o.o, differed by 0.01 to 1.19 from those of the original 
analysis. However, the change in lod scores, with the 
reclassification of the five individuals, did not alter the 
nature of the conclusions drawn: the APOCl, APOE, LDLR and 
LPL fragment length polymorphisms remained uninformative, 
while the lod scores for the APOAl, APOA2, APOC2 and APOD 
RFLPs remained less than -2, and so provided evidence for 
the exclusion of these loci from linkage with 
hypertriglyceridemia. 
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Table 5.5 Extreme plasma triglyceride pedigrees. 
Pedigree Ind. t Status§ Locus 
Al A2 Cl C2 D E LDLR LPL 
L 
Cl 1 AA AA AA BB AB BC AB 
C2 2 AB AB AA BB AB BC BB AA 
C3 1 AA AB AA AB AB BB AA 
C4 1 AB AB AA AB AB BB AA 
M 
Cl 1 AB AB AA AB BB BB AA 
C2 1 BB AA AA BB BB BB AA 
C3 2 BB AB AA BB BB BB BB AB 
E 
Mo 2 AA AB AB AB BB BB AB AB 
Fa 2 AB AB AA BB BB BB BB AA 
Cl 2 AB AB AA BB BB BB AB AA 
C2 1 AA AA AA BB BB BB AA 
C3 1 AB AA AB AB BB BB BB AA 
C4 2# AB AB AB AB BB BB AB 
cs 2 AA AB AA BB BB BB AB 
C6 2 AA AB AA BB BB BB AA 
N 
Cl 1 AA AB AA 
C2 1 BB AB AA AB AB AC AA 
C3 1 AB AB AA AB AB AC AB AA 
C4 2 AB AB AA AA AB BB AB AA 
0 
Cl 1 AA BB AA AB BB BB AB 
C2 2 AA BB AA AB BB BB BB AB 
C3 1# AA AB AA AB AB BB AB 
C4 2 AB AA AA BB BB BB BB BB 
cs 2 AB BB AA BB BB BB BB AA 
t Ind. Individuals:- Mo - mother; Fa= father; 
en= numbered children. 
§ Status 1 = affected; status 2 = unaffected. 
Continued overleaf 
# Plasma triglyceride level above the 75th percentile. 
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Table 5.5 Cont'd. Extreme plasma triglyceride pedigrees. 
Pedigree Ind. t Status§ Locus 
Al A2 Cl C2 D E LDLR LPL 
p 
2# Cl AB AA AB AB BB BB BB AB 
C2 1 BB AA AA AB BB BB AA 
CJ 1 BB AA AA AA BB BB 
C4 2 BB AA AA AB BB BB BB AB 
Q 
Mo 2 AB AB AA AA BB AB AB AA 
Cl 2 AA AB BB 
C2 1 AA AB AA AB AB BB AB AA 
CJ 1 AB AB AA AA BB AB AA 
R 
Fa 2 AB AA AA AA BB BB AB AB 
Cl 2 AA AA AB BB BC BB BB 
C2 2 AB AA AB AA BB BB AB BB 
CJ 1 AB AA AA AA BB BB BB 
C4 2# AA AA AB AA BB BB AB AB 
cs 2# AB AA AB AA BB BB AB AB 
C6 2 AB AA AA BB BB BB BB 
C7 2 AB AA AA BB BB AB 
CB 1 AB AA AA AA BB BB BB 
K 
Mo 2 AB AB AA AB BB BC AB 
Cl 1 AA AA AB BB BC AA 
C2 1 BB AB AB BB BB cc AA 
t Ind. Individuals:- Mo - mother; Fa= father; 
en= numbered children. 
§ Status 1 = affected; status 2 - unaffected. 
# Plasma triglyceride level above the 75th percentile. 
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Table 5.6 Lad scores for linkage of hypertriglyceridemi a 
with lipoprotein gene fragment length polymorphisms. 
Locus 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(DraI) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.99 
-0.04 
-0.17 
-0.45 
-0.98 
-2.34 
-0.04 
-0.18 
-0.46 
-1.01 
-3.33 
0.12 
0.31 
0.39 
0.27 
-0.38 
-0.05 
-0.23 
-0.69 
-1.82 
-4.85 
-0.01 
-0.05 
-0.16 
-0.50 
-2.29 
0.00 
-0.02 
-0.19 
-0.72 
-1.69 
0.01 
0.04 
0.09 
0.16 
0.22 
0.01 
-0.03 
-0.12 
-0.37 
-1.30 
Dominant 
Penetrance 
0.90 
-0.04 
-0.15 
-0.39 
-0.82 
-1.80 
-0.02 
-0.12 
-0.32 
-0.64 
-1.32 
0.10 
0.26 
0.35 
0.30 
-0.05 
-0.07 
-0.28 
-0.74 
-1.62 
-3.08 
0.00 
-0.05 
-0.16 
-0.45 
-1.26 
0.00 
-0.04 
-0.17 
-0.47 
-0.79 
0.00 
0.03 
0.06 
0.10 
0.15 
0.02 
0.00 
-0.03 
-0.15 
-0.35 
0.80 
-0.03 
-0.13 
-0.34 
-0.71 
-1.54 
-0.01 
-0.07 
-0.19 
-0.40 
-0.75 
0.07 
0.20 
0.30 
0.39 
0.07 
-0.05 
-0.20 
-0.52 
-1.12 
-2.08 
-0.01 
-0.06 
-0.15 
-0.37 
-0.94 
0.00 
-0.04 
-0.14 
-0.34 
-1.56 
0.00 
0.02 
0.03 
0.06 
0.09 
0.01 
0.03 
0.04 
0.03 
0.05 
t Sf - female recombination fraction; 8m - male 
recombination fraction. 
Recessive 
Penetrance 
1.00 
-0.06 
-0.25 
-0.70 
-1.72 
-1.75 
0.01 
0.07 
0.16 
0.16 
0.65 
0.04 
0.09 
0.12 
-0.04 
0.42 
-0.05 
-0.20 
-0.58 
-1.42 
-2.56 
-0.02 
-0.06 
-0.16 
-0.40 
-1.18 
0.00 
-0.02 
-0.17 
-0.62 
-0.75 
0.00 
0.00 
0.00 
-0.02 
-0.02 
0.05 
0.18 
0.39 
0.66 
1.01 
5.4.3 Micronesian lipoprotein genes in non-insulin 
dependent diabetes mellitus - linkage analysis 
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The pedigrees used in the analysis of linkage of the eight 
lipoprotein genes with diabetic status are presented in 
Table 5.7. Lod scores were calculated under models of 
recessive inheritance with full penetrance, and dominant 
inheritance with 99%, 90% and 80% penetrance, at values of 
Sf= Sm from 0.0 to 0.5 (Table 5.8). Lod scores were 
uninformative under a model of recessive inheritance. When 
dominance penetrance of 99% was modelled, close linkage 
could be excluded for APOAl, APOC2, APOD and APOE. The lod 
scores for APOA2, APOCl, LDLR and LPL were uninformative 
under models of dominant inheritance. 
The exclusion of linkage under a dominant model with 99% 
penetrance for APOAl, APOC2, APOD and APOE was mainly due 
to the contribution of lod scores from one or two families, 
with these lod scores accounting for from 65% to 82% of the 
magnitude of the combined lod scores. 
The lod scores for APOD were also calculated over a range 
of Sf+ Sm from 0.05 to 0.50, assuming dominant inheritance 
with 99% penetrance. However, the magnitudes of the lod 
scores from this analysis were no greater than those 
calculated when Sf= Sm. 
The positive, but uninformative lod score of 1.50 at Sf 
Sm= o.o, for APOA2, calculated under assumptions of 
dominant and recessive inheritance, with 99% and full 
penetrance respectively, prompted further investigation. 
The lod scores for APOA2 were recalculated over a range of 
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8f f 8m from 0.05 to 0.50. None of the resultant lod scores 
were larger than those calculated under assumptions of 
equal recombination rates for females and males. The lod 
scores of individual families were examined (Table 5.9), 
and under a recessive model four families were found to be 
the maJor contributors to a positive lod score of 1.87. 
Under a dominant model three families accounted for the 
majority of a positive lod score of 1.70. 
Linkage analysis was also performed modelling for a gene 
dosage effect. In this situation the likelihood of 
diabetes, given two "affected" alleles was 0.99, and given 
one "affected" allele was 0.50. The corresponding allele 
frequencies were p = 0.469, q = 0.531; where pis the 
frequency of the "affected" allele and q is the frequency 
of the "normal allele". Under the assumption of a gene 
dosage effect, lod scores at 8f 8m = 0.0, ranged from 
-0.50 to 0.49, and consequently provided insufficient 
evidence to accept or exclude linkage of these markers with 
diabetic liability. 
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Table 5.7 Diabetic liability pedigrees. 
Pedigree Ind. t Status§ Locus 
Al A2 Cl C2 D E LDLR LPL 
A 
Mo 1 AB AA AB AB BB AB BB AA 
Cl 1 AB AA AB AA AB BB AB 
C2 AA AA AA BB AB AB BB AA 
CJ AB AA AA AB AB AB AB AB 
C4 2 AB AA AB BB AB BB AA 
B 
Cl AB AB AA AA AB BB BB AB 
C2 2 AB AA AA AB AB BB AA 
CJ 1 AB AA AA AB AB BB AA 
C 
Cl AB AA AB BB 
C2 2 AA AA AB AB AB BB BB AA 
CJ 1 AA BB AA BB AA BC AA 
C4 AA AA AB BB AA BC BB AA 
cs 1 AA AB AB AA AB BB AA 
C6 2 AB AB AA BB AB BC AA 
D 
Mo 1 AB AA AA AB BB BB BB AB 
Cl 1 AA AB AA AB BB BB BB 
C2 2 AA AA AB AB BB BC AB AB 
CJ AB AB BB BC 
C4 2 AA AA AB AB BB BC AB AA 
cs 2 AB AA AA AB AB BB AA 
E 
Mo 2 AA AB AB AB BB BB AB AB 
Fa 1 AB AB AA BB BB BB BB AA 
Cl 1 AB AB AA BB BB BB AB AA 
C2 2 AA AA AA BB BB BB AA 
CJ 2 AB AA AB AB BB BB BB AA 
C4 2 AB AB AB AB BB BB AB 
cs 2 AA AB AA BB BB BB AB 
C6 2 AA AB AA BB BB BB AA 
t Ind. Individuals:- Mo - mother; Fa= father; 
en= numbered children. 
§ Status 1 = affected; status 2 - unaffected (not liable); 
blank= unknown. 
Continued overleaf. 
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Table 5.7 Cont'd. Diabetic liability pedigrees. 
Pedigree Ind. t Status§ Locus 
Al A2 Cl C2 D E LDLR LPL 
I 
Cl 2 AA AA BB AB BB AB AA 
C2 2 AB AB AB BC AA 
CJ BC 
C4 1 AB BB BB BB AA 
cs 2 AA AA BB AA BB BC AA 
K 
Mo 2 AB AB AA AB BB BC AB 
Cl 1 AA AA AB BB BC AA 
C2 2 BB AB AB BB BB cc AA 
N 
Cl 1 AA AB AA 
C2 2 BB AB AA AB AB AC AA 
CJ 1 AB AB AA AB AB AC AB AA 
C4 2 AB AB AA AA AB BB AB AA 
Q 
Mo 2 AB AB AA AA BB AB AB AA 
Cl 2 AA AB BB 
C2 1 AA AB AA AB AB BB AB AA 
CJ 1 AB AB AA AA BB AB AA 
R 
Fa AB AA AA AA BB BB AB AB 
Cl 1 AA AA AB BB BC BB BB 
C2 AB AA AB AA BB BB AB BB 
CJ AB AA AA AA BB BB BB 
C4 2 AA AA AB AA BB BB AB AB 
cs 2 AB AA AB AA BB BB AB AB 
C6 2 AB AA AA BB BB BB BB 
C7 1 AB AA AA BB BB AB 
C8 2 AB AA AA AA BB BB BB 
t Ind. Individuals:- Mo - mother; Fa= father; 
en= numbered children. 
§ Status 1 = affected; status 2 = unaffected (not liable); 
blank= unknown. 
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Table 5.8 Lod scores for linkage of diabetic liability 
with lipoprotein gene fragment length polymorphisms. 
Locus 
APOAl 
(MspI) 
APOA2 
(MspI) 
APOCl 
(Dr a I) 
APOC2 
(TaqI) 
APOD 
(TaqI) 
APOE 
(CfoI) 
LDLR 
(PvuII) 
LPL 
(PvuII) 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.4 
0.3 
0.2 
0.1 
0.0 
0.99 
-0.05 
-0.24 
-0.68 
-1.68 
-5.76 
0.13 
0.45 
0.81 
1.16 
1.50 
-0.03 
-0.11 
-0.27 
-0.56 
-1.03 
-0.01 
-0.08 
-0.36 
-1.15 
-5.22 
-0.03 
-0.13 
-0.34 
-0.75 
-2.21 
-0.01 
-0.10 
-0.37 
-0.99 
-2.83 
-0.01 
-0.03 
-0.08 
-0.19 
-0.45 
0.02 
0.04 
0.02 
-0.04 
-0.16 
Dominant 
Penetrance 
0.90 
-0.03 
-0.16 
-0.43 
-0.98 
-2.19 
0.11 
0.36 
0.68 
0.99 
1.30 
-0.02 
-0.08 
-0.19 
-0.38 
-0.65 
-0.01 
-0.08 
-0.30 
-0.82 
-2.26 
-0.02 
-0.10 
-0.25 
-0.52 
-1.05 
-0.01 
-0.07 
-0.24 
-0.60 
-1.36 
0.00 
-0.02 
-0.05 
-0.11 
-0.22 
0.01 
0.02 
0.01 
-0.06 
-0.18 
0.80 
-0.02 
-0.10 
-0.26 
-0.56 
-1.13 
0.08 
0.29 
0.55 
0.82 
1.10 
-0.01 
-0.06 
-0.13 
-0.25 
-0.43 
-0.02 
-0.09 
-0.26 
-0.64 
-1.49 
-0.02 
-0.08 
-0.19 
-0.38 
-0.69 
-0.01 
-0.06 
-0.17 
-0.41 
-0.88 
0.00 
-0.01 
-0.02 
-0.05 
-0.11 
0.01 
0.01 
-0.01 
-0.06 
-0.17 
t 8f - female recombination fraction; 8m - male 
recombination fraction. 
Recessive 
Penetrance 
1.00 
-0.01 
-0.07 
-0.21 
-0.54 
-1.27 
0.15 
0.49 
0.88 
1.24 
1.50 
-0.08 
-0.34 
-0.87 
-1.97 
-0.63 
-0.06 
-0.27 
-0.80 
-2.11 
-0.51 
-0.05 
-0.22 
-0.58 
-1.29 
-0.83 
-0.03 
-0.15 
-0.48 
-1.33 
-0.98 
0.02 
0.08 
0.16 
0.21 
0.19 
-0.03 
-0.18 
-0.57 
-1.48 
-0.62 
Table 5.9 Family lod scores for linkage of diabetic 
liability with APOA2 MspI restriction fragment length 
polymorphism. 
Pedigree Mode of inheritance 
D 
Q 
E 
C 
D, Q, 
I 
K 
R 
I' K, 
A 
N 
B 
A, N, 
Total 
E, and C 
and R 
and B 
Dominant 
Penetrance 0.99 
0.89 
0.44 
0.29 
0.08 
1.70 
0.03 
0.00 
0.00 
0.03 
-0.02 
-0.07 
-0.14 
-0.23 
1.50 
8f = female recombination fraction 
recombination fraction= 0.50. 
5.5 DISCUSSION 
Recessive 
Penetrance 1.00 
0.90 
0.47 
0.30 
0.20 
1.87 
0.05 
0.00 
0.00 
0.05 
-0.02 
-0.09 
-0.31 
-0.42 
1.50 
0.50; 8m = male 
5.5.1 Exclusion of linkage to hypercholesterolemia, 
hypertriglyceridemia, and diabetic liability 
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Linkage of diabetic liability, hypercholesterolemia and 
hypertriglyceridemia to a number of the marker loci tested 
has been excluded in Micronesians. The APOAl, APOC2, and 
APOD fragment length polymorphisms were excluded from 
linkage to all three disorders, when modelled under a 
dominant mode of inheritance. Under the same model APOE 
polymorphism was excluded from linkage with diabetic 
liability and hypercholesterolemia. The three diallelic 
markers, APOAl, APOC2 and APOD, had the highest polymorph ic 
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information content (PIC) (Section 3.4.3, Table 3.9). 
Whilst the PIC for APOE was not as high, this marker was 
successfully typed for every individual, in every pedigree. 
This was not the case for the LDLR PvuII RFLP, which was 
consequently uninformative in all but one of the analyses. 
Under a model of dominant inheritance the APOA2 locus has 
been excluded from linkage to hypertriglyceridemia, and the 
APOCl and LPL loci excluded from linkage to 
hypercholesterolemia. 
The two loci, APOC2 and APOD, which showed associations 
with plasma triglyceride levels and diabetes respectively 
(Section 4.4), where not implicated in these disorders in 
formal linkage analysis. Indeed APOC2 was excluded from 
linkage to hypertriglyceridemia under models of both 
dominant and recessive inheritance, and from linkage to 
diabetic liability, under dominant inheritance. The APOD 
locus was excluded from linkage to all three disorders, 
under dominant inheritance, though from 
hypercholesterolemia only under a recessive model of 
inheritance. 
This highlights the problem of undertaking linkage analysis 
when the precise mode of inheritance is unknown. 
Segregation analysis for hypercholesterolemia and 
hypertriglyceridemia has not been undertaken in the 
Micronesian population. As a result it is not known whether 
the modes of inheritance for these disorders are indeed 
compatible with assumptions of either dominant inheritance, 
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with reduced penetrance, or recessive inheritance wi th full 
penetrance. 
Segregation analysis of hypoglycaemia in the Micronesian 
population has been performed, and results favour a 
dominant mode of inheritance (Serjeantson and Zimmet, 
1989). However, the results of the segregation analysis are 
also compatible with a codominant mode of inheritance. One 
possible expression of a codominant genotype in this 
situation could be a lowered chance of phenotypic 
expression of the disorder; that is a gene dosage effect, 
where the chance of diabetes given affected homozygosity at 
the disease locus, would be 0.99, and given heterozygosity, 
would be 0.50. Under such assumptions, the lod scores from 
the current analysis were uninformative. The possibility of 
linkage between the lipoprotein loci under investigation, 
and diabetic liability, inherited as a codominant disorder 
with an accompanying gene dosage effect has therefore not 
been excluded. 
The APOC2 TaqI polymorphism was found to affect plasma 
triglyceride levels above and below the 75th percentile 
(Section 4.4.1.5) and when plasma triglyceride 
concentration was treated as a quantitative variable 
(Section 4.4.3.1). In the current analysis the 
reclassification of "unaffected" individuals to "unknown" 
on the basis of possession of plasma triglyceride levels 
over the 75th percentile did not alter the nature of the 
conclusions made on the basis of lod scores. Linkage of the 
APOC2 RFLP with hypertriglyceridemia, was excluded under 
dominant inheritance with 99% penetrance. 
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The exclusion of linkage of the APOC2 and APOD RFLPs to 
hypertriglyceridemia and diabetic liability may indicate 
that the assumptions concerning mode of inheritance made in 
the linkage analyses were not valid. 
5.5.2 Limitations of single marker linkage analysis 
The use of single-markers may be inefficient and not a 
powerful enough technique to successfully establish linkage 
in complex traits (Lander and Botstein, 1986b). In 
particular, genetic heterogeneity can confound single-
marker linkage analysis. Two sources of genetic 
heterogeneity may affect linkage analysis. Firstly, the 
term "genetic heterogeneity" will be used to refer to the 
situation where alterations in different genes may result 
in the same disorder; within one ethnic group, but most 
particularly between ethnic groups, the predisposing 
genetic defect or defects may be different. Secondly, the 
term "polygenic heterogeneity" will be used to refer to the 
situation where disorder may be polygenic, with a number of 
loci, or different combinations of subsets of that number, 
having an influence in setting the genetic predisposition 
to the disorder. 
A locus of interest may be responsible for only a fraction 
of the occurrences of a heterogeneous trait. According to 
Lander and Botstein (1986b) the chance that the marker will 
fail to cosegregate with the disorder is the apparent 
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recombination fraction 8' = 8a + 1/2(1 - a), where a is the 
fraction of occurrences of the disorder attributable to the 
locus of interest. If a is small, linkage will appear to be 
loose, even when 8 is also small. Even if linkage is 
detected it is difficult to estimate the values of a and 8, 
as the effects of low a and high 8 are the same. 
When there is an a priori reason for expecting genetic 
heterogeneity, families may be subdivided on the basis of 
positive or negative lod scores. To establish whether the 
heterogeneity between the families is significant Morton 
(1956) applied the likelihood ratio test, in what is now 
referred to as the pre-divided sample test (Hodge et al., 
1983). However, this test relies on asymptotic theory for 
its interpretation, which is thought to be very imprecise 
for small families (White and Lalouel, 1987). The practice 
of subgrouping families according to lod score values, can 
greatly inflate the sum of the lods. It is not thought 
appropriate to emphasise the resultant higher positive lod 
scores in the current study, where the families are too 
small for application of the predivided sample test. In 
addition, there is no evidence for clinical heterogeneity 
in hypercholesterolemia, hypertriglyceridemia, or NIDDM in 
the Micronesian population. 
Although only those individuals who claimed Nauruan 
ancestry were included in the samples, financial benefits 
can and have accrued from such claims, and it is not 
unreasonable to expect some respondents to have falsely 
stated their ethnicity. It has been noted that it is more 
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likely for Nauruan individuals of mixed ethnicity to inter-
marry, leading to a concentration of non-Micronesian 
genetic influences within particular pedigrees {pers. comm. 
Prof. S.W. Serjeantson). 
The effect of foreign admixture on the occurrence of NIDDM 
in Nauru has been recognised (Serjeantson et al., 1983). In 
over forty year olds, 83% of full blooded Nauruans, as 
determined by HLA typing, were diabetic, compared with only 
17% of those with ancestral foreign admixture. In addition, 
the presence of HLA-Bw22(Bw56) was found to be associated 
with a small increased risk for early onset of diabetes. 
The increase of HLA-Bw56 frequency in diabetics was 
consistent with its increase in Micronesians in general. 
HLA-Bw56 is a marker for Nauruan ancestry not NIDDM 
(Serjeantson and Zimmet, 1989). 
APOC2 and APOD, were implicated as genetic markers for 
hypertriglyceridemia and diabetes respectively (Section 
4.4). The difference in APOC2 TaqI allele frequencies 
between Micronesians and Caucasoids, although significant 
was only 0.120 (Presence of site: Micronesians 0.530 ± 
0.035; Pooled Caucasoids 0.41 ± 0.02). The APOD TaqI site, 
whilst being more frequent in Micronesians (0.363 ± 0.037), 
was present at a relatively high frequency in Caucasoids 
(0.18 ± 0.03). For the lipoprotein fragment length 
polymorphisms examined there was no reason to suspect that 
the difference in allele frequencies in affected and 
control groups was the result of foreign admixture. Indeed, 
APOAl and LPL, the two markers whose allele frequencies 
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differed most markedly between Caucasoids and Micronesians 
did not show associations with hypercholesterolemia, 
hypertriglyceridemia or NIDDM. It is unlikely that 
population stratification can account for the 
APOC2/hypertriglyceridemia and APOD/NIDDM associations. 
Even so, as the differences between lipoprotein allele 
frequencies between Micronesians and Caucasoids were not 
extreme, the lipoprotein markers may be poor indicators of 
the presence of foreign admixture. Though the Micronesian 
population is relatively homogeneous, the degree of foreign 
admixture present (12.1% of randomly selected, non-NIDDM 
adults had a demonstrably foreign HLA class I type, 
Serjeantson et al., 1983) may be high enough to impinge on 
linkage analysis if there were different linkage 
disequilibrium relationships in chromosomal segments 
involved in predisposition to hypercholesterolemia, 
hypertriglyceridemia or NIDDM. 
The power of RFLP data in linkage analysis may be improved 
if a map rather than single-markers is used. It is then 
possible to perform interval mapping, to test whether a 
putative locus lies between two markers whose locality has 
been previously determined, or to undertake a simultaneous 
search examining several candidate genes in concert (Lander 
and Botstein, 1986b). Even with the increased power 
obtained when using RFLP maps, it is felt that for 
heterogeneous disorders it would be preferable to obtain 
pedigrees with three affected individuals. Moreover, the 
use of RFLP maps in analysis does not overcome the 
sensitivity of linkage analysis to errors of diagnos i s 
(Lander and Botstein, 1986b). 
5.6 CONCLUSIONS 
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1) Under a dominant model of inheritance the APOAl, 
APOC2, and APOD fragment length polymorphisms were 
excluded from linkage to hypercholesterolemia, 
hypertriglyceridemia and non-insulin dependent 
diabetes among Micronesians. 
2) Under the same model the APOA2 fragment length 
polymorphism was excluded from linkage to 
hypertriglyceridemia, and the APOCl, and LPL RFLPs 
from linkage to hypercholesterolemia among 
Micronesians. 
3) Under the same model linkage of the APOE fragment 
length polymorphism was excluded from linkage to 
hypercholesterolemia and non-insulin dependent 
diabetes among Micronesians. 
4) Linkage of the APOD RFLP to hypercholesterolemia was 
excluded under a recessive model. 
5) Linkage of the APOC2 RFLP to hypertriglyceridemia 
was excluded under a recessive model. 
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SECTION 6 
GENERAL DISCUSSION 
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This thesis has examined the effect of genetic variation at 
eight lipoprotein loci on non-insulin dependent diabetes 
mellitus, obesity, central adiposity, hypercholesterolemia 
and hypertriglyceridemia. The Taql site at the APOC2 locus 
was more often present in individuals with high plasma 
triglyceride levels and central adiposity. The APOD TaqI 
site was more often absent in individuals with NIDDM, high 
plasma cholesterol levels and central adiposity. The 
frequency of the APOE*2 allele was increased, with marginal 
significance, in NIDDM patients, but not in individuals 
with hypercholesterolemia or hypertriglyceridemia. However, 
linkage analysis has excluded linkage of the APOC2 and APOD 
loci with NIDDM, hypercholesterolemia and 
hypertriglyceridemia, modelled under dominant inheritance. 
The APOC2 and APOD loci where also excluded from linkage 
with hypertriglyceridemia and hypercholesterolemia 
respectively, when modelled under a model of recessive 
inheritance. In addition, the APOE locus has been excluded 
from linkage with NIDDM and hypercholesterolemia, under a 
model of dominant inheritance. 
The apparent anomaly between a strong population 
association for APOD alleles and NIDDM and the exclusion of 
c !os~ linkage between APOD and a putative NIDDM locus under a 
dominant model of inheritance could indicate that the model 
for inheritance is excluded rather than linkage. 
Segregation analysis of NIDDM in Micronesians shows that a 
codominant model fits segregation patterns equally well as 
a dominant model (Serjeantson and Zimmet, 1989), suggesting 
a possible gene dosage effect. A gene dosage effect has 
177 
also been suggested for NIDDM by O'Rahilly et al. (1987 ) . A 
gene dosage effect upon the expression of the disorder is 
modelled as for a dominant mode of inheritance, but with 
50% penetrance in heterozygotes. The low penetrance value 
makes analyses, and lod scores, relatively uninformative. 
Apparent anomalies between population and linkage analyses 
could also arise if an allele at the locus of interest was 
necessary, but not sufficient, for disease without some 
contribution from an additional unlinked gene. Then family 
members could share the susceptibility allele of interest 
but have different disease phenotypes. If this was the case 
those families monomorphic at the second locus could have 
high lod scores at the primary locus, while other families 
would not. This scheme is not inconsistent with the broad 
range of lod scores observed in families in this study for 
APOD and NIDDM, and for APOC2 and hypertriglyceridemia. 
If this is the case, other loci of interest may need to be 
re-examined in the Micronesian population. Genes affecting 
insulin activity are obvious candidates, given the body of 
knowledge accumulating concerning their involvement in 
hyperinsulinemia and insulin-resistance. Hyperinsulinemia 
is associated with impaired glucose tolerance in many 
ethnic groups (Reaven and Miller, 1968; Sicree et al., 
1987; Lillioja et al., 1988; Saad et al., 1988) and 
progression from a state of impaired glucose tolerance to 
diabetes is correlated with a decline in insulin response 
in Japanese (Kadowaki et al., 1984), Nauruans (Sicree et 
al., 1987) and Pima Indians (Saad et al., 1988). 
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Hyperinsulinemia has been shown to be associated with 
insulin resistance in the Pima Indians (Lillioja et al., 
1987) and both of these metabolic alterations are 
predictive of the development of diabetes (Knowler et al., 
1989). Hyperinsulinemia is also predictive of progression 
to diabetes among Nauruans with normal glucose tolerance 
(Sicree et al., 1987). 
Insulin resistance is a major causal factor for 
hyperglycaemia in NIDDM (Reaven et al., 1976; Taylor et 
al., 1990) and molecular defects have been identified in 
individuals with insulin resistance (Bell, 1991). These 
defects occur either in the insulin receptor gene, 
genes of the glucose transporter family. Seventeen 
. 
or in 
mutations in patients with extreme insulin resistance have 
been identified (Bell, 1991), including missense and 
nonsense mutations (Kadowaki et al., 1990) and deletions 
(Taira et al., 1989). The mutations result either in the 
complete absence of the receptor molecule, or in defects in 
insulin receptor function, ranging from defective insulin 
binding and internalization of the insulin/insulin receptor 
complex to inefficient recycling of the receptor and 
impairment of tyrosine kinase activity. It has been 
suggested that if heterozygotes for these mutations are at 
risk for NIDDM, the gene may account for as much as 5-10% 
of the occurrence of NIDDM (Taylor et al., 1990; Bell, 
1991). 
The family of glucose transporter proteins are responsible 
for the transport of glucose across the plasma membrane. 
,I 
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Facilitative glucose transporters are membrane proteins, 
present on the surface of all cells, which accelerate the 
passive and energy independent transport of glucose across 
the lipid bilayer (Bell et al., 1990). Insulin has been 
shown to stimulate glucose transport by increasing the 
number of plasma membrane associated glucose transporters 
(Cushman and Wardzala, 1980; Suzuki and Kono, 1980) and so 
cause an increase in the rate of glucose uptake. However, 
in insulin resistant states there are fewer glucose 
transporters in both adipocytes and muscle cells (Simpson 
and Cushman, 1986). 
Five functional glucose transporter genes and a glucose 
transporter pseudogene-like sequence have been identified 
(Bell et al., 1990; Kayano et al., 1990). Recent studies 
have indicated that decreased expression of the GLUT2 and 
GLUT4 genes may be responsible for insulin resistance in 
adipocytes and reduced insulin secretion in ~-cells (Berger 
et al., 1989; Sivitz et al., 1989). 
Molecular defects in the insulin receptor gene and altered 
expression of glucose transporters do not account for all 
cases of insulin resistance (Bell, 1991). However, progress 
has been made in identifying the defects and alterations 
listed above, and if, as previously suggested, insulin 
receptor gene defects contribute to insulin resistance in a 
subgroup of NIDDM patients, molecular screening techniques 
may be used to screen for further defects. The application 
of the polymerase chain reaction (Saiki et al., 1985) and 
single stranded conformation and denaturing gradient 
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electrophoresis (Orita et al., 1989; Sheffield et a l ., 
1989) greatly enhance the ability to detect molecular 
alterations and make more extensive molecular screening of 
diabetic individuals and at risk family members feasible. 
Insulin resistance is also common in obese individuals and 
is often the result of a reduced number of glucose 
transporter molecules (Garvey et al., 1988). There is a 36 % 
decrease in GLUT4 mRNA in the subcutaneous adipocytes of 
obese compared to lean individuals. The amount of GLUT4 
mRNA shows an even larger decline (86%) in NIDDM patients 
when compared with weight-matched controls (Garvey et al., 
1991). The suppression of GLUT4 expression in obesity does 
not account for all of the suppression observed in NIDDM. 
However, GLUT4 suppression is a major mechanism in insulin 
resistance in both disorders, and has also been observed in 
individuals with impaired glucose tolerance. Consequently, 
GLUT4 suppression may represent an early marker for 
progression to diabetes (Garvey et al., 1991). 
The suppression of GLUT4 expression is an interactional 
effect and does not appear related to any defects in the 
gene itself. A preliminary study of a GLUT4 KpnI RFLP in 
Micronesians has not revealed any association of the locus 
with NIDDM (pers. comm. Prof. S.W. Serjeantson). Nor has 
the GLUT4 gene been implicated in the pathogenesis of NIDDM 
in the North American population (Bell et al., 1990). 
Although obesity is associated with an increased incidence 
of NIDDM (Kawate et al., 1979; Stanhope and Prior, 1980 
Mather and Keen, 1985), recent studies have indicated that 
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the distribution of body fat is an important factor in 
determining the nature of this association (Kissebah and 
Peiris, 1989). Diabetics have been shown to have more 
subscapular subcutaneous fat and a general excess of fat on 
the torso when compared with non-diabetics (Feldman et al., 
1969; Joos et al., 1984). 
The degree of central adiposity has also been shown to be 
related to insulin resistance. In a study of NIDDM in 
Japanese-American men both high fasting C-peptide levels, 
assumed to be present as the result of a compensation 
response to insulin resistance, and degree of central 
adiposity where found to be predictive of progression to 
diabetes. Moreover, the level of C-peptide was correlated 
with intra-abdominal fat area as determined by computer 
tomography (Bergstrom et al., 1990), indicating that 
central adiposity may be associated with insulin 
resistance. 
Both waist-to-hip and waist-to-thigh ratios have been used 
as an index of the degree of central adiposity and both 
have been shown to be associated with diabetes (Hartz et 
al., 1984). Moreover, waist-to-hip ratio is predictive of 
both diabetes and cardiovascular disease (Ohlson et al., 
1985; Lapidus et al., 1984), with the prediction of 
cardiovascular disease being independent of the overall 
level of obesity. The frequency of peripheral vascular 
disease, coronary heart disease and hypertension has been 
shown to be higher in diabetics with abdominal fat masses 
(van Gaal et al., 1988). An increase in WHR has been found 
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to be associated with an increase in fasting plasma glucose 
and insulin levels, and with higher glucose and insulin 
responses to an oral glucose challenge. The 
hyperinsulinemia and peripheral resistance to glucose 
action found in subjects with abdominal obesity may lead to 
a decrease in activity of adipose lipoprotein lipase 
(Kissebah and Peiris, 1989). 
The relationship of body fat distribution and diabetes has 
been observed in both men and women, over a range of ethnic 
groups and is also predictive of hyperlipoproteinemia 
(Kissebah and Peiris, 1989). In a study comparing waist-to-
hip ratio with percentage of body fat and body mass index 
as correlates of plasma lipids, waist-to-hip ratio was 
positively associated with triglyceride, cholesterol, LDL-
cholesterol and VLDL-cholesterol, and negatively associated 
with HDL-cholesterol. Moreover, after adjusting for the 
degree of central adiposity, overall obesity was not 
significantly associated with any of these variables (Terry 
et al . , 19 8 9) . 
The WHR correlates highly with intra-abdominal visceral 
mass and it is suggested that the correlative power of WHR 
with diabetes, hypertension, cardiovascular disease and 
hyperlipoproteinemia is the result of its ability to 
predict the volume of abdominal visceral fat. Although 
central adiposity has been shown to be predictive of 
diabetes and hyperlipoproteinemia it is not suggested that 
the increased abdominal visceral fat mass is the primary 
causative agent in these metabolic alterations. Central 
I 
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adiposity may be a visible early marker for diabetes and 
hyperlipoproteinemia at the same time as acting as an 
"environmental" stressor which may impact upon an 
underlying genetic predisposition towards poorly regulated 
hepatic glucose production with consequent decreased 
insulin secretion (Kissebah and Peiris, 1989). 
Results presented in this thesis are in accordance with the 
general scheme of alterations in glucose and lipoprotein 
metabolism with increasing levels of central adiposity. The 
APOC2 locus was significantly associated with plasma 
triglyceride levels and the APOD locus with diabetic 
status. Both plasma triglyceride levels and diabetic status 
are associated with WHR. Consequently both the APOC2 and 
APOD loci were associated with WHR. 
The limitations of single marker linkage analysis have been 
discussed (Section 5.5.2). Linkage analysis using genetic 
maps or highly variable markers will be required in future 
studies if the problems of detecting linkage with a single 
locus, against a background of genetic or polygenic 
heterogeneity are to be overcome. It is also clear that the 
application of a wider range of molecular techniques and 
the further clarification of the underlying biochemical 
mechanisms and inter-relationships of NIDDM, obesity and 
hyperlipoproteinemia are necessary if the primary genetic 
defects for these disorders are to be revealed. 
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